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ABSTRACT 
The primary aims of this study were to develop research methodology in order to investigate the 
efficacy of herbal medicine in alleviating menopausal symptoms, and to prepare an application 
for submission to the Medicines Control Agency (MCA) to gain approval to run a randomised, 
double blind, placebo controlled clinical trial. A research protocol was developed which 
outlined the key stages of the study for subsequent review and approval by an ethics committee. 
An operations manual was developed to guide and instruct clinicians on how the study should 
be implemented. This required the development of case history notes, screening procedures, 
timetable flow charts and adverse event reporting cards specifically for this study. An original 
herbal formula was developed for this study based on a literature review of medicinal plants. A 
54-page exemption from licences MLA-164 application was completed, which set out in detail 
the design of the study. The pharmacological properties of the medicinal plants were reviewed 
from the literature and listed in detail to satisfy the MCA's requirements for scientific evidence 
of efficacy and safety. Heavy metal analysis was performed for quality control purposes to 
examine the feasibility of being able to meet specification limits for metal contamination in 
medicinal herbs. This was conducted using Inductively Coupled Plasma-Atomic Emission 
Spectroscopy on a total of 16 herb samples, eight samples of Hypericum perforatum L. and 
eight samples of Salvia officinalis L. from cultivation sites in the UK and Europe. Mean metal 
ion concentrations of lead, cadmium, mercury, copper, zinc, nickel and chromium were found 
to be below statutory limits and guidelines, and would therefore satisfy the requirements of an 
MLA- 164 application for metal contamination. High Performance Liquid Chromatography was 
performed using UV detector and Diode-Array detector systems to determine the suitability of 
each method to provide a `fingerprint' analysis of the medicinal herbs for the purposes of 
establishing plant authenticity. The diode-array analysis was superior to simple UV detector 
methodology because it was able to provide greater accuracy to determine the chemical group 
for some unknown constituents. However, neither system provided adequate phytochemical 
profiles to authenticate the medicinal plants. The research study provided a novel insight into 
the processes required for the design and implementation of a herbal medicine clinical trial, and 
has expanded the current knowledge of the requirements for completing a clinical trials 
application (MLA-164) to the MCA. 
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CHAPTER 1 
INTRODUCTION 
1.1 Background 
Menopause is the permanent cessation of menstruation in women, as a result of 
declining oestrogen hormones. This normal transition usually occurs at the mean age 
of 51 and can be accompanied by unpleasant vasomotor symptoms such as hot flushes 
and night sweats. Declining oestrogen levels are also associated with increased risk of 
osteoporosis (Gambacciani et al 1995), cardiovascular disease (De Aloysio et al, 
1999), urogenital atrophy (Samsoie, 1998), cognitive decline (Solerte et al, 1998) and 
Alzheimer's disease (Inestrosa et al, 1998). 
By the year 2000, an estimated 31.2 million women will have undergone the 
menopausal transition (Wolinsky, 1994), a number that is expected to increase to 1.3 
billion by the year 2030 (WHO, 1996). These increases will inevitably lead more 
women to seek medical attention for the immediate symptoms of the menopause. This 
will ultimately require more resources being made available to meet the increasing 
costs of medical care in the ageing population. 
Medical expenses in England and Wales, associated with osteoporosis, have been 
estimated at £940 million every year (Dolan, 1998) and menopausal osteoporotic 
related fractures can result in both morbidity and mortality. Fractures are not the 
immediate problems facing menopausal women, since most of them occur later in life, 
usually around 70-80 years. However, skeletal atrophy increases around the time of 
the menopause by 2.5% per year (Slemenda et al, 1987) and continues, to a lesser 
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degree, into old age. Strategies aimed at slowing the rate of bone loss could reduce 
NHS expenditure and alleviate suffering later in life. 
The main treatment for menopausal complaints is Hormone Replacement Therapy 
(HRT), which is used to relieve symptoms such as hot flushes and night sweats. HRT 
helps to prevent atrophic vaginitis, osteoporosis and atherosclerosis (Smith, 1995), 
and consists of synthetic oestrogens that mimic the female hormones, or so-called 
natural oestrogens made from the urine of pregnant mares (premarin). Both are 
different in chemical structure from natural hormones (Rogers, 1995). Side effects 
from HRT include nausea, vomiting, fluid retention, headaches, depression and 
uterine cancer (BNF, 2001). 
In the USA, it has been estimated that between 10%-35% of menopausal women are 
using HRT (Utian and Schiff, 1994), while in the UK, as few as 7-10% of women use 
HRT (Hunter, 1994). This low use of HRT has been attributed to women being 
unwilling to use this treatment for a number of reasons including concerns regarding 
the risks of breast cancer and other hormone dependent cancers, side-effects of the 
treatment and medicalisation of a normal physiological process (Siddle, 1993). 
Furthermore, oestrogen therapy is not an option for some women because of side- 
effects or contraindications (Barlow, 1992). A safe and efficacious herbal alternative 
to HRT would therefore be welcome. The reluctance of women to use HRT, is 
indicated by the fact that many women who begin HRT stop within a few months 
(Kaufert, 1986), with the average duration of use being only 9 months (Sheehy, 1992). 
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It is questionable whether, historically, much emphasis was focused on developing 
treatment strategies for menopausal symptoms, given that the low life expectancy 
would have limited such prevalence. Life expectancy for women in the United States 
had only reached 49 by the 1900's (Speroff, 1999). Yet today, women have a life 
expectancy of 79.7 years and can expect to spend one-third of their lives 
postmenopausal, a significant number suffering from initial vasomotor problems such 
as hot flushes and the later complications of osteoporosis. Historical documentation of 
the use of herbal medicine to alleviate menopausal symptoms is scarce. In Traditional 
Chinese Medicine the therapeutic treatment of the menopause does not exist, as it is 
not regarded as a physiologic modality requiring treatment. However, treatment 
strategies were developed in China during the Song Dynasty (1119 A. D) for a pattern 
of disharmony similar to menopausal symptoms. In the European herbal tradition, 
Salvia officinalis (sage), was prescribed in the 1800's for excessive sweating 
(Culbreth, 1927) while in North America, native Indians have used Cimicifuga 
racemosa (Black cohosh) for menstrual irregularities. The importance of C. racemosa 
as a medicinal plant was recognised in the first works on American herbs, which date 
back to 1801. C. racemosa was an official drug of the United States Pharmacopoeia 
from 1820 to 1926 and was used as an aid for child birth (Foster, 2000). Whilst S. 
officinalis and C. racemosa have had a relatively long traditional use in menopausal 
complaints, other herbs such as Eleutherococcus senticosus (Siberian ginseng) appear 
to have been incorporated, more recently, into the therapeutic strategy of practitioners 
(Fulder, 1988). 
It has been suggested that herbal medicine may offer an alternative to HRT due to 
plant constituents that have been found to mimic or interact with oestrogenic receptor 
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sites in animals. More than 20 compounds have been identified in at least 300 plants 
from 16 different plant families. These compounds, referred to as phytoestrogens, are 
weaker than natural oestrogens and are found in herbs, grains and vegetables (Knight 
et al, 1996; Thompson et al, 1991). 
Certain phytoestrogens have been investigated as having potential in the treatment of 
menopausal symptoms and osteoporosis and may also have cancer preventative 
qualities. Laboratory experiments and comparisons of Asian and Western human 
populations suggest that diets rich in phytoestrogens may play a role in these types of 
health problems. One study found that Asian populations who eat substantially greater 
amounts of soy products (which contain phytoestrogens such as genistein and 
daidzein), have lower rates of hormone dependent cancers such as breast and 
endometrial cancers and a lower incidence of menopausal symptoms and osteoporosis 
than Westerners (Barrett, 1996). Furthermore, Somekawa et al (2001) found that 
Japanese menopausal women who consumed a diet high in soy based products, 
containing isoflavones, had higher bone mass density. 
In patient trials, Cimicifuga racemosa, soy based products and genistein which is a 
commonly found phytoestrogen, have been shown to be effective in the treatment of 
hot flushes (Brzezinski and Debi, 1999). Isoflavones and other phytoestrogens found 
in soybeans, as well as flaxseed, have beneficial effects on vasomotor symptoms and 
bone health (Anderson, 1999). 
4 
These studies along with the majority of phytochemical medical research reflect the 
current emphasis on research into single herbs or their constituents and are not 
representative of the usual practice of herbal medicine. 
In herbal practice, treatment usually takes the form of a complex herbal formula 
aimed at treating the whole patient and stressing the importance of individualised 
treatment. Herbs will often be added to a formula in order to attenuate the action of 
other herbs for example fennel is commonly used to alleviate colicky griping pain that 
can occur with strong herbal purgatives (Bone and Mills, 2000). Furthermore, 
synergism is a well known concept in phytotherapy and evidence is accumulating to 
suggest that this does occur in extracts of herbs and in mixtures (Williamson, 2001). 
Designing appropriate clinical trials in which investigations take into account the 
individualised nature of the treatments as well as satisfying the demands for scientific 
rigour is important to the progress of research in this area. 
The need for an improved evidence base for the practice of herbal medicine was 
recognised in a Lords Select Committee report on Complementary and Alternative 
Medicine (CAM) published in November 2000. In this report the growth in the use of 
complementary medicine was acknowledged, estimating that approximately one third 
of the UK population are now using complementary medicine (Zollman and Vickers, 
1999). Complementary medicine in the UK remains largely outside of mainstream 
provision. One reason identified by the select committee report as a hindrance to the 
integration of complementary medicine into the NHS is the lack of research studies. 
5 
The report states: 
"There has been increased public interest in the use of complementary and 
alternative medicine in recent years. CAM is a thriving feature of the private 
health care sector, and may owe some of its commercial success to the fact 
that it currently enjoys relatively light regulation. CAM can also play a part in 
treating NHS patients, but if it aspires to be an equal player with other forms 
of NHS treatment, it must meet the same standards required of them and it 
must be clear and realistic about the contributions it can make. In our opinion 
any therapy that makes specific claims for being able to treat specific 
conditions should have evidence of being able to do this above and beyond the 
placebo effect. This is especially true for therapies, which aim to be available 
on the NHS (The National Institute of Medical Herbalists [NIMH], the main 
governing body representing herbal medicine practitioners in the UK, aspires 
to make herbal medicine available either within the NHS or through referrals). 
We recommend that if a therapy does gain a critical mass of evidence to 
support its efficacy, then the NHS and the medical profession should ensure 
that the public have access to it and its potential benefits" (House of Lords, 
2000). 
The recognition of the important contribution that complementary medicine has made 
in private health care and the potential that it has to offer to the NHS, once greater 
evidence of efficacy is established has given an impetus to research in this area. This 
need is reflected by patients who seek out alternatives to prescription medication 
because of concerns for potential side effects or absolute contraindication, or simply 
because there is no effective pharmaceutical therapy available. 
As well as the need to develop appropriate methodologies for investigating the 
efficacy of herbal medicines there is also a need for this area to succeed in attracting 
research funding. Currently, only 0.08% of NHS funding goes to complementary 
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medicine, (Ernst et al, 2001). Also, the Medical Research Council provided no 
research expenditure for complementary therapies between 1998 and 1999 and British 
medical research charities spent only 0.05% of their total research budget during 1999 
in this area (Rees and Weil, 2001). The reason why there is little research funding 
made available to complementary medicine is unclear. Possible explanations may 
relate to research applications not being sufficiently rigorous, lack of expertise in 
complementary medicine, or biased attitudes within the orthodox medical profession. 
However, there is sufficient published research demonstrating efficacy of herbal 
medicine (Sheehan et al 1992; Woelk, 2000; Stoll, 1987) to justify additional funding 
or a reassessment in budget allocations. 
Summary 
There is a need to investigate alternatives to HRT and there is some evidence to 
suggest that treatment based on herbal practice may be efficacious. There is also a 
recognised need to develop appropriate methodologies for research in this area, which 
is sufficiently scientifically rigorous to attract research funding, and reflects the actual 
practice of herbal medicine. 
1.2 Aims and Objectives of the Research 
The aim of this work was to develop a research study to investigate the efficacy of 
herbal medicine to alleviate menopausal symptoms, including the use of a poly-herbal 
formula to reflect the traditional practice of herbal medicine, whilst retaining the 
rigour of a randomised, double-blind placebo controlled trial. The project aimed to 
develop an understanding of the research process pertinent to herbal medicine, thus 
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potentially highlighting areas of difficulty encountered with (CAM) research. This 
was achieved through the following objectives: 
1) Develop a generic herbal formula for menopausal complaints, i. e. aiming to 
treat multiple symptoms. 
2) Ensuring adequate quality control procedures was used in the process of 
producing the formula to satisfy MCA requirements. 
3) Producing a clinical trial protocol for an ethics committee to ensure the 
research study met the requirements of the Helsinki agreement. 
4) Producing an operations manual to enable clinicians to implement the study. 
5) Designing advertising media to promote the clinical trial. 
6) Completing initial quality control procedures for heavy metal analysis and 
HPLC fingerprint analysis. 
7) Completing a MLA-164 (CTX) application for submission to the Medicines 
Control Agency. 
1.3 Overview 
The first objective, which was to develop a novel generic herbal formula for 
menopausal symptoms, was achieved by reviewing the current literature on the 
endocrinology of the menopause to determine the impact hormonal variations have on 
menopausal symptoms. The hormonal changes that occur during the menopausal 
transition show wide variations in women, and are not related to the severity of hot 
flushes. These variations mean that measurement of hormone levels is not a reliable 
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method to determine the menopausal status of women. Furthermore, the failure to 
establish a definite link between hormonal levels and symptom severity is pertinent to 
this research, because the rationale of the treatment should not have to be based solely 
on the plants providing a hormonal action, given the lack of evidence correlating 
symptom severity with hormone levels. This fact is important in fulfilling the 
requirements of the MLA- 164 document, given the need to provide a therapeutic 
rationale for the herbal formula. A further literature search was then conducted to 
determine which herbal medicines might be efficacious for the alleviation of 
menopausal symptoms, based on clinical studies and empirical evidence. The 
information derived from the literature provided the basis for the development of the 
herbal formula. 
The second objective, which was to ensure adequate quality control procedures were 
devised for the production of the herbal formula, was achieved by investigating the 
different quality control processes available to ensure good manufacturing procedures 
(GMP) and safety standards would be applied in the production of the herbal drug. 
This required scrutinising quality control guidelines and good manufacturing 
procedures from sources sich as, The Soil Association, International Conference on 
Harmonisation, government publications, and various research papers that have 
investigated quality control methods specific to herbal medicines. The relevant 
information was then extracted and collated into a novel and unique set of safety 
procedures specifically for this herbal medicine study as a means of demonstrating to 
the MCA that appropriate quality control methods would be implemented. 
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The third objective, which was to produce and submit a clinical trials protocol to the 
university's ethics committee, was achieved based on the development of a novel 
research design for a double-blind placebo controlled clinical trial with menopausal 
women. The protocol set out how participants would be selected, the number of 
participants to be used in the study, the type of measurement tools used and methods 
of obtaining patient consent in accordance with the principles set out in the Helsinki 
agreement. These procedures set out in the protocol were essential to demonstrate to 
the MCA that the study would be both feasible and ethical. 
The fourth objective, which was to develop an operations manual for the study, was 
achieved by producing a detailed set of unique instructions to. enable the clinicians to 
administer the clinical trial uniformly. Patient case history notes and screening 
questions were specifically developed for the study to assess the participant's health 
status and eligibility. This was essential to avoid methodological errors and to 
demonstrate to the MCA that appropriate measures would be undertaken to ensure 
patients' welfare was addressed. This manual has provided a novel and valuable 
example of the procedures which need to be followed in a study to ensure it is 
methodologically robust, uniformly administered and meets the ethical requirements 
of the Helsinki agreement. 
The fifth objective, which was to design advertising media for the clinical trial, was 
achieved by the production of a novel poster and leaflet for the study. The poster was 
designed to include the essential aspects of the trial, whilst being sufficiently bold to 
attract the attention of our target audience. The leaflet was produced to provide 
additional information about the trial for the potential participants. Also, other 
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methods of recruiting patients were investigated which involved examining the typical 
cost of advertising, which was found to be relatively expensive. 
The sixth objective, which was to conduct initial quality control procedures on the 
medicinal plants, was achieved by performing an analysis of the levels of heavy 
metals present in Hypericum perforatum and Salvia officinalis, using Inductively 
Coupled Plasma-Atomic Emission Spectroscopy (ICP-AES). This information was 
particularly valuable because there is a paucity of data available on metal contaminant 
levels in medicinal plants. This resulted in new and novel information being made 
available on the typical levels of heavy metal contaminants found in Hypericum 
perforatum and Salvia ofcinalis from UK and European sources, and thus provided a 
valuable reference to determine the potential of being able to meet the MCA's safety 
specifications. High Performance Liquid Chromatography (HPLC) was also conduced 
to perform a `fingerprint' analysis of the medicinal plants using UV and diode-array 
detector systems to determine whether either system would be an appropriate tool to 
aid plant authenticity. The results of the HPLC analysis provided a new understanding 
of the benefits and limitations that liquid chromatography offers for establishing plant 
authenticity in relation to the MCA specifications. 
The seventh objective, which was to complete an MLA-164 application ready for 
submission to the MCA, was achieved by the completion of a 54-page document 
specifically for the study. The completed MLA- 164 document set out how the clinical 
trial was to operate, the quality control measures to be used, and provided a unique 
and extensive synthesis of the scientific supporting evidence on the herbs, to enable 
the MCA to determine the safety and validity of the proposed study. 
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The process of completing an MLA-164 application for a herbal medicine clinical 
trial was novel, and elucidated an area of knowledge that has, until now, been 
inadequately reported. The MCA normally receives applications from pharmaceutical 
drug companies who are proposing to test a drug consisting of a single compound. In 
contrast, the active constituents of medicinal herbs are often unknown and many of 
the phytochemicals within plants have not been identified. Fulfilling the MLA-164 
pharmaceutical requirements for the herbal formula that contained numerous 
compounds was challenging especially because of the limited data available on the 
pharmacology and pharmacognosy of medicinal plants. 
In this thesis, the author has attempted to elucidate the processes necessary for 
designing a herbal medicine clinical trial for submission to the MCA. This is an area 
that is both poorly researched and understood. The completed MLA-164 document, 
the protocol, operations manual, advertising media, and patient time-tables were 
specifically designed for this project and provide a novel insight into the processes 
necessary for the design of a herbal medicine clinical trial with menopausal women. 
These documents are placed in the appendices for clarity and easy reference. 
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CHAPTER 2 
THE PHYSIOLOGY OF THE MENOPAUSE 
2.1 Background 
A review of the physiological processes that occur during the menopause and pre-and 
post menopause was conducted. This was performed to explain the hormonal and 
physiological changes that lead to menopausal symptoms and ultimately infertility. 
2.2 Definition of the Menopause 
The World Health Organisation's definition of the menopause is `the time of 
permanent cessation of menstruation due to loss of ovarian follicular activity' and is 
usually established, retrospectively, after 12 months of amenorrhoea (Richardson, 
1993). From the standpoint of the ovary, the menopause is not a sudden event but is a 
cumulative process from foetal life, since the maximum number of follicles, estimated 
between 2x 106 and 6x 106, is reached whilst in utero. During further foetal 
development follicles begin to disappear as a result of atresia (cell death) which 
continues until just before menopause is reached (Richardson, 1990). 
2.3 The Perimenopause 
The perimenopause is the phase from the onset of menopausal symptoms to one-year 
after the final menstrual period, with a mean onset of 45.5-47.5 years and an average 
duration of 5 years, as established in longitudinal studies, (McKinlay et al, 1992). 
Traditional concepts about the endocrine changes around the perimenopause include 
gradually declining oestrogen levels and rising gonadotropins (Burger and Teede, 
1999). However, wide variations in hormonal profiles of lutinising hormone (LH), 
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follicular stimulating hormone (FSH) and oestradiol can occur in serum during the 
perimenopause (Gow et al, 1994), although evidence suggests that oestrogen and FSH 
levels rise during the perimenopause, with raised FSH being the most consistent 
feature. LH may rise in some women before menopause although LH remains in the 
normal range in most women despite the rise in FSH (Metcalf and Livesey, 1985). 
Studies of perimenopausal women have shown the variations in FSH, inhibin, and 
oestrogen levels to be transient, and therefore, unreliable in diagnosing approaching 
menopause or in predicting the stage of menopausal transition for any woman 
(Burger, 1994). 
2.4 The Menopause 
The precise endocrinological changes during the menopause are still being clarified, 
although it is known there is an exponential decline in oocyte numbers as menopause 
approaches. The pattern of gonadotrophin, oestradiol and progesterone production 
fluctuates, especially in women whose last cycles may be irregular in length (Sherman 
et al, 1976). This shows that mean data may not necessarily apply to any one 
individual. The first sign of approaching menopause is a decline in fertility and the 
first endocrine change is a fall in inhibin production by the ovary. The role that 
inhibin plays is significant, with reduced negative feedback on the pituitary resulting 
in increased FSH production. The glycoprotein inhibin blocks the production of FSH 
by the anterior pituitary and hence, with the loss of restraint, plasma FSH 
concentration begins to rise above the pre-menopausal upper limit of 5 IU/i (Campbell 
and Monga, 2000). At the menopause, LH levels rise and plateau after about 12 
months of amenorrhoea (Longcope et al, 1986). Much of this rise is caused by the 
decline in ovarian oestrogen secretion and the resultant loss of the negative feedback. 
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During the menopause, there is a decline in the ovarian secretions of oestrogens, and 
only about 10% of menopausal women are able to secrete significant quantities of 
ovarian oestradiol (Longscope et al, 1980). Oestrone levels decrease by 50 to 80% at 
the menopause, and due to the decline in oestradiol, oestrone becomes the prominent 
circulating oestrogen (Gow et al, 1994). For most menopausal women, the major 
source of circulating oestradiol is from the peripheral aromatisation of androgens 
(Siiteri and MacDonald, 1973). Figure 1 shows the typical hormonal changes that 
occur during peri-and post menopause. 
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Fig. I Blood plasma hormone changes in pre-and-post menopausal women (Yen, 1977). 
FSH =Follicular Stimulating Hormone 
LH =Lutinising Hormone 
E1 =estradiol 
E2 =estrone 
A =androstenedione 
T =testosterone 
DHEA =dehydroepiandrosterone 
GH =growth hormone 
PRL =prolactin 
TSH =thyroid stimulating hormone. 
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2.5 Summary 
There is a decline in fertility and alteration in menstrual cycle prior to the menopause. 
A wide variety of hormonal patterns of LH, FSH and oestradiol can occur in 
perimenopausal women, although raised FSH appears to be a prominent feature, 
which is accompanied by a decline in oocyte numbers and inhibin levels. 
Measurement of serum hormones to determine menopausal status is unreliable due to 
wide hormonal fluctuations and there are no objective means of determining 
improvements in menopausal symptoms, since hormonal levels are unreliable 
predictors of either menopausal status or symptom severity (WHO, 1996). The decline 
in ovarian function that culminates in the menopause gives rise to a hormone deficient 
state. Postmenopausally, oestrone becomes the major circulating oestrogen derived 
from the conversion of adrenal androstenedione in adipose tissue. 
The lack of evidence to establish an association between hormone levels and the 
frequency and severity of hot flushes is pertinent to this study. It is known that so 
called phytoestrogens found in plants have a weak endocrine effect compared with 
HRT or endogenous hormones. However, since hormone levels are not determinants 
for the severity of hot flushes, the relative lack of an endocrine effect should not be a 
determinant of the efficacy of herbal medicines. In fact the therapeutic activity may be 
due to some other, as yet unknown, action of medicinal plants. 
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CHAPTER 3 
DEVELOPING A GENERIC HERBAL FORMULA 
3.1 Introduction 
One aim of this study was to develop a novel herbal formula to alleviate or ameliorate 
menopausal symptoms. The formula was based on the traditional practice of using 
`polypharmacy' for the symptomatic relief of menopausal symptoms, i. e. prescribing 
several herbs, typically four or five, rather than herbs individually. This approach was 
chosen because the study aimed to determine the benefits of herbal medicine, in the 
context of traditional practice, whilst working within the framework of a double blind 
randomised placebo-controlled trial. This method also addressed the Lord's report 
recommendation for more (CAM) research. A study using a single herb would not 
have been representative of the current practice of prescribing herbs as part of an 
individualised formula. Once the formula was completed its specifications were 
included in the research protocol for review by the university ethics committee (see 
Chapter 4 and Appendix I). The formula and placebo to be used were also described 
explicitly in the MLA-164 application (see Appendix VIII) to enable the MCA's 
panel of experts to form a judgement on issues such as safety, efficacy and quality 
control. These issues were addressed during the completion of the MLA-164 
application by including information, where available, from the literature to form an 
extensive database on each of the plants. This work has provided a unique record of 
the processes of developing a herbal formula with supporting data to substantiate the 
efficacy and safety of the formula. 
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3.2 
. 
Developing a Herbal Formula 
The approach that was used to design the herbal formula was based primarily on the 
traditional treatment approaches used by medical herbalists for menopausal 
complaints, which are documented in herbal pharmacopoeias. This method was 
appropriate because the treatment rationale was based on empirical knowledge, thus 
reflecting the practice of herbal medicine. Scientific articles were also obtained, when 
available, on in vitro and in vivo menopause research with herbs and also clinical 
trials. This helped to provide a further rationale for the inclusion of the herbs and 
helped to narrow the choice of sixteen initially identified herbs down to five. 
While the choice of herbs for inclusion in the formula aimed to reflect traditional 
usage, the need to develop a single generic herbal formula for all the participants does 
have limitations due to the standardised methodology. In the UK, herbal medicine is 
normally prescribed to patients from the synthesis of their symptoms into a unique 
individual prescription (Adams, 1999). While subjects presenting with menopausal 
symptoms will often experience similar symptoms such as hot flushes and night 
sweats, these will vary in severity, and many will present with additional symptoms 
such as headache, depression and palpitations (Campbell and Monga, 2000). A 
generic formula is preferable in research to providing individual formulae for patients 
because the results are easier to interpret, since the number of variables is kept to a 
minimum. Furthermore, a trial using a generic formula will have a greater possibility 
of being successful when using a Quality of Life (QoL) questionnaire if the formula is 
designed to encompass a broad range of symptoms, since patients are more likely to 
report improvements in their well-being. 
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The basis of designing a generic herbal formula is problematic since the MCA 
requires a scientific rationale to justify the inclusion of individual herbs within the 
formula, and the ratios and dosage regimes used. Historically, the development of 
herbal medicine has been based on empiricism and not on modem pharmaceutical 
methods. The limited pharmacological and toxicological data available on herbal 
remedies restricts the justification for including herbs in a formula. Justification for 
the dosage and formula based wholly on traditional use may not be accepted as 
sufficient supporting evidence for safety and efficacy. This is true even when citations 
are taken from the official herbal pharmacopoeias, such as the British Herbal 
Pharmacopoeia and the British Herbal Compendium, since the basis of these works 
comes primarily from practitioner based anecdotal evidence. 
There are a number of herbs traditionally used in the treatment of menopausal 
symptoms, which are derived mostly from empirical work recorded in old herbal 
pharmacopoeias or practitioner experience (see table 1). 
Table 1. Herbs that are cited in herbal pharmacopoeias for the alleviation of 
menopausal symptoms 
Botanical name Common name Family Main use 
Achillea millefollium L. Yarrow Compositae Antipyretic 
Avena sativa L. Oat Graminae Tonic 
Capsella bursa-pastoris L. Shepherds purse Cruciferae Diuretic 
Cimic fuga racemosa L. Black cohosh Ranunculaceae Antihydrotic 
Daucus carota L. Wild carrot Umbelliferae Antihydrotic 
Dioscorea villosa L. Wild yam Dioscoriaceae Adrenal tonic 
Eleutherococcus senticosus M. Siberian ginseng Araliceae Adaptogen 
Glycyrrhiza glabra L. Licorice Leguminosae Tonic 
Hypericum perforatum L. St. John's wort Hypericaceae Antidepressant 
Leonurus cardiaca L. Motherwort Labiatae Nervine 
Panax ginseng C. A. Meyer Ginseng Araliaceae Adaptogen 
Paeonia lactiflora Pall. Bai Shao Ranunculaceae Tonic 
Piper methysticum Forst. Kava Kava Piperaceae Anxiolytic 
Salvia officinalis L. Sage Labiatae Antihydrotic 
Tilia europea L. Lime flowers Tiliaceae Anxiolytic 
Vitex aznus castus L. Agnus castus Verbenaceae Hormone regulator 
Source: BHP, 1990; BHP, 1983 ESCOP, 1997. 
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A small number of herbs such as Cimicifuga racemosa have been subjected to 
scientific scrutiny and found to be efficacious for alleviating menopausal symptoms. 
From the literature review, it was found that Hypericum perforatum and Cimicifuga 
racemosa have been clinically proven as beneficial in symptoms associated with the 
menopause (Boblitz et al, 2000) and are used in clinical practice for menopausal 
complaints. Both herbs also have a good safety profile and pharmacological profile. 
Salvia ofcinalis has been demonstrated to have antihydrotic activity (Wake et al, 
2000; Perry, 1996) and according to the herbal pharmacopoeias, is indicated for hot 
flushes. It is an official drug of ESCOP with a good safety profile. Glycyrrhiza glabra 
has been found to be efficacious in several conditions such as gastric ulcer and 
hepatitis and is used traditionally in Western and Chinese herbal medicine as a tonic, 
and as part of formulae aimed at treating menopausal symptoms (Bensky, 1992). It 
has a good safety profile and its pharmacological properties have been researched. 
Dioscorea villosa has not been subjected to any major research, although its genus 
`equivalent' Dioscorea opposita (Shan Yao) is used in Chinese herbal medicine for 
menopausal complaints (Bensky and Gamble, 1992). It is a herb that is used by herbal 
practitioners for menopausal complaints and has no known contraindication or safety 
concerns related to its use. 
The dosage of the herbal formula was kept within the recommendations given in 
herbal pharmacopoeias for the therapeutic and safety dosage ranges. Hypericum 
perforatum and Cimicifuga racemosa were considered to be the principal therapeutic 
herbs given the research finding for the treatment of depression and hot flushes. 
Salvia ofcinalis and Dioscorea villosa were used at a lower ratio to H. perforatum 
and C. racemosa because traditionally, the dosage ranges used are lower. Glycyrrhiza 
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glabra was used at the lowest dosage. Its main use is as an adaptogen or `tonic' herb 
and is used to treat conditions, such as the menopause that are traditionally considered 
to manifest from exhaustion or the ageing process. Administration of G. glabra at 
dosages greater than eight grams per day has been found to cause hypertension 
(Bernardi et al, 1994) and therefore a dosage was used that allowed a large safety 
margin. 
The chosen formula and the ratio of herbs to be included are shown in Table 2. 
Table 2. The herbal formula- stating the botanical name, the quantities proposed 
and the pharmacopoeia reference. 
Herb % per 
capsule 
Weight per 
capsule 
Dosage per 
da 
Pharmacopoeia 
reference dosage 
Hypericumperforatum L 27.8% 0.125g 1.25g 2-4g/day (BHP, 1983) 
Cimicifuga racemosa L. 27.8% 0.125g 1.25g 0.3-2g/day (BHP, 1983) 
Dioscorea villosa L. 16.7% 0.075g 0.75g 2-4g/day (BHP, 1983) 
Salvia officinalis L. 16.7% 0.075g 0.75g 1-4g/day (BHP, 1983) 
Glycyrrhiza glabra L. 11.0% 0.05g 0.5g 1-4g/day (BHP, 1983) 
3.3 Placebo 
To ensure the double-blind placebo controlled trial remains valid, the herbal treatment 
and placebo need to be sufficiently matched to prevent the subjects from discovering 
which treatment they are receiving and inadvertently unblinding the trial. The two 
treatments need to be similar in size, colour, taste, texture and shape. Matching drugs 
can be more difficult for liquid medicines than tablets or capsules, because both smell 
and taste are likely to be noticeable. Capsules are the easiest to match, especially 
when they are opaque, since visual differences, taste, size, texture and smell, are 
eliminated. The material that is used as the placebo also needs to be as inert as 
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practicable. Rice flour was chosen for this study because it is economical and has no 
known medical benefits in menopausal symptoms. The type of capsule chosen was an 
0-sized methylcellulose opaque vegetarian capsule capable of holding 0.45g of the 
herbal formula and has no known medicinal property that would affect the results of a 
menopause study. 
3.4 Quality control 
To ensure patient safety and provide a framework for rigorous research, quality 
control methods needed to be used throughout the study to provide information on the 
chemical characterisation of the plants. Medicinal products intended for research and 
development trials are not subject either to EU marketing or manufacturing 
legislation, and thus, in principle do not require as rigorous quality control procedures. 
However, it was agreed in "Rules and Guidance for Pharmaceutical Manufacturers 
and Distributors" (1996) that medicinal products intended for human use should 
comply with the principles of good manufacturing practice (GMP) during the 
manufacture of products intended for use in clinical trials. 
Deciding on the type of quality control methods and the specification required for an 
MCA submission using an MLA- 164 application was difficult since no 
comprehensive information was available from the MCA to instruct the applicant on 
the types of tests necessary to satisfy their requirements. The MLA-164 document 
outlines criteria that must be fulfilled in terms of principles and guidelines. To satisfy 
the requirement of the MLA-164, quality control procedures and safety requirements 
need to be established and documented by the producer and manufacturer, including 
procedures relating to harvesting and storage, and identity and stability tests. 
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3.5 Harvesting and Storage 
The main requirements for harvesting and storage are to ensure that drying equipment, 
storage areas, and vehicles used are clean and free from contaminants. Crude plant 
material that is unprocessed should be kept in a clean, separate storage area that is 
ventilated and protected from insects and animals. The time of harvesting, 
geographical origin, stage of growth, drying and storage conditions and any chemical 
treatment should be recorded, (Rules and guidance for pharmaceutical manufacturers 
and distributors, 1996). Specifications for the starting material should include as far 
as possible: 
" Botanical name, including the author, for example, Linnaeus. 
" Origin of the plant, including the country and area. 
" Cultivation time, harvesting time, and collection procedures. 
" Details of any pesticides used. 
" Details of the part(s) of the plant used and the stage of growth. 
" If the plant material used is dried, the drying system should be stated. 
" The plants should be micro-and-macroscopically examined & described. 
9 Suitable identification tests should be used, including tests for known active 
ingredients, or markers and reference specimens. 
" An assay of active constituents or markers. 
" Determination of potential pesticide contamination. 
" Tests for insect, fungal and microbiological contamination. 
" Test results of heavy metal contamination or adulterants. 
Source: (Rules and Guidance for Pharmaceutical Manufacturers and Distributors, 
1997). 
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3.6 Authentication and Documentation 
The MCA's requirements for authentication tests and documentation are to ensure that 
the correct genus and species are obtained, to safeguard patients from potential toxic 
plants being inadvertently used and to provide a documented history of the drug 
substance. A botanist, who is able to issue a voucher number, can be consulted for this 
purpose, since identifying the herbs against a specimen is unlikely to be acceptable. 
Further measures to confirm the identity include: High Performance Liquid 
Chromatography (HPLC), Gas Chromatography Mass-Spectroscopy (GC-MS) and 
Thin Layer Chromatography (TLC). 
Guidelines have been given for the labelling of medicinal products in clinical trials, 
which include: 
" Name of the sponsor. 
" Pharmaceutical dosage form, route of administration, quantity of dosage units 
(and name of the product and strength/potency in case of an open trial). 
" The batch and/or code number to identify contents and packaging operation. 
" The trial subject identification number (where applicable). 
" Directions for use. 
" State `For clinical trial use only'. 
" The name of the investigator (if not included as a code in the trial reference 
code). 
"A trial reference code enabling identification of the trial site and investigator. 
" The storage conditions. 
" The period of use (use by date, expiry date or re-test date as applicable) in 
months/year. 
" The warning: `Keep out of reach of children' except when the product is for 
use only in a hospital. 
Source: Rules and guidance for pharmaceutical manufacturers and distributors 
(1996). 
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3.7 Stability Testing 
The purpose of stability testing is to establish how long the product can be safely used 
whilst retaining acceptable levels of quality and efficacy once the container is opened. 
A requirement of MLA-164 is to ensure that the active constituent(s) and non- 
characterised compounds (unidentified constituent) in the herb(s) meet limits for 
degradation set by the International Conference of Harmonisation (ICH, 1996). The 
tolerances are set at ±10%, if the active constituent(s) are not known or, ± 5% when 
the active constituent(s) are known. This criteria set for pharmaceutical drugs applies 
to herbal products when they are either sold as medicinal products, or used in clinical 
trials. The MCA's guidelines recommend using a minimum of two batches, preferably 
on a production scale, or a pilot study scale if this is representative of the scale of 
production. 
Being an organic product, herbal medicine naturally decays through oxidation, and 
evaporation, especially when the plant material is fresh, or contains volatile oils. 
Therefore, the chemical profile of each batch will vary. It is desirable to use a single 
plant batch in a research trial to ensure maximum uniformity of the drug substance, 
since chemical assays may vary between different batches depending on their origin, 
growth conditions and the date of harvest (Thieme, 1985). Discrepancies in 
processing procedures such as time variation between harvesting and storage may 
further contribute to variations in constituent concentrations and affect quality and 
uniformity. 
The difficulty of meeting the MCA's stability limits set by the ICH was highlighted 
by Bilia et al (2001) who tested the thermal stability and photostability of Hypericum 
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perforatum. Photostability tests found all constituents (flavonols, hyperforins and 
hypericins) to be photosensitive, whilst long term thermal stability tests revealed low 
stability of less than four months for hyperforins and hypericins. Even when ascorbic 
and citric acid were added as antioxidants, the degradation exceeded the ICH limits. 
In a further study, Sloley et al, (2000) found that the chemical profile of standardised 
Hypericum extracts varied substantially in the concentration of various characteristic 
chemicals, whilst Southwell and Bourke (2001) found seasonal variations of hypericin 
and pseudohypericin in the range of 100ppm to 5000ppm. 
3.8 Stability Program and Test Conditions 
During the stability study, the product should be stored at ICH recommended 
conditions, which is 25 C/60% relative humidity for the Northern hemisphere. The 
physical, chemical and microbiological properties should be evaluated, using tests 
appropriate to the formulation. There is no standard stability criterion utilised by the 
MCA and justification may be required if certain tests are either omitted or do not 
meet limits. Most stability studies require physical, chemical and microbiological 
testing such as: 
i) Physical tests: Colour, clarity, closure integrity, presence of particulate matter 
and particle size, moisture content. 
ii) Chemical tests: Active substance assay(s), antimicrobial preservative and 
antioxidant content(s), degradation product level(s) and pH. 
iii) Microbial tests: Total viable count and antimicrobial determination. 
The stability studies are usually conducted using normal and accelerated test 
conditions. Reducing or omitting pesticide residues tests is allowed if the applicant is 
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able to demonstrate that the herbal drug is grown under strict organic conditions and 
any potential contamination from adjacent plantations has been eliminated. 
A stability study needs to have run for a minimum of 6 months duration at the time of 
submission. A production batch manufactured post-approval should be placed on long 
term stability studies (minimum of 12 months) using the same stability protocol and 
submitted when available. The test methods need to be described in detail and the 
results summarised, for example, using tables or graphs. A public accredited analyst 
with prior experience of phytochemical analysis is desirable to meet the quality 
standards. Samples of each production batch should be retained for at least one year 
beyond the final shelf life, or two years after the completion of the clinical trial 
whichever is the longest. Source: Rules and guidance for pharmaceutical 
manufacturers and distributors (1996). 
Table 3. ICH Test Conditions for Stability Studies 
Test conditions Conditions Minimum time period at 
submission 
Long term testing 25 C±2 C/ 60% Relative 12 months 
Humidity 5±% 
Accelerated testing 40 C± C/ 70% Relative 6 months 
Humidity 5±% 
Testing frequency 
Testing is performed normally every 3 months over the first year and every six 
months over a second year, and then annually if further testing is required. 
Microbiological testing needs to be performed to ensure microorganisms are within 
safety limits or absent for pathological organisms. The European Pharmacopoeia 
(2001,4t' ed. ) provides microbiological limits for microorganisms as follows: 
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" Total viable count: Not more than 1,000,000 
" Fungi not more than 100,000 per g 
" Absence of Escherichia coli 
" Absence of Salmonella 
3.9 Summary 
When developing the herbal formula, consideration was given to the choice of herbs 
based on traditional use, since this forms the basis of herbal medicine practice. 
Choosing herbs for a clinical trial based on the outcomes of individual constituents 
used in in vitro studies will not be suitable since the effects will probably be different 
from whole plant extracts. The formula was developed specifically to address the 
wide range of symptoms that menopausal women may present with, such as hot 
flushes, depression, anxiety, night sweats and lethargy. The placebo was adequately 
matched to prevent unblinding and the filling material (rice flour) was chosen to be as 
inert as practicable. Quality control procedures were identified for the study that 
would be appropriate to satisfy the requirements of the IvICA, such as harvesting and 
storage procedures for medicinal plants. The identification, stability and safety testing 
procedures were developed for the study in preparation for a clinical trial. 
28 
CHAPTER 4 
RESEARCH STUDY DESIGN 
4.1 Introduction 
To provide a framework for testing the herbal formula in a double blind placebo 
controlled trial and to demonstrate to the MCA that the study is methodologically 
robust, a research study was developed detailing how the project would be 
implemented. The guidelines for this study design were based on the principles and 
methods suggested by Pocock (1998), and Friedman (1996), which were then 
specifically adapted to the needs of this project. Several factors were considered when 
designing the study, such as ethical considerations, the viability of acquiring sufficient 
patients and ensuring the study is well designed to avoid biases and flawed research 
methodology. The following tasks were developed specifically for this study and 
provided a unique record of the prerequisites of a clinical trial for assessing the 
efficacy of herbal medicine in the treatment of menopausal symptoms: 
9 The key elements to produce a research protocol for subsequent assessment by 
an ethics committee. 
" The production of an operations manual to enable clinicians to administer the 
study. 
" Recruitment procedures to ensure that sufficient numbers of patients are 
entered into the study. 
" The choice of appropriate questionnaire tools to assess patients' response to 
treatment intervention. 
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" The calculating of the power of the study to estimate the number of patients 
required, ensuring that treatment differences are detected. 
" Randomisation procedures to reduce the potential for bias. 
4.2 Research Protocol 
To gain initial approval for the clinical trial, a protocol outlining the aims and 
objectives of the study was submitted to the School of HeBES ethics committee. The 
protocol is attached (Appendix I). The Declaration of Helsinki (WMA, 1964) provides 
a framework for ethical consideration, however each committee will have its own 
guidelines to follow. Clinical trials share several core features that need to be 
addressed to enable an ethics committee to reach a decision (see below). 
The main features of a research protocol are listed below: 
" Background to the study 
" Aims of the project 
" Research question(s) 
" Methodology 
" Patient recruitment 
" Inclusion criteria 
" Exclusion criteria 
" Data collection procedures 
" Data analysis techniques 
" Planned research outputs 
" Timescale for the proposed research 
" Patient consent 
The protocol developed for this research forms the basis of the study and essentially 
comprises of two key sections: the methodology, which is specific to the study and 
patient consent which, whilst being pertinent to the study, shares many features that 
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are applicable to other clinical trials, since patients' rights will be in accordance with 
the Helsinki agreement. 
4.3 Background 
The background to the study enables both the ethics committee and the MCA to 
understand why the work is necessary and what it potentially offers in terms of new 
research findings, since it would be unethical to subject patients to 12 weeks of 
medication if the design offered nothing different from previous research. An 
alternative to HRT is desirable since, as stated previously, for many women, HRT 
may not be a viable option due to contraindication and concern for the side-effects. 
The aim of the study stated in the research protocol is to determine whether the herbal 
formula is efficacious for the alleviation of menopausal symptoms. 
4.4 Methodology 
The protocol includes a methodology section outlining how the study will operate. A 
set of inclusion and exclusion criteria was developed specifically for menopausal 
women to ensure that only patients suitable for the trial were enrolled. The key 
criterion was to ensure that patients were actively experiencing menopausal 
symptoms, rather than simply being menopausal. This necessitated the development 
of a symptom scoring list to delineate subjects who were eligible for the study, from 
those who were not. Patients with potentially life-threatening medical conditions, 
mental health problems or patients receiving certain prescription drugs (Appendix I) 
would be screened out by an initial telephone administered health check to avoid 
ethical and medical dilemmas. The treatment duration that patients would be exposed 
to was set out in the proposal to enable committee members to determine whether the 
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proposed treatment regime was safe and ethical. The length of treatment is an 
important consideration since it can determine the outcome of the study, as 
insufficient time could produce a false-negative, whilst a study that is too long will 
require more resources. Furthermore, it would be unethical to expose patients longer 
than was necessary to both medication and trial participation. 
4.5 Patient Consent 
Patient consent forms were produced specifically for this study to ensure patients 
were not unwittingly subjected to any undue risk or denied their rights, as set out in 
the Helsinki agreement. The patient consent forms described the nature of the study 
and explained each aspect of subject participation, including the potential benefits and 
risks that they would be exposed to. It was made clear to the subjects in the consent 
form that they would receive either the placebo or the new treatment, and that the 
placebo had no benefit. This was to emphasise to subjects that there was an equal 
possibility of receiving the placebo, which would have no therapeutic benefit. The 
standard clause section was included because it is important to state the rights that 
patients have and to clarify what they are agreeing to in the consent letter (Appendix 
I). 
4.6 Operations Manual 
The operations manual was designed specifically for this study to enable the 
practitioner to administer the trial in a step-by-step process through each patient visit. 
The information contained within an operations manual should strive to be as 
comprehensive as possible, so that every conceivable eventuality is considered. Clear 
criteria of the entry requirements and procedures to be followed by the practitioners 
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are important. The operations manual (Appendix II) used in this study is partly an 
extension of the protocol since the main points of the protocol (background, patient 
screening and treatment) are restated in the document, but with more emphasis on 
how the study should be conducted. 
4.7 Practitioner Instructions 
Instructions were developed to provide information on how long the consultations 
should last to ensure that the trial would be kept to schedule. The operations manual 
also sets out procedures for checking patient eligibility, obtaining informed consent, 
administering the questionnaires, dispensing the medicine, and providing patients with 
adverse event reporting cards to monitor potential side-effects. 
4.8 Case History Notes 
Patient case history notes were developed specifically for the research trial. The case 
history notes were designed to provide information in four areas: 
1. Personal details 
2. Demographic information 
3. Screening questions 
4. Patients' medical status 
The patient's personal details (name, address, telephone number) were included to 
enable practitioners to identify patients for appointment purposes and to ensure that 
patients could be contacted in the event of an emergency. The demographic questions 
(weight, height, marital status, occupation, number of children, cigarette smoking, 
alcohol usage and exercise) were incorporated to allow comparisons between patient 
groups to check for homogeneity and to enable comparisons with other menopause 
study populations. Screening questions were developed for the study to ensure only 
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subjects that met the entrance criteria were enrolled. The screening was to be repeated 
again at the initial appointment to recheck eligibility, since patients may have 
subsequently become ineligible during the intervening period. 
The patient's health status would be evaluated from a systematic enquiry of their 
medical history including: the cardiovascular, respiratory, gastrointestinal, urological, 
musculoskeletal, nervous and reproductive system, and by checking their blood 
pressure. Physical examinations would be conducted only if a medical need arose. 
A method of pre-screening patients by telephone was developed for the study to 
ensure that only eligible participants were enrolled onto the clinical trial. This type of 
pre-screening is useful to save practitioner time and is therefore more economical. 
4.9 Patient Recruitment and Appointments 
It is necessary before a clinical trial can commence to have recruited enough subjects 
for the study. A study with too few participants is unlikely to have sufficient power to 
detect any real treatment difference and therefore a strategy for patient recruitment 
needs to be employed. An advertising strategy using local newspapers and radio is 
one method of raising public awareness. The cost of newspaper advertising (Table 4) 
can be considerable and other strategies such as displaying posters in local hospitals 
and GP surgeries should be considered to recruit patients. 
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Table 4. Typical costs of newspaper advertising 
Newspaper Type Size of 
Advertisement 
Readership Cost of single 
advertisement 
Scotsman Daily '/o page 209,000 £1,244.40 + vat 
Evening News Daily '/4 page 173,000 £1,152.60 + vat 
Herald & Post Free paper '/4 page 260,000 £999.64 + vat 
South Wales Echo Daily '/4 page 235,000 £1,119.28 + vat 
Wales on Sunday Weekend '/4 page 199,000 £ 408.00 + vat 
Western Mail Daily '/4 page 200,000 £826.00 + vat 
Posters can help to attract the attention of potential subjects, and leaflets situated 
nearby for patients to take are useful to provide more details for the interested reader. 
The poster (Appendix III) was developed for the menopause study with the aim of 
being eye-catching and the leaflet (Appendix IV) was designed to provide additional 
information on the study. 
To enable patients to be recruited and studied for 12 weeks, time allocation slots were 
devised (see Appendix V) to enable patients to be enrolled onto the study and treated 
sequentially. Four appointment days were given which enabled the patients to be 
treated and reassessed as follows: 1 S` appointment (week one), 2 °d appointment (week 
2), 3rd appointment (week 7), 4th appointment (week 12). In the example of this 
process in Appendix V, 45 patients (groups A-F) can be enrolled and assessed on four 
occasions over a four-month period. 
4.10 Questionnaire Development 
To determine a patient's response to medical intervention, an instrument was required 
that would accurately measure any treatment induced changes. There is no objective 
instrument that can determine improvements in menopausal symptoms, since 
hormonal levels are not reliable predictors of either menopausal status or symptom 
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severity (WHO, 1996). One method that can be used to assess treatment interventions 
is a Quality of life (QoL) questionnaire. By definition, QoL is a subjective parameter 
and direct questioning is therefore a simple and appropriate way of gathering 
information about how patients feel and function. The content of QoL instruments 
typically concern psychosomatic factors (Table 5). These subjective QoL instruments 
should not be perceived as inferior to objective measurements. For example, QoL 
instruments have been found to be superior to conventional rheumatological measures 
as predictors of long-term outcomes in rheumatoid arthritis in terms of both morbidity 
and mortality (Wolfe and Cathey 1991; Leigh and Fries, 1991) 
Table 5. Typical dimensions of quality of life instruments 
Physical function- Mobility, self care 
Emotional function- Depression, anxiety 
Social function- Intimacy, social support, social contact 
Role performance- Work, housework 
Pain- Frequency, severity 
Other symptoms- Fatigue, nausea, disease specific symptoms 
When choosing a QoL questionnaire, it is important to consider how well it will 
perform and this can be determined from its psychometric properties (see Table 6). 
An instrument needs to be reliable, i. e. it must produce the same results on repeated 
use under the same conditions. This can be examined by test-retest reliability. An 
instrument needs to be valid, i. e. it measures what it was designed for. Validity is 
initially checked by face validity, i. e. by asking whether the instrument seems to cover 
the full range of relevant topics. A more formal approach is to examine construct 
validity, which is concerned with the pattern of relationships of the QoL instrument 
with other more established measures, for example, laboratory or clinical measures. 
Sensitivity to change is a crucial requirement for a QoL instrument since a subtle 
response may be undetected if the instrument lacks sensitivity. Sensitivity is an 
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important aspect in any QoL questionnaire since the more responsive an instrument is, 
the greater its ability to detect treatment effects, and thus the sample size used can be 
lowered. 
Table 6. Factors influencing the selection of instruments 
Measurement property Type of instrument Methods of administration 
Validity Generic Self-administration 
Reliability Condition specific Interviewer administration 
Responsiveness Dimension specific Cultural setting 
Source: (Fletcher et al 1992) 
There are two basic types of QoL questionnaire: generic and condition specific. A 
consideration for this study was whether to use a generic or condition specific 
questionnaire as both have advantages and disadvantages (see Table 7). Generic 
instruments cover a broad range of QoL dimensions in a single instrument. Amongst 
the more commonly used generic tools are the Sickness Impact Profile, the 
Nottingham Health Profile, Quality of Well-being Scale and the Short form or SF-36 
Health Survey (Schneider et al, 2000). These generic measures have the advantage of 
covering multi-dimensional aspects of quality of life in a wide range of health 
problems, although evidence suggests they may be less responsive to treatment 
induced changes (Fitzpatrick et al, 1992). 
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Table 7. Benefits and shortcomings of Generic as compared with Condition 
Specific questionnaires 
Generic Disease/Treatment Specific 
Comprehensiveness Comprehensive & wide in scope Deliberately narrow in scope 
& scope 
Applicability General applicability over populations; Targeted to a specific patient 
low in precision group, condition or treatment; 
high in precision 
Generalisability Can be generalised over populations Focuses on its target and cannot 
and used for comparisons, norms or be used for comparisons; norms 
references values available or reference values not applicable 
Familiarity Well-known with a wide spread use Unfamiliar, used to a limited 
over many years extent 
Relevancy Too general for a specific patient Highly relevant to its target 
population; low in patient and clinician population; credible to patient 
credibility and clinician 
Responsiveness Less responsive to treatment induced Highly responsive in detecting 
Chan es small, clinically relevant changes 
Practical, motivational Lengthy, time consuming, less Short, acceptable 
considerations acceptable 
Source: (Wiklund and Dimenas, 1990) 
Condition specific instruments have the potential benefit of reducing patient burden 
by being more concise, increasing acceptability by including only relevant dimensions 
and they are more responsive to health interventions. A disadvantage is that they may 
inadvertently exclude some health effects by being too narrow. Menopause specific 
instruments available include the Women's Health Questionnaire (WHQ) (Hunter, 
1994), the Greene Climacteric Scale (GCS) (Greene, 1998), Blatt-Kupperman Index 
(BKI), (Alder, 1998) Menopause Rating Scale (MRS) (Schneider, et al 2000), 
Menopause Symptom List (MSL) (Perz, 1997) and the Menopause-specific quality of 
life instrument (MENQOL) (Hilditch et al, 1996). 
The ability of QoL instruments to detect treatment-induced changes over time was 
examined by Wiklund et al (1998) in a study evaluating the effects of oestrogen 
therapy. The Kupperman Index, the Visual Analogue Scale (VAS), the Women's 
Health Questionnaire (WHQ), the McCoy Sex Scale, the Psychological General Well- 
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being Index (PGWBI) and the Nottingham Health Profile (NHP) (Table 8) were 
evaluated for size effect differences to oestrogen therapy. The menopause specific 
QoL instruments were found to be more responsive to treatment than the generic QoL 
questionnaires. 
The Kupperman index is a menopause specific QoL questionnaire that has been used 
in early menopause studies and is sensitive to change. It was developed in the 1950's 
and later revised by Blatt, into the Blatt-Kupperman index (BKI). It is limited by 
focusing primarily on hot flushes, whilst factor analysis has only established test re- 
test reliability (Hilditch et al, 1996). Critiques of the BKI, such as Greene (1998), 
have stated that menopausal symptoms are a multifaceted phenomenon with differing 
aetiology and therefore should be measured and summated to yield scores within 
categories like somatic, vasomotor and psychological rather than summating all 
values into a single score as in the BKI. Alder (1998) considers the BKI wording as 
archaic and regards its application as being no longer viable. 
Table 8. Treatment effect differences for generic and menopause specific QoL 
auestionnaires 
Total Score Oestrogen Placebo Treatment 
comparison 
Kupperman Indext 2.46 0.84 1.62 
Visual Analogue Scale (VAS)t 1.24 0.34 0.90 
Women's Health Questionnairet 1.09 0.32 0.77 
McCoy sex scale* 0.36 0.01 0.35 
Psychological General Well-being Index * 0.69 0.34 0.35 
Nottingham Health Profile* 0.69 0.20 0.49 
Source: (Wiklund et al, 1998) 
t Menopause specific QoL questionnaire 
* Generic QoL questionnaire 
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The Greene Climacteric Scale (GCS), the Menopause Rating Scale (MRS), the 
Menopause Specific Quality of Life instrument (MENQOL) and the Women's Health 
Questionnaire (WHQ) are all menopause-specific quality of life instruments that use 
different subscales to categorise questions (Table 9). The Greene Climacteric scale 
was developed to focus on core climacteric symptoms and consists of 11 questions. It 
therefore has an advantage over the 36-question WHQ by being easier to administer 
and analyse, although being shorter, it provides less information on different 
symptoms. The MRS has similar advantages and disadvantages to the GCS, again 
having only 11 questions. Its psychometric properties have been established but it has 
not been used as widely as the WHQ in clinical trials. MENQOL was developed in 
1996. This questionnaire has been subjected to factor analysis for reliability and 
validity, and has been shown to be sensitive to change (Hilditch, et al 1996). One 
minor criticism of MENQOL by Hilditch et al (1996) is that the construct validity for 
the somatic domain was found to be low. However, overall, the merits for this 
menopause specific QoL instrument are satisfactory. Table 9 shows the subscales 
used in the menopause specific QoL questionnaires. 
Table 9. Subscales used for the factorially derived questionnaires 
WHQ (36)' GCS (i i) MRS (11) MENQOL (30) 
Vasomotor Vasomotor Somatic Physical 
Somatic Somatic Psychological Psychological 
Anxiety Anxiety Urogenital Sexual 
Depression Depression Working life 
Cognitive 
Sleep 
Sexual function 
Attraction 
Menstrual 
s toms 
The number of questions contained in each questionnaire 
40 
4.11 Questionnaires Chosen for the Clinical Trial 
The WHQ has been used in several clinical trials to monitor treatment-induced 
changes over time. It is a 36-item self-administered menopause specific instrument 
that provides a detailed examination of minor psychological and somatic symptoms 
experienced by menopausal, perimenopausal and postmenopausal women. The items 
are combined into nine dimensions: depressed mood, somatic symptoms, cognitive 
difficulties, vasomotor symptoms, anxiety/fears, sexual functioning, sleep problems, 
menstrual symptoms and attractiveness. It has been subjected to factor analysis, which 
correlates symptom clusters to form groups (Hunter, 1995). It is then possible to 
construct an instrument consisting of several separate subscales that measure different 
aspects of the symptom picture (Greene, 1999). It was developed in England, and has 
been demonstrated to be valid in terms of reliability and sensitivity and was chosen 
for this study as it offered a menopause specific QoL tool sensitive to treatment 
effects with proven psychometric properties (see Appendix VI). 
A second measurement tool was chosen for the study to provide a further evaluation 
of potential therapeutic response based on the patient's own personal experiences. 
This may potentially provide a more sensitive measure of treatment induced changes 
compared with the WHQ since patients will be able to choose the symptoms that are 
affecting their lives and then evaluate any changes that have occurred. Furthermore, it 
enables a perspective to be gained from patients that may not be acquired from an 
`off-the shelf pre-set questionnaire. The Measure Yourself Medical Outcome Profile 
(MYMOP) was developed by Patterson (1996), and is a patient specific measure that 
allows individual patients to choose the symptom to be monitored. While MYMOP is 
not specific to the menopause, it attempts to incorporate patient's personal 
experiences of illness into the measurement process. The patient is involved in 
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deciding which symptoms or aspect of their illness are affecting them the most. 
Patients choose an activity that they consider important and rate how this activity is 
affected by their health problems. Patients also rate their well-being using a likert- 
scale over a 7-day period (see Appendix VII). 
4.12 Data Analysis 
The data generated from the questionnaire(s) can be analysed using the Statistical 
Program for Social Science (SPSS). Non-parametric tests (Wilcoxon matched-pairs 
signed-rank test and the Friedman test) can be used to compare patient change over 
time. 
4.13 Statistical Power of the Study 
The purpose of calculating the power of a study is to maximise, as far as practicable, 
the chances of finding a real and important clinical effect if it is present, and to be 
fairly certain that a negative outcome indicates no real treatment difference exists, 
thus reducing the possibility of a false-negative. Sample size calculations are 
important both practically and ethically. A study with an overlarge sample may be 
deemed unethical through involvement of unnecessary patients and will incur extra 
costs, whilst a study with too few patients will be unable to detect clinically important 
effects (Altman, 1980). 
To calculate a sample size, the treatment differences need to be known, or at least 
there should be a good idea of where they may lie. Often, before a full-scale clinical 
trial is conducted, pilot studies are used to derive toxicological information and 
treatment scores can be gathered to enable an estimate of the sample size required. For 
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this study, no information was available to estimate the size of any treatment effects 
with the herbal formula. The sample size was calculated by extrapolating from the 
treatment differences found in a study by Murkies et al (1995), which used soya as the 
treatment for menopausal symptoms and wheat flour as the placebo. Calculating the 
sample size based on the treatment effects of HRT trials would have been unsuitable 
and misleading since hormone replacement therapy is not comparable with herbal 
medicine because our study was not attempting to replace depleted endogenous 
oestrogens with exogenous oestrogens. Murkies's study shared similar characteristics 
to the proposed trial in that both treatment and placebo were derived from plant 
material (soya and wheat flour). This trial reported the incidence of hot flushes to be 
significantly reduced in the group receiving soya (40% reduction) compared with the 
placebo group given wheat flour (25% reduction). Thus p' = 25 and p2 = 40, where p' 
is the percentage of successes expected from one treatment and p2 is the percentage of 
successes on the other treatment which one desires to detect as being different from p' 
(Pocock, 1998). 
To calculate the trial size, some parameters need to be chosen for the equation. 
1) The level of significance for the statistical test needs to be stated. 
Using a Wilcoxin signed-rank test to compare the scores between the 
treatment and placebo groups, a 5% significance level was chosen as showing 
evidence of a treatment difference denoted as a. 
a= the level of the significance test used for detecting a treatment 
difference. A type I error (a) results when it is falsely concluded that there is a 
difference between the groups. The a value represents the pre-established 
acceptable probability of type I error (often set at a=0.05). 
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2) The type of result anticipated with the standard treatment needs to be 
determined. 
Wheat flour was chosen as the standard treatment, based on the findings by 
Murkies et al (1995) who found a 25% improvement in vasomotor symptoms 
(p' = 25). 
3) A decision needs to be made on what size of treatment differences is important 
to be detected and with which degree of certainty. 
This depends on what is the smallest difference that is considered of such 
clinical value that it would be undesirable to fail to detect. Thus a percentage 
can be set dependent on the clinical importance, for example, 50,60,70,80, 
90,95%. For this calculation, a 90% confidence level was set. 
P, a type II error denotes the mistake of concluding that there is no difference 
between groups, i. e. (pI- p2 ) when a clinically important difference exists, and 
the probability of it occurring is represented by 0 often set between 0.05,0.1, 
0.2 and 0.5. 
1 -ß = the degree of certainty that the difference p' - p2, if present, would be 
detected (often at set I -ß = 0.90). 
The required number of patients for the trial, n, is obtained using the following 
formula where p1= 25 and p2 = 40. 
p'x(100-p' )+ p2 x (100-p2) 
n=xf (a, ß) 
(P - P) 
where f (a , 
ß) is a function of a and ß, the value of which is derived from 
Table 10. 
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Table 10. Values of f (a , ß) to be used in formula for required number of 
a (type I error) 0.1 
0.05 
0.02 
0.01 
Source: (Pocock, 1998) 
Therefore, 
25x75+40x60 
n= 
(-15) 
(type II error) 
0.05 0.1 0.2 0.5 
10.8 8.6 6.2 2.7 
13.0 10.5 7.9 3.8 
15.8 13.0 10.0 5.4 
17.8 14.9 11.7 6.6 
x 10.5 = 199.5 = 200 patients required for each group 
It was found from a power calculation test using a 0.05 level of significance, that a 
minimum of 200 patients for each treatment group is necessary to be able to conclude 
at a 90% confidence level that a genuine treatment effect has occurred. 
4.14 Randomisation 
To minimise bias either knowingly or unwittingly, patients enrolled onto the study 
need to be allocated treatment in such a way that the clinical team involved is unaware 
of which type of treatment patients are receiving. One method is to assign random 
numbers to patients enrolled on the study. 
For allocation of two treatments, odd and even numbers can be used to indicate 
treatments A and B respectively. From Table 11, an arbitrary number is chosen as a 
starting point and also the direction in which to read the table. For example, the first 
10 two-digit numbers from a starting place in column 4 are 95,93,8,13,98,88,78, 
39,36,30 which translate into the sequence `A ABABBBAB B' for the first ten 
patients. 
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Table 11. Random numbers list 
83 97 83 53 56 
20 68 35 73 83 
52 45 84 95 85 
82 52 56 93 80 
39 71 97 8 62 
99 72 79 13 36 
89 54 34 98 96 
43 99 69 88 52 
02 78 09 78 17 
16 84 89 39 17 
14 44 24 36 23 
41 20 39 30 87 
94 77 75 77 18 
81 24 33 39 93 
71 86 22 01 11 
The weakness of this method is that because the numbers are random, A and B will 
not be split evenly. Thus, more patients could be given the placebo rather than the 
treatment. For a small sample size, this could mean a false-negative, i. e. a real 
undetected treatment effect. The probability of a random numbers list creating 
unbalanced treatment groups is shown in Table 12. 
Table 12. The probability of imbalances occurring in two treatment groups for 
various trial sizes 
Total number 
of patients 
Differences in numbers 
with a probability of 0.05 
Differences in numbers 
with a probability of 0.01 
10 2: 8 1: 9 
20 6: 14 4: 16 
50 18: 32 16: 34 
100 40: 60 37: 63 
200 86: 114 82: 118 
500 228: 272 221: 279 
1000 469: 531 459: 541 
Source: (Pocock, 1998). 
Random number lists can be checked to see if the table generates any serious 
imbalances. If this happens, a new list can be generated. Block randomisation (also 
called restricted randomisation) is another method to ensure the treatment group split 
is similar. 
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4.15 Summary 
The production of a research protocol needs to cover all the major elements of the 
study in order to inform the reviewer of the aims and objectives, and to be able to 
demonstrate that the work is feasible and ethical. This was achieved by producing the 
protocol based on the principals of the Helsinki agreement and the research guidelines 
of the School of Health, Biological and Environmental Sciences. The operations 
manual is an essential document to enable clinicians to implement the study uniformly 
and therefore avoid clinical errors occurring. This task was accomplished by stating 
the aims and objectives of the trial and providing detailed instructions for the 
clinicians, and developing screening questions and case notes specifically for the 
subjects being investigated. Patient recruitment is a crucial aspect of any research 
project since difficulties may be encountered in acquiring sufficient patient numbers 
for a trial. The costs of advertising were investigated and they were found to be 
relatively high. Therefore, consideration needs to be given to the considerable 
financial resources required in advertising if the research budget is limited. Recruiting 
patients by advertising in GP's surgeries is one method of both reducing advertising 
costs and sourcing potential subjects. 
From the preliminary background research it became apparent that there were no 
objective assessment tools available to measure symptom changes in menopausal 
women. It was found that questionnaires could provide a useful tool to assess 
treatment interventions accurately and sensitively, which can also be more reliable 
than objective tools. This study found that there are several QoL questionnaires 
available to assess changes in menopausal symptoms. It was determined from 
examining the psychometric properties of each questionnaire that the WHQ was the 
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most appropriate for the study. Calculating the number of patients required for the 
study is essential to provide meaningful data from the statistical results. A power 
calculation was performed using existing data from a similar study to determine the 
number of patients for this study. It was found that 200 patients per treatment group 
were necessary to detect a genuine treatment affect. Randomisation procedures were 
developed to avoid biases with treatment allocations. It was found that the method of 
patient randomisation could be achieved by the use of a random numbers list. This 
method can also take the form of a software package specifically designed for the 
purpose. 
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CHAPTER 5 
CLINICAL TRIAL APPLICATION TO THE MEDICINES CONTROL 
AGENCY 
5.1 Introduction 
The preparatory work for this study, which included the research design and 
methodology was undertaken, in part, to demonstrate to the University ethics 
committee that the study was both feasible and ethical and that the study was at a stage 
where it could be implemented. This initial work also provided the framework for the 
completion and submission of the MLA-164 application to the MCA in order to seek 
permission to conduct the clinical trial. 
Clinical trials utilising herbal medicines present a particular difficulty for the MCA to 
evaluate because the MLA application forms are designed for pharmaceutical drugs, 
and not complex herbal products. The latter contain a multitude of constituents, some 
of which have not been identified and the majority of those identified have not had 
their pharmacological properties established. The rationale for the herbal intervention, 
choice of herbs, stability studies and the research design, as discussed in earlier 
chapters, are an integral part of the submission. This chapter elaborates on the 
procedures necessary to complete a MLA- 164 application and the particular problems 
associated with a submission using herbal medicines rather than a single chemical 
compound. A 54-page MLA-164 application (Appendix VIII) was completed for this 
study in order to gain approval from the MCA to conduct a clinical trial, and in doing 
so provides a novel insight into an area of research, which so far has been poorly 
understood. 
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5.2 The Medicines Control Agency's Remit 
The role of the Medicines Control Agency is primarily to safeguard public health by 
ensuring that all medicines on the UK market meet appropriate standards of safety, 
quality and efficacy. This remit also applies to medicines given to patients enrolled 
onto clinical trials. The control of medicines in the UK for marketing or clinical trials 
purposes is arranged through a system of licensing and conditional exemptions which 
have been established in EC legislation and the Medicines Act 1968. Licences or 
exemption certificates are only issued once the criteria for the safety, efficacy and 
quality of the product are satisfied. Restrictions are placed on the claims made in 
promotional advertising of the medicinal product. The MCA is also required to 
monitor the safety of licensed medicinal products and to take action when adverse 
effects are recognised. The MCA's responsibilities, as an Executive Agency of the 
Department of Health, are to the Secretary of State for Health. 
5.3 Clinical Trial Exemption Scheme 
Previously, all new active substances were evaluated under a clinical trial certificate 
(CTC). In 1981, a new scheme was introduced, called the Clinical Trial Exemption 
Scheme (CTX) or the Doctors and Dentists Exemption Scheme (DDX) that were 
aimed at speeding up the application process. The key point is that a manufacturer's 
licence is no longer required for a clinical trial. To obtain a CTX certificate, the 
supplier of the therapeutic agent needs to notify the MCA of their intention to provide 
a medicinal product for a clinical investigation. Also the application should be 
supported by pharmaceutical data and pre-clinical safety data, usually based on animal 
testing. The CTX scheme is computer based, and information submitted by the 
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applicant is recorded on disc and assessed by a team of doctors, pharmacists and 
scientists. The assessment time is normally 35 days but can be extended by another 28 
days if required. 
5.4 Clinical Trial Application Forms 
Research trials are submitted for scrutiny to the MCA using an MLA-164 CTX 
application or a MLA-162 DDX application. These two documents are distinct in 
their requirements. An MLA-162 (DDX) is aimed at research conducted by doctors 
and dentists who are the sole suppliers of the drug. This comes under the Provisions 
of the Medicines Exemptions from Licences, Special Cases and Miscellaneous 
Provisions order 1972. This DDX application has to be submitted by a registered 
medical practitioner. An MLA-162 application requires less pharmacological, 
toxicological and safety data than an application made via a MLA- 164. The 
requirements for pre-clinical safety data, technical specifications and trial design 
specifications are considerably reduced using an MLA- 162 application, and therefore 
has a financial advantage to an MLA-164 based study. However, for this route to be 
followed, a doctor needs to be the sole supplier of the drug without any commercial 
involvement and a doctor has to directly oversee patient care. For the purposes of this 
study, the supplier is the research team (Neal's Yard Remedies) and the herbal `drug' 
would be administered by medical herbalists without the involvement of a doctor and 
therefore an MLA-164 application is to be used. 
An MLA- 164 requires the applicant to submit, amongst other criteria, data on the 
pharmacokinetics, pharmacodynamics, pharmacology, toxicology, and drug stability. 
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An application through this route will require greater time and expenditure but is 
taken as a measure of the quality of a study by editors of peer reviewed journals. 
5.5 MCA Requirements 
The MCA requires that all plant material is authenticated to ensure that the herbs are 
correctly identified, to avoid the wrong plant species being administered. A further 
safety requirement is that each herb should be shown to be non-toxic, both on an 
individual basis and when used in combination with other herbs. The herbal product 
needs to be shown to be stable over time without deteriorating into harmful 
compounds. The process of ensuring the herbs are stable and free from toxic 
substances becomes more complex and costly with the increasing complexity of the 
formula. The cost of toxicological testing can be prohibitive, especially for a poly- 
herbal formula. A five herb formula was used for this study to reflect the current 
practice within herbal medicine of using polyformulas rather than a single herb 
formulation. 
The MCA's documentation is not precise in its technical requirements, and therefore, 
meetings with the MCA's representatives were conducted to obtain clarification. 
Drugs have to be demonstrated to be stable over time within a certain degradation 
limit of its constituents. The stability specifications limits for constituent degradation 
have been set by the ICH (1986) for herbal remedies. However, these specification 
limits have been shown to be unworkable by Bilia (2001) and this issue was addressed 
at one of the meetings. The MCA suggested that they may provide some leeway on 
this issue, but did not specify the degree to which they would allow the limits to be 
extended. A further requirement discussed was the need to identify the active 
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constituents of each herb and a rationale for the pharmacological action of a 
polyformula. The difficulties of this task were outlined as currently only a minority of 
constituents have so far been identified in the herbs proposed for the formula. This 
issue has been discussed in chapter 3. The question of the need for animal testing was 
raised at a meeting to determine whether this would be a requirement as both the 
NIMH and Neal's Yard Remedies are explicitly opposed to animal testing. The 
outcome was not entirely satisfactory since the MCA panel expressed differing 
viewpoints, although the lead consultant indicated that animal testing would probably 
not be necessary. 
5.6 Completion of the MLA-164 Application 
An MLA- 164 application is set out into two main sections. The first section relates to 
the study design, drug composition and manufacturing processes. The details of the 
proposed trial were stated in the MLA-164 (Appendix VIII) and included: the study 
aims, length of treatment and the duration of the study, number of subjects, inclusion, 
exclusion and withdrawal criteria to be used, safety monitoring procedures, 
formulation of the drug and placebo, dosages and the age range of the patients. 
The second section relates to the scientific supporting information, which has to be 
supported under headings such as developmental pharmaceutics. The herbal formula 
was not a new entity and had not undergone the usual developmental procedures of a 
pharmaceutical drug. Instead, this section was completed, based on the therapeutic 
uses of the herbs, to justify their inclusion in a formula to treat menopausal 
complaints. 
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The manufacturing processes were described in the MLA- 164 document after 
consultation with the proposed company to produce the herbal capsules, which 
included a description of the manufacturing and quality control procedures used, such 
as grinding methods, handling procedures for the raw material and the plants traceable 
history. 
A vegetable drug monograph (i. e. a detailed morphological description of each plant 
and their constituents) was provided, based on information available from herbal 
pharmacopoeias and herbal monographs. Often information stated in previous sections 
of the MLA- 164 document, such as chemical constituents, had to be restated again as 
many sections overlapped in their content. 
Control tests on the finished product needed to be undertaken. This task was to be 
subcontracted to a UKAS public analyst who would perform quality control tests 
based on the tests and specifications in the BHP (1990), which was to include 
microscopic and macroscopic identity checks, ash value determination, 
microbiological tests, heavy metal tests, and chromatographic tests. 
Stability tests were to be undertaken by a UKAS accredited public analyst. The types 
of tests and specification necessary to demonstrate stability were not stated in the 
MLA- 164 document. The tests were based on the criteria stipulated by Chauhan and 
Agrawal (1999) and included stability tests for: 
" Capsule appearance 
" Capsule powder appearance 
" Average weight 
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" Moisture content of capsule powder 
" pH of 2% aqueous suspension 
" Disintegration time 
" TLC and HPLC analysis to monitor changes in chemical profile 
A description of the pharmacological and toxicological studies of the herbs was 
required. An extensive literature search was conducted to source bibliographic 
information on each herb since the MCA will, in principle, accept bibliographic 
information to support an application. The information that was required included: 
" Actions of the plants relevant to the proposed therapeutic use 
" Drug interaction 
" Toxicological studies 
" Mutagenicity 
" Carcinogenicity 
" Reproductive toxicology 
" Pharmacology 
Hypericum perforatum and Cimicifuga racemosa have both been the subject of patient 
and animal studies, and justifying their therapeutic action was made possible by 
extracting information from the various studies that have been performed. However, 
there was no data available for the mutagenic, carcinogenic or reproductive 
toxicological effects of H. perforatum. C. racemosa did not have any supporting 
information on drug interaction, pharmacokinetics, carcinogenicity studies and 
reproductive toxicology. Salvia offlicinalis had sufficient infonnation available to 
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support the claim for its therapeutic action, although there were no pharmacokinetic 
and toxicological data available. Dioscorea villosa had no data available to support the 
criteria in the phannacological and toxicocolgical sections. The basis of the inclusion 
of D. villosa would rest on its established use status. Glycyrrhiza glabra is an official 
drug of the British Pharmacopoeia (2001) and its actions have been demonstrated. The 
pharmacological, pharmacokinetic and toxicological properties have been established, 
although no information is available for mutagenic, carcinogenic or reproductive 
toxicological effects. It was stated in the document 'No data available' when there 
was no information available in the pharmacological section. A meeting with the 
MCA was arranged to clarify the types of data that would be essential for the 
application. However, their representatives were unable to specify exactly which tests 
and supporting information would be necessary to fulfill the pharmacological section. 
It was suggested that reproductive toxicology data may not be necessary given that the 
subjects will be infertile. Similarly it was suggested that carcinogenic data may not be 
necessary for a short-term study as proposed, whereas for marketing purposes, LD-50 
toxicology data would probably be a requirement. 
5.7 Summary 
Considerable preliminary work was carried out before submitting a clinical trials 
application to the MCA to ensure that their requirements were achievable within both 
budgetary and time constraints. The CTX fornis appeared to be specifically designed 
for pharmaceutical drugs. Translating the MCA's safety requirements for herbal 
medicines was problematic given the lack of clarity on the types of tests and 
specifications needed. Attending meetings with members of the MCA was valuable 
and was advisable, given the potential for a submission to be rejected. The completion 
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of the MLA-164 application (Appendix VIII) provided a novel insight into the 
requirements for an herbal medicine study, and the difficulties that may be 
encountered with the application process. 
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CHAPTER 6 
HEAVY METAL ANALYSIS 
6.1 Introduction 
Heavy metal analysis is an important aspect of quality control and is a requirement of 
the MLA-164 application to ensure the plant material is not contaminated with toxic 
metals. It is important to analyse herbs to ensure they are not contaminated with 
harmful metals such as cadmium, lead and mercury, since contamination of medicinal 
herbs is always a potential risk, as was reported by Bayley et al (1995). Lead, 
cadmium and mercury are all harmful to humans. Cadmium is toxic and accumulates 
in the body throughout a lifetime. Lead is toxic and has been shown to exert toxic 
effects on the CNS, reproductive, renal, haematopoietic and immune systems 
(Weeden, 1984), and it has been identified with impaired I. Q. (Tong et al, 1996). 
Heavy metal contamination of herbs can occur either during cultivation or the 
subsequent harvesting and processing procedures. Therefore, a medicinal herb, which 
is cultivated on soil that is relatively free from heavy metal ions, cannot necessarily be 
guaranteed to be free of contaminants at the final stage of production. 
Inductively Coupled Plasma Atomic Emission Spectroscopy (ICP-AES) is a reliable 
analytical technique for the determination of metals in plants (Kos el al, 1996). Heavy 
metals analysis was conducted using ICP-AES to determine if the herbal material 
could meet the guidelines for an MLA-164 application. A total of 16 herb samples, 
eight Hypericum perforatum L. and eight Salvia ojficinalis L., were analysed for the 
heavy metals: lead, cadmium, mercury, copper, zinc, nickel, and chromium. 
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6.2 Materials 
Herb samples of H. perforatum and S. officinalis were obtained from private and 
commercial growers in the UK and Southern Europe. Samples obtained in the UK 
were from London (Enfield and Finchley), Dorset, Leicestershire, the Scilly Isles and 
Kent. European herb samples were obtained from Bosnia, Spain, Hungary, Turkey and 
Albania. High purity nitric acid (69%) was obtained from the company BDH and the 
metal ions standards were obtained from Merck. 
6.3 Methods 
A sample of each herb (2g dry weight) was placed in a Teflon beaker and 50 ml nitric 
acid (69%) were added. The beakers were placed in a sand bath at 900C and left 
overnight in a fume cupboard to digest the herb material. 20 ml of nitric acid (10%) 
were then added to dissolve the dried residue using a glass rod. The beaker contents 
were filtered through a Whatmans No. 41 filter paper and washed through with 
deionised distilled water into a (50ml) volumetric flask. To improve methodological 
reliability, samples were prepared in triplicate thus enabling the mean metal ion 
concentrations and their standard deviations to be calculated. 
A combined standard of mercury, cadmium, lead, chromium, zinc, nickel and copper 
was prepared by serial dilution to a concentration of 1 mg/L. A 10-ml aliquot of each 
metal ion (1000 mg/L stock Merck SpectrosoL grade) was put into a volumetric flask 
and made to (100 ml) with distilled deionised water. AI ml aliquot of the combined 
standards was then put into a volumetric flask and made to 100ml to give a lppm 
standard solution. This solution was then analysed at the required wavelength for each 
metal ion. The emission intensity was recorded by the ICP-AES computer system and 
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background corrections were made. ICP-AES (Perkin Elmer Emission Spectrometry, 
model plasma 40) instrument was used to determine the concentration of metal ions. 
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RESULTS 
6.4 Heavy Metal Concentrations 
The mean metal ion concentrations in the samples H. perforatum and S. officinalis 
collected from the different cultivation sites are presented in Tables 13 and 14. 
Mercury levels in all samples of H. perforatum and S. officinalis were found to be 
below the limits of detection. Concentrations of all other metal ions measured were 
detectable and found to be within the guideline limits. 
Table 13. Mean metal ion concentrations (ppm) in H. perforatum from different 
locations in the UK and Europe. 
Site Hg Cd Pb Cr Zn Ni Cu 
Leicestershire *<LOD 0.37 1.43 0.29 16.29 21.78 5.93 
t (0.05) (0,44) (0.15) (2.29) (2.88) (0.80) 
Enfield <LOD 0.21 1.10 0.97 28.55 8.24 5.04 
(0.08) (0.29) (0.06) (2.62) (1.46) (1.18) 
Spain a <LOD 0.65 1.05 0.70 23.80 8.28 5.66 
(0.13) (0.11) (0.33) (1.06) (0.39) (0.49) 
Bosnia <LOD 0.68 1.23 0.85 27.45 8.48 9.09 
(0.32) (0.56) (0.33) (10.58) (3.31) (3.65) 
Finchley <LOD 0.29 1.23 0.50 18.67 5.71 4.00 
(0.10) (0.16) (0.13) (1.94) (1.22) (0.89) 
Scilly Isles <LOD 0.20 1.41 1.48 45.20 5.84 4.73 
(0.08) (0.66) (0.98) (1.13) (0.09) (0.29) 
Dorset <LOD 0.33 0.90 0.73 32.85 5.09 4.43 
(0.02) (0.22) (0.09) (2.87) (0.04) (0.52) 
Spain b <LOD 1.03 0.97 0.38 25.45 13.59 4.04 
(0.10) (0.36) (0.05) (0.57) (1.33) (0.49) 
*LOD (Below limits of detection) 
f Figures in brackets refer to the standard deviation of each sample prepared in 
triplicate 
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Table 14. Mean metal ion concentrations (ppm) in S. officinalis from different 
locations in the UK and Europe. 
Site Hg Cd Pb Cr Zn Ni Cu 
Leicestershire *<LOD 0.38 1.48 1.05 29.67 13.48 6.79 
t(O. 03) (0.12) (0.16) (0.15) (1.74) (0.13) 
Enfield <LOD 0.07 1.53 0.80 32.69 8.09 4.60 
(0.08) (0.38) (0.27) (2.0) (1.10) (0.66) 
Hungary <LOD 0.28 1.43 0.84 20.71 16.87 3.59 
(0.01) (0.04) (0.03) (1.45) (1.81) (0.12) 
Albania <LOD 0.13 1.05 0.88 17.48 11.45 3.61 
(0.06) (0.48) (0.30) (4.87) (3.41) (1.08) 
Turkey <LOD 0.43 1.75 0.85 18.85 9.91 3.83 (0.21) (0.31) (0.52) (1.51) (0.28) (0.23) 
Finchley <LOD 0.33 2.08 0.63 29.68 7.26 4.19 
(0.09) (0.61) (0.21) (1.25) (0.77) (0.34) 
Dorset <LOD 0.38 1.44 0.68 21.54 2.98 2.64 
(0.09) (0.43) (0.11) (5.58) (0.12) (0.17) 
Kent <LOD 0.31 1.66 0.83 16.34 4.59 4.26 
(0.03) (0.72) (0.10) (0.86) (0.32) (0.19) 
*LOD (Below limits of detection) 
t Figures in brackets refer to the standard deviation of each sample prepared in 
triplicate. 
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6.5 Discussion 
The statutory limits for heavy metal concentrations in food items and herbs exist only 
for lead and cadmium. The Medicines Control Agency does not specify what are 
considered to be acceptable levels of contamination and interpretation of results has to 
be based on existing UK or European legislation and guidelines. The existing UK 
legislation has only set statutory limits for lead, cadmium and mercury. Mercury is 
potentially a serious risk to health. However, there are no UK legal limits in 
agricultural food items. Legal limits for mercury have been set only for seafood, which 
may present a contamination risk from industrial and effluent discharge. Only 
guideline limits are available from The Food Standards Agency (previously MAFF) 
for the remaining metals. Where no regulations exist in UK law for metal 
contamination in herbs, a general provision in the Food Safety Act (1990) attempts to 
control contaminants outside specific limits. This act only states that foods should be 
fit for human consumption, and free from harmful contaminants, but does not attempt 
to set limits or guidelines. The UK Food Standards Agency has set a statutory limit for 
lead of I mg/kg (Ippm) in food and a separate limit of 10.0 mg/kg in dried herbs 
(10ppm). Lead metal ion concentrations in this study were found to range between 
0.90 and 2.08ppm and were within the limits. The highest concentrations of lead 
occurred in samples from the London area, Finchley and Enfield, which probably 
reflect air-borne pollution. These results are similar to findings from previous work, 
which has found lead levels to range from 0.05 to 3. Oppm (DW) in samples analysed 
from 1970 to 1980 (Kabata-Pendias and Pendias, 1992). 
Cadmium is toxic, accumulates in the body throughout a lifetime and is subject to the 
general provisions of the Food Safety Act (1990). The European Commission has 
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proposed a draft regulation setting maximum limits for cadmium in foods that 
contribute significantly to dietary intakes. Whether herbs are considered significant is 
not clear, although the proportion of herbal products consumed is small relative to 
fresh plant-based products. Herbs contribute a small proportion of total metal 
consumed in the diet (herbal tea products have a 0.06% share of the daily amount of 
plant-based food eaten) (Kabelitz, 1997). The latest version of this proposal sets limits 
of 0.2 mg/kg (0.2ppm) for cadmium in fresh herbs (Rowles, 2000). If a concentration 
factor of 10 was applied for dried herbs, as was previously used for lead by MAFF, a 
limit of 2-ppm for cadmium would be set. The cadmium levels in this study ranged 
between 0.07-1.03ppm, falling within the proposed European commission limits. 
Plants in the UK have an average cadmium concentration ranging between 0.27-4ppm 
with a mean of Ippm. (Bradley, 1980) and therefore, the levels found in this study 
were representative of existing levels. 
There are no statutory limits for zinc in food items or herbs in the UK. However, 
guideline limits are set at 5mg/kg in beverages and 50mg/kg in other foods (MAFF, 
1998). Based on these values, the zinc concentrations were within this guideline, 
ranging between 16.29-45.20ppm and therefore, would meet the general safety criteria 
required by the MCA. 
The Food Standards Committee report, cited by MAFF (1998), recommends a 
guideline limit of 20 mg/kg for copper in foods. Copper levels in the herbs were 
within this guideline limit, ranging from 2.65-9.09ppm. The copper content of plants 
from different cou4tries has been previously reported to range from 1-8ppm (Tinker, 
198 1) and is consistent with the levels observed. 
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There are no UK statutory limits for chromium in food items or herbs. However, the 
working party on dietary supplements and health food (MAFF, 1998) considered that 
chromium would have undesirable effects above a chronic dose of 1-2g/kg per day. 
The chromium concentrations in this study were found to range between 0.29- 
1.48ppm and therefore meet the guideline limits. The nickel concentrations were 
found to range between 2.98-21.78ppm. To date, there are no statutory or guideline 
limits available for nickel. 
Conclusion 
The quality control requirement of the Medicines Control Agency for heavy metal 
contamination would be met, based on the results obtained, since all metals tested fell 
within the statutory and guideline limits where available. However, sample testing 
prior to use is important, even when using herbs from the same cultivation area, since 
atmospheric pollution and effluent contamination will always present a risk. 
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CHAPTER 7 
HPLC ANALYSIS 
7.1 Introduction 
The MCA requires plant material to be correctly identified before being used in a 
clinical trial. This is because contamination may occur in the herbal drug either due to 
deliberate adulteration by a supplier or from the inclusion of plant material that has 
been misidentified. The consequences of a wrongly identified plant can be lethal as 
was the case with the Aristolochia species (Gottlieb, 2000). This led to a prohibition 
order being introduced by the Department of Health (2000) because of concerns over 
its safety, after patients using a slimming aid containing Aristolochia species 
developed renal failure. High Performance Liquid Chromatography (HPLC) can 
potentially be used to assist in confirming the identity of a plant by examining its 
chemical 'fingerprint' profile against reference chromatograms and phytochemical 
standards that are commercially available. 
HPLC provides both qualitative and quantitative data and is a more versatile technique 
than thin layer chromatography (TLC) because it allows rapid, reproducible, high- 
resolution separation (Pietta et al, 1991), even with trace amounts of the compounds, 
which is why pharmacopoeias are changing from TLC to HPLC (Andrade et al, 
1998). Other techniques such as gas chromatography (GQ, capillary electrophoresis 
(CE) and nuclear magnetic resonance (NMR) can also be incorporated to aid and 
improve identification. 
66 
One of the problems of analysing herbs with HPLC is a lack of established analytical 
methods and standards available (Lazarowych et al, 1998). HPLC is mainly used for 
plant constituents that are non-volatile, for example, higher terpenoids, phenolics and 
all types of alkaloids, lipids and sugars (Harborne, 1998), making it a suitable 
technique for polyphenolic compounds like flavonoids (Rehwald et al, 1994). 
The herb samples proposed for the clinical trial contain mostly phenolic derivatives 
and therefore HPLC is an appropriate method, given its sensitivity and suitability to 
the chemical constituents of the plants. The purpose of the HPLC fingerprint analysis 
was to examine its suitability as a method for confirming plant identity solely for an 
MLA-164 application to the MCA and therefore no quantitative measurements were 
undertaken. The established HPLC methodology used by Kew Gardens will be 
adopted for this project. 
7.2 High Performance Liquid Chromatography spectra 
High performance liquid chromatography apparatus fitted with diode-array detector 
displays the spectral shape of each peak. This spectral shape can assist in identifying 
flavonoids, such as isoflavones, flavonols, and flavones. This is because each type of 
flavonoid has a characteristic shape and maximum absorbance (Figures 2,3 and 4). 
The examination of the spectral shape is particularly valuable in phytochernistry due to 
the limited availability of standards. For example, isoflavones (Fig. 2) when observed 
at 260nm (their maximum absorbance) and 335nm (a low absorption frequency for 
isoflavones) have a characteristic peak shape that is distinguishable from other 
flavonoids, such as flavonols (Fig. 3) and flavones (Fig. 4) (Greyer, 2000). 
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260nm 
340nm 
Fig 2. Peak shape of the isoflavone- genistein (Greyer, 2000). 
260nm 
340nm 
Fig 3. Peak shape of the flavonol- kaempferol (Greyer, 2000). 
Fig 4. Peak shape of the flavone-apigenin (Greyer, 2000). 
7.3 Plant Extraction 
Prior to HPLC analysis, solvent extraction of the plant material is necessary. There is 
no single method available for extraction of phytochemicals, since this will depend on 
the particular constituents of interest and the type of plant material being used. The 
different plant extraction methods were reviewed from the literature (Table 15). It was 
found that the majority of flavonoid extraction methods used methanol as the solvent 
of choice, although ethanol was frequently used, and occasionally acetone. Methanol 
is a more polar solvent that ethanol and is a cheaper alternative. Reflux times varied 
between 15 minutes to four hours. However, this type of lengthy extraction 
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methodology is more suitable for quantitative analysis, because it increases the 
concentration of constituents due to the repetition of pure alcohol passing over the 
herb material, which further draws constituents from the plant sample. For qualitative 
'fingerprint' analysis of the aerial parts of plants, shorter extraction times can be 
utilised. For example, an extraction method used by Kew Gardens is to boil the herb 
in methanol for 5 minutes and allow cooling for 30 minutes. This extraction method 
has been found to produce chromatograms that are sufficient for fingerprint analysis 
because the aerial parts of the plants, unlike root material, are sufficiently thin to 
enable penetration and extraction by the solvent (Greyer, 2000). Soxhlet apparatus is 
often used for the extraction of dried plant material, especially root material. 
Generally, if fresh plant material is used, the herb should be submerged into the 
solvent immediately to prevent further enzymatic oxidation from occurring. 
A Soxhlet extraction method was used for the HPLC fingerprint analysis, based on the 
established methodology used by the National Herb Centre (Cole, 2000) which 
routinely performs commercial HPLC analysis. This method was chosen because it is 
a more exhaustive extraction process than simple infusion of plant material in hot 
methanol and is therefore suitable for the root material to be tested in this project. 
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Table 15. Existing solvent extraction methods 
Herb Constituent Extraction HPLC Solvent system 
Method 
Ginkgo biloba Flavonoids Reflux 15min in A= water-2propanol (95: 5) 
(Pietta et al, 199 1 60% acetone B= 2propanol-THF-water 
(40: 10: 50) 
Hypericurn perforaturn Flavonoids Hot Methanol A=water phosphoric acid (99.7: 0.3) 
(Brolis el al, 1998) extraction B=acetonitrile 
C=methanol 
Hypericum perforaturn Flavonoids Refluxed in Methanol-buffer 2.1 pH-Ethyl acetate 
(Kurth and Spreeman, methanol (4h) (1893: 618: 526) 
1998) 
Crataegus. Oxycanthus Flavonoids Refluxed in 80% A=Tetrahydrofuran-acetonitrile- 
Rehwald el al, 1994) methanol (1h) methanol (92.4: 3.4: 4.2) 
B= orthophosphoric acid 0.5% 
Lippia citriodora Flavonoids Ethanol 40% A=water-formic acid (19: 1) 
(Valentao, et al, 1999) agitated (2h) B=methanol 
Onion Flavonoids Methanol 80% A=acetonitrile-water-formic acid 
(Andlauer et al, 1999) Centrifuge (2h) at (10: 90: 5) 
room temp. B= acetonitrile-water-formic acid 
(90: 10: 5) 
Trifolium pratense Flavonoids Refluxed in 70% A=Water -HOAc 0.25% 
(He et al, 1996) ethanol for (1h) B= Methanol 
Trifolium spp. Isoflavones Ethanol 80% with Acetonitrile with 0.1% TFA 
(Klejdus et al, 1999) 3Mol HCL 
Ajuga iva Flavones Refluxed in 80% Acetonitrile- water- 2% acetic acid 
(Sabri et al, 198 1). methanol (1h) 
Alhagi pseudoalhagi Flavonols Ethanol 48% (1h) Not given 
(Khaiitbaev, et al 1993) 
Solidago gigantea Saponins Methanol 80% Methanol mater (53: 47) pH 5 
(Reznicek, et A 1996) percolation 
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MATERIALS AND METHODS 
7.4 Materials 
Methanol HipersolvS (analytical grade) supplied by Merck 
Acetic acid supplied by BDH 
o HPLC grade water supplied by Merck 
e Dried herb(s) supplied by Middlesex University herb garden, The Nation Herb 
centre, The Herbal Apothecary and Neal's Yard Remedies. 
7.5 Method- Plant Extraction 
Dry herb material was spread over an area of 300cm2 and samples were taken at 
random. Herb material (2g) was weighed out, coarsely chopped, and added to the 
soxhlet thimble. 130ml of 80% analytical grade methanol was placed in the soxhlet 
and refluxed for one hour. The solvent extract was filtered using a Buchner flask and 
transferred to a rotary evaporator. The sample was evaporated, under vacuum, to 
dryness and reconstituted with 20ml of 99% methanol. The sample was stored at (- 
5'Q, prior to use, and prepared for HPLC injection by filtering through a 0.45 
micropore nylon disc. 
7.5.1 High Performance Liquid Chromatography 
The analysis was carried out using two different HPLC systems. The first system was 
a Kontron(& HPLC with UV detector and 15cm reverse phase C-18 column. The 
second system consisted of a WatersO HPLC with diode array detector and 25cm 
reverse phase C18 column. 
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The HPLC programme and mobile phase used for the analysis followed the 
methodology used by Kew Gardens (Greyer, 2000). This method was used on both 
HPLC systems because it is used routinely in the pharmacognosy department at Kew 
for qualitative analysis and is therefore an appropriate and convenient method for this 
study. 
The analysis was first carried out on the HPLC apparatus fitted with the UV detector. 
The programme settings for the HPLC apparatus were set up as follows: 
9 Solvent system A: HPLC grade water with 2% acetic acid 
0 Solvent system B in the ratio: Methanol (18): Water (1): Acetic acid (1) 
00 minute 75% A and 25% B 
0 20 minutes 0% A and 100% B 
24 minutes 0% A and 100% B 
25 minutes 75% A and 25% B 
40 minutes 75% A and 25% B 
Flow rate Iml/min; oven temperature 30'C 
The HPLC programme was then run and the spectral data was acquired over a 40- 
minute duration for each of the five herbal extracts. This procedure was then repeated 
at The koyal Botanic Gardens Kew, on a WatersO system fitted with a diode-array 
detector (DAD). This enabled a comparison of the two detector systems. The same 
extraction method and program settings were used for all the herb samples. The diode 
array detector enables identification of chemical groups by providing the spectral 
shape of each peak. This method is advantageous when chemical standards are 
unavailable. 
72 
7.6 Results 
The results of the HPLC analysis using UV and diode array detectors are shown in 
Figures 5 to 14. 
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Fig. 5 Chromatogram of Hypericum perforatum extract acquired with a UV detector 
(260nm) using a 15cm C- 18 reverse phase column. 
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Fig. 6 Chromatogram. of Hypericum perfibrawn extract acquired with a diode array 
detector (260nm) using a 25cm C- 18 reverse phase column. 
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Figures 5 and 6 are the Hypericum perforatum chromatograms obtained from HPLC 
analysis using UV and diode array detectors respectively. The result of the analysis 
using the UV detector shows a chromatogram with approximately 16-18 peaks. The 
first peak is most likely to be the solvent front, given its shape and early elution. The 
peaks have eluted broadly into two regions across the chromatogram. The Hypericum 
perforatum chromatogram (Fig. 6) acquired with the diode-array detector (DAD) 
produced 16 peaks. The spectral shape of each peak is shown at the top of the 
chromatogram. The peaks shown in Figure 6 are clustered into two regions similar to 
Figure five, but are separated further apart due to a longer (25cm) column being used. 
The first 6 peaks in Figure 6 were acquired between approximately 2 and 6 minutes, 
followed by the 10 remaining peaks being acquired between II and 19 minutes. Peaks 
9-15 cannot be identified with complete confidence. However, the peaks may be 
flavonols because their spectral shape and maximum absorbance are similar to the 
known spectral characteristic of flavonols i. e. producing maximum absorbance at 
approximately 260 and 340nm (Greyer, 2000; Brolis, 1998). Also, peak 8 (Fig. 6) 
shows a maximum absorbance at 290nm, with a slight 'shoulder' at 340nm, which is 
the characteristic spectrum of flavanones (Brolis, 1998). Determining the type of 
flavanone was not possible because the spectral information provided with DAD- 
HPLC did not allow further delineation because the differences between the types of 
flavanones were too small. 
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Fig. 7 Chromatogram of Cimicifuga racemosa extract acquired with a UV detector 
(260nm) using a 15cm C- 18 reverse phase column. 
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Fig. 8 Chromatogram of Cimicifuga racemosa extract acquired with a diode array 
detector (260nni) using a 25cm C- 18 reverse phase column. 
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The Cin-&ifuga racemosa chromatograms (Fig. 7 and 8) both show peak drifting from 
the base line on the initial peaks that have eluted. This may be due to impurities, 
temperature fluctuations, electronic noise or variations in the sample composition 
(Pearce, 2000). The peaks appearing between 0 and 15 minutes have not completely 
separated. In contrast, the Cimicifuga racemosa chromatograin in Figure 8 has superior 
peak separation due to a longer column used. In Figure 7, there are 6 peaks appearing 
very closely together between 2 and 3.5 minutes. These constituents share a similar 
retention time and a longer column would have ftirther enhanced peak separation. 
j. ---r-- 
Fig. 9 Chromatogram of Dioscorea villosa extract acquired with a UV detector 
(260nm) using a 15cm C- 18 reverse phase column. 
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Fig. 10 Chromatograrn of Dioscorea villosa extract acquired with a diode array 
detector (260nm) using a 25cm C-18 reverse phase column. 
The Dioscorea villosa chromatogram acquired with the UV system (Fig. 9) has 
produced approximately 6 peaks, but the peak height is low, indicating possible poor 
sample resolution. In contrast, the DAD derived chromatogram (Fig. 10) has acquired 
15 peaks with greater height. One possible explanation for the increased number of 
peaks and their greater height is that the HPLC system with DAD has greater 
sensitivity. 
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Fig. II Chromatogram. of Salvia officinalis extract acquired with a UV detector 
(260nm) using a 15cm C-18 reverse phase column. 
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Fig. 12 Chromatogram of Salvia officinalis extract acquired with a diode array detector 
(260nm) using a 25cm C- 18 reverse phase column. 
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The Salvia officinalis chromatogram acquired on the UV system (Fig. 11) shows good 
peak separation and acquired approximately 27 peaks. There is considerable peak drift 
occurring from the base line. In contrast, the DAD derived chromatogram (Fig. 12) has 
acquired only 21 peaks. This may be due to degradation of the extract. Peaks 10 and 
13 in Figure 12 may be flavones because the spectral shape of both peaks is similar to 
the typical spectral shape of a flavone having its maximum absorbance at 260 and 
340nm (Greyer, 2000). 
Fig. 13 Chromatogram. of Glycyrrhiza glabra extract acquired with a UV detector 
(260nm) using a 15cm C- 18 reverse phase column. 
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Fig. 14 Chromatogram of Glycyrrhiza glabra extract acquired with a diode array 
detector (260nm) using a 25cm C- 18 reverse phase column. 
The Glycyrrhiza glabra chromatogram acquired on the UV system (Fig. 13) acquired 
approximately 48 peaks. The peaks are not in all cases fully separated and have begun 
to 'split' during elution. The splitting may have been caused by pH mismatch or 
contamination (Pearce, 2000). Drift has also occurred during peak elution. The DAD 
derived chromatograrn (Fig. 14) has in contrast acquired only 23 peaks, which may be 
due to extract degradation or differences between IHPLC apparatuses. Peaks 19 and 20 
(Fig. 14) may be isoflavones, (see Figure 2) showing the same spectral shape with 
maximum absorbance, at 260nm with a slight 'shoulder' at 340nm (Greyer, 2000). 
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7.7 Discussion 
High Performance Liquid Chromatography 'fingerprint' analysis using diode array 
detection is a superior method for identifying plant groups compared to simple UV 
detection because it can aid identification of individual peaks. However, identifying 
the type of isoflavone, flavanone or flavone was not possible because their 
characteristics are too similar. 'Finger print' analysis is also a convenient method of 
analysing changes in the extracts, which can be re-run using the original program. 
However, the two chromatograms produced on different HPLC systems for each plant 
extract showed considerable variation in the number of peaks eluted and the overall 
'fingerprint' profile. This variability has also been observed in the chromatographic 
profile of Hypericum perforatum and Cimicifuga racemosa (Brolis, 1998; Sloley, 
2000; Institute for Nutraceutical Advancement, 2000). Furthermore, Lazarowych and 
Pekos (1998) also reported similar inconsistencies in the chromatographic 'fingerprint' 
of different samples of Tanacetum parthenium and consistent 'fingerprints' were only 
achieved using plants grown from the same seed bank. These variations can partly be 
explained by the differences with the different systems used such as the detector, 
columns, packing material and inconsistencies in the flow rate and temperature. The 
chemical profile of the same plant species can also vary significantly due to factors 
such as the variations in soil conditions, growing locations and the time of harvest. 
These natural variations make fingerprint analysis difficult, particularly as a method to 
confirm the plant identity against a reference 'fingerprint' chromatogram. 
Due to the variability in the chromatographic profile of plants and the lack of 
phytochernical standards available to identify individual constituents, HPLC 
fingerprint analysis is not an adequate method of establishing a plants authenticity on 
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its own for the purpose of satisfying the requirements of the MCA. It would be 
preferable to use a botanist who would be able to issue a voucher specimen number, to 
confirm plant authenticity. However, HPLC could be used alongside other techniques 
such as gas chromatography, thin layer chromatography, bioactivity fractionating 
assays and nuclear magnetic resonance imaging to add supporting evidence if 
required. 
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CHAPTER 8 
DISCUSSION AND CONCLUSIONS 
8.1 The Menopause and Hormone Replacement Therapy 
The menopausal transition for some women will include the development of hot 
flushes and other hormonally related symptoms. A further consequence of the 
menopause may be the development of osteoporosis, which can lead to infirmity or 
mortality. HRT is one form of treatment that provides relief for some women. 
However, it is not an option for all women due to side-effects, contraindication and 
the personal preferences of some women, and therefore other forms of treatment need 
to be developed. 
8.2 Research Funding for Herbal Medicine 
Herbal medicines have been shown to be effective for a variety of health problems, 
including the menopause. The research funding for herbal medicine is presently less 
than 1% of the total research expenditure in health care in the United Kingdom. The 
dilemma for herbal medicine research is that funding is unlikely to be made available 
by private companies since the costs of conducting clinical trials are considerable, 
especially if data is required to demonstrate the pharmacological, and toxicological 
properties. These costs are unlikely to be recouped because plants cannot be easily 
patented. Therefore, the potential for a financial return on any investment is tenuous 
and as a consequence the inclusion of (CAM) into the NHS based on clinical evidence 
will be hindered by the limited research output. However, the potential benefits of 
herbal medicine may include: the effective treatments of many acute and chronic 
conditions, avoidance of iatrogenic illness, minimal side-effects in contrast to 
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pharmaceutical drugs and financial savings for the NHS. A two- tier situation exists 
for complementary medicine, since only those who can or are willing to pay privately 
are able to access it. Maintaining an orthodox health care system that excludes other 
medical philosophies will limit patient access to other forms of treatment and may 
stifle medical progress. 
8.3 Research Methodology for Herbal Medicine 
The probability of producing positive research findings becomes more difficult when 
the 'gold standard' of a double-blind, placebo controlled trial is used because of the 
increased requirements for narrow objective evidence. Furthermore, this methodology 
does not reflect the practice of herbal medicine. Patients with the same biomedically 
defined illness may be treated differently, as the basis of treatment is formed from the 
clinical manifestations of the condition rather than the diagnostic label. 'Pigeon- 
holing' patients into receiving standard medication may reduce the potential of finding 
a positive result, whilst a negative outcome may be a reflection on the study design 
rather than the treatment. 
8.4 The limitation of the MLA-164 application process 
To conduct a clinical trial, permission has to be obtained from the MCA, which is 
granted once the criteria for safety have been met. The MCA's requirements for the 
applicant to demonstrate the stability of herbal remedies in accordance with the 
International Conference on Harmonisation degradation limits of ±10% (ICH, 1996) 
are not achievable for herbal remedies, since constituent degradation levels in excess 
of 10% appear to be the norm rather than the exception. However, it is unlikely that 
the efficacy of medicinal herbs will be diminished to a degree where no therapeutic 
85 
value remains, based on the observations of clinicians. The validity of the ICH limits 
for herbal remedies is questionable, since they were not developed using a therapeutic 
index for medicinal herbs against constituent degradation. The MCA's requirements 
within the MLA-164 document for batch analysis on the herbs are also unworkable 
since the chemical profile will inevitably vary between different batches used. The 
chemical constituents in herbs are affected by different times of harvest, soil 
conditions and weather patterns. Different varieties of the same species can show wide 
variances in constituent concentrations. The ICH stability limits were originally 
devised for pharmaceutical drugs. 
A system of transferring the safety stipulations of pharmaceutical drugs to herbal 
remedies is inappropriate. Herbal remedies appear to have a long established history of 
safe use, unlike pharmaceutical drugs where side-effects and contraindications are the 
norm rather than the exception, as shown in the British National Formulary (2001). 
Furthermore, herbal medicines are not new drugs entering the market for the first time 
since they have so called 'established use' status. Given that herbal remedies do not 
easily fit into pharmaceutical legislation, separate legislation would be welcome to 
specifically control traditional medicines. 
The conundrum between the theory and practice of an MLA- 164 application is a 
concern that has been raised by representatives of health food manufacturer 
associations. These concerns were addressed in a speech given to the Health Food 
Manufactures Association in November 2001 by MCA representatives for herbal 
policy who stated: 
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"They (the applicants) [sic] may read the relevant guidance and recognise thatfor a 
particular herbal remedy it would be difficult or impossible to assay constituents or to 
demonstrate stability in a meaningful way. " 
"It is typicalfor applicants to persuade the MCA that it can bejustified not to provide 
detailed data on impurities or degradation products. Indeed we are well aware that 
for many herbal ingredients the constituents responsible for their effects are simply 
not known. " 
Unfortunately, persuading the MCA that stability testing should be omitted for 
constituent levels and degradation products is not as easily achieved as the above 
statement implies. The outcome from previous discussions with the MCA was that 
stability testing would have to be performed. However, it was suggested that some 
leeway might be given with the ICH specification limits. 
8.5 Bibliographic Information to Support an Application 
Satisfying the MCA's requirements within the MLA-164 document to provide 
experimental and biological data on the herbs, through bibliographical supporting 
evidence, was difficult due to the limited research available. Hypericum perforatum, 
Cimicifuga racemosa and Glycyrrhiza glabra had good supporting evidence for 
efficacy and safety in human subjects, but there was minimal research for Salvia 
offiCinalis and none for Dioscorea villosa. There was no mutagenic or carcinogenic 
research available in the literature for the herbs. As the treatment was designed for 
menopausal women it was unlikely that the MCA would require mutagenic testing to 
be performed. However, from previous meetings with the MCA, it was not established 
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if carcinogenic testing would need to be performed before a licence could be granted 
as the MCA's representatives gave differing opinions. The MCA are prepared in 
theory to accept bibliographical evidence for the safety and efficacy of herbal 
medicines. However, once herbs are combined within a formula the supporting 
bibliographical information may be considered irrelevant by the MCA because of the 
perceived risks of herbal interactions occurring. The MCA may then insist on 
toxicological studies being performed. 
8.6 Quality Control Procedures 
The procedures necessary to obtain a clinical trial certificate from the MCA are 
complex, and involve considerable developmental work to satisfy the safety 
requirements. Identification tests and quality control procedures based on 
specifications stated in British and European Pharmacopoeias, and herbal 
pharmacopoeias need to be conducted by a UCAS accredited public analyst, since in- 
house quality control is unlikely to be acceptable, given the need for independent 
evaluation. However, with increasing safety requirements being demanded of the 
applicant, authenticity tests conducted by a UCAS accredited laboratory may not 
necessarily be sufficient. Confirmation may have to be obtained through a botanist 
who is able to issue a voucher number to confirm identity. Microbiological testing is 
an important procedure to ensure the patient's safety, especially as powdered herbs 
may not be able to meet the microbiological specification limits for bacteria as 
demonstrated by Czech et al (2001). Alternative formulations and processing may be 
required in order to meet the safety criteria such as sterilising tablets by autoclave to 
control microbiological contamination. 
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8.7 The Production of Medicinal Herbs 
A problem for herbal medicine research is the sourcing of a supplier who is able to 
provide a complete documentary history of the plants. Producers of organically 
certified herbs in Europe, have to maintain records of the life-cycle of the herbs 
including the origin of the seeds or cuttings, place of cultivation, and harvesting and 
storage methods, similar to those governed in the United Kingdom by the Soil 
Association. However, none of the major companies contacted in the United Kingdom 
were able to provide documentation, from their suppliers, to the standards stipulated 
by the Soil Association. This was due to growers from Europe and the United States 
not having such records available. Therefore, herbs may need to be grown specifically 
for a clinical trial to ensure the necessary documentation is available. 
8.8 Experimental Results 
The quality control requirement of the Medicines Control Agency for heavy metal 
contamination would be met, based on the results obtained, since all metals tested fell 
within specified limits. However, sample testing prior to use is important, even when 
using herbs from the same cultivation area, since atmospheric pollution and effluent 
contamination will always present a risk. 
The results of the HPLC analysis showed that performing fingerprint analysis as an aid 
to confirming plant authenticity is not an appropriate method given the variations 
found in the results and comparisons with published works. This situation may change 
once the number of phytochemical, standards increases to assist with plant analysis. 
However, using a botanist to confinn plant identity, through the issue of a voucher 
number, is a method that would be accepted by the MCA. BPLC fingerprint analysis 
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may be of value for quality control purposes, such as stability studies by monitoring 
changes in the peak area of a plant. 
8.9 Conclusions 
There is a scarcity of published information detailing the specifications and procedures 
necessary to prepare herbal medicine based applications to the MCA. Furthermore, the 
MLA- 164 is, in parts, both ambiguous and unworkable in relation to herbal medicines. 
This work has highlighted these issues and furthered the knowledge of conducting 
double-blind, randomised, placebo controlled trials specifically for herbal medicines. 
The research has brought to the fore important issues that future researchers will 
encounter. In particular, a greater understanding has been achieved of the application 
process through the completion of a Medicines Control Agency MLA- 164 dossier. 
The main dilemma for herbal medicine research is developing the herbal drug 
intervention since this will be the main focus for scrutiny. The development of an 
herbal formula presents unique problems because of their complex pharmacology and 
largely unknown chemistry. Developing the herbal formula for this study has 
elucidated several important issues which herbal medicine based research applications 
will encounter, and advanced the knowledge in this poorly understood area. In 
particular, it was demonstrated how a herbal medicine formula is developed based on 
traditional usage and the type of quality control procedures that need to be 
implemented. However, it became clear whilst completing the MLA-164 application 
that the level of bibliographic information available to support an application was 
insufficient to address all of the MCA's requirements for pharmaceutical data and 
some aspects of quality control were unachievable. In addition, it emerged during 
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meetings with the MCA that it was their view that herbal medicines might be viewed 
as unknown entities when combined into a formula and thus invalidating bibliographic 
safety data on individual plants. 
One conclusion that can be drawn from the work completed is that applications to the 
MCA for clinical research trials into the efficacy of herbal medicine would be assisted 
by the provision of evidence collected by conducting an initial pilot study (via an 
MLA-162 application) incorporating a toxicological study. Toxicological data gathered 
through liver and kidney function tests could be used to demonstrate the safety of a 
formula and thus support a larger MLA- 164 based study. 
Developing a well designed research protocol and operations manual is essential to 
enable a study to achieve its aims within an ethical framework. The merits of a well 
designed double-blind, randomised controlled trial cannot be overstated since the 
generalisation of the results will be related to the quality of the trial. Nevertheless, this 
methodology does not reflect the way in which herbal medicine is actually practised 
and the potential benefits of this therapeutic discipline may become submerged within 
a standardised controlled trial. Future work would need to address this issue. The 
research protocol for this work was successfully submitted to the university ethics 
committee, and the operations manual was developed to ensure the study would be 
systematically implemented. These two documents were developed specifically for 
this study and provide the 'blueprint' for the running of the clinical trial. 
In addition to furthering the knowledge of research applications for herbal medicines, 
the thesis has also completed much of the preliminary work necessary to submit an 
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MLA- 164 application to the MCA. The work could be used as the basis for 
implementing a clinical trial to evaluate the benefits of herbal medicine in menopausal 
symptoms. 
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Appendix I 
Research Protocol Submitted to the University Ethics Committee 
Background 
Although menopause is a normal developmental process, the resulting decline in 
endogenous oestrogen levels can have serious clinical consequences. Oestrogen 
deficiency has been implicated in an increased risk for vasomotor symptoms, 
osteoporosis, cardiovascular disease, urogenital atrophy, cognitive decline, and 
Alzheimer's disease (Greendale, 1997). 
Onset of menopause 
Natural menopause occurs at a median age of 51.4 years, with a gaussian distribution 
ranging from 40-58 years. Several factors appear to determine the onset age for the 
menopause (Kato, 1998). Multiparity and increased body mass index are associated 
with later onset (Hardy, 1999), whereas smoking (Cramer, 1995; Windham, 1999) 
nullparity, medically treated depression, toxic chemical exposure and treatment of 
childhood cancer with abdominal-pelvic radiation and alkylating agents have been 
associated with a younger age of onset (Silbergeld, 1999). 
Clinical features 
One of the key symptoms in menopausal women is hot flushes (Bachmann, 1999), 
which can cause insomnia, irritability, fatigue, and reduced ability to concentrate. 
However, a recent study suggests that psychological changes commonly attributed to 
chronic sleep disturbance may be due to changing hormonal levels (Empson, 1998). 
Hot flushes typically last from 0.5 to 5 years after natural menopause but may persist 
for 15 years. They tend to last longer and be more severe with surgically induced 
menopause (Bachmann, 1999). 
Hormone replacement therapy 
Hormone replacement therapy (HRT) is given to relieve menopausal symptoms such 
as hot flushes and excessive sweating at night. HRT helps prevent atrophic vaginitis, 
osteoporosis and atherosclerosis (Smith, 1995). HRT consists of synthetic oestrogens 
that mimic the female hormones, or so-called natural (conjugated) oestrogen made 
from the urine of pregnant mares (premarin). Both are different in chemical structure 
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from natural hormones (Rogers, 1995). Side-effects from HRT include, nausea, 
vomiting, fluid retention, headaches, depression and uterine cancer (BNF, 1996). 
Bone density and HRT 
Studies have shown that only women who have taken HRT for 7 years had 
significantly higher bone density than women who had not taken oestrogen (Aloia, 
1996). Even women who had been on oestrogen therapy for 10 years were not 
protected against fractures. Their bone density declined rapidly as soon as they 
stopped taking oestrogen. By the time they were between 75 and 80 years of age (the 
age at which most fractures happen) their bone density was only marginally higher 
than women of comparable age, who had not taken oestrogen (Glenville, 1997). 
HRT Contraindications 
In the USA, it has been estimated that between 10% to 35% of women are using HRT 
(Utian and Schiff, 1994), while in the UK, as few as 7 to 10% of women use HRT 
(Hunter, 1994). This low use of HRT has been attributed to women's unwillingness to 
use this treatment for a number of reasons, including concerns regarding the risks of 
breast cancer and other hormone dependent cancers, side-effects of the treatment and 
medicalisation of a normal physiological process (Siddle, 1993). In addition, there is a 
significant number of women who are unable to take HRT because of absolute or 
relative contra-indications (Barlow, 1992). A safe, efficacious alternative to HRT 
would therefore be welcome as a useftil addition to available approaches to treating 
menopausal symptoms. 
Phytoestrogens 
Many different plants produce compounds that may mimic or interact with 
oestrogenic hormones in animals. More than 20 compounds have been identified in at 
least 300 plants from 16 different plant families. These compounds, referred to as 
phytoestrogens, are weaker than natural oestrogen and reside in herbs, grains and 
vegetables (Colborn, 1996). 
Phytoestrogens have been investigated as treatment for the symptoms of the 
menopause and osteoporosis, as well as possible cancer preventatives. Laboratory 
experiments and comparisons of Asian and Western human populations suggest that 
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diet has a large role in these types of health problems. One study found that Asian 
populations that eat large amounts of soy products (which contain large amounts of 
phytoestrogens such as genistein and daidzein), have lower rates of hormone 
dependent cancers (breast, endometrial) and lower incidence of menopausal 
symptoms and osteoporosis than westerners (Barrett, 1996). 
Plant Pharmacology 
The principle compounds associated with phytoestrogen activity are isoflavones and 
plant steroidal saponins. The isoflavone biochanin A has been identified in 
Cimicifuga racemosa and this may in part be responsible for the menopausal 
therapeutic effect (McCoy, 1996). In general, plants containing steroidal saponins are 
thought to have a hon-nonal regulating action. Saponins from Tribulus terrestris 
appear to increase follicular stimulating hormone, which in turn increases levels of 
oestradiol (Milanov, 1985). This may happen via saponins weakly binding with 
hypothalamic oestrogen receptors, which are part of a negative feedback mechanism 
of oestrogen control (Bone, 2000). This may be the therapeutic mechanism behind 
saponin containing herbs such as Glycyrrhiza glabra (triterpenoid saponins) and 
Dioscorea villosa (saponins). 
Clinical trials 
Patient trials suggest that the herb, Cimicifuga racemosa, and soy based products 
containing isoflavonoids, are effective in the treatment of hot flushes (Brzezinski, 
1999). Further studies have shown that soybeans and flaxseed have beneficial effects 
on vasomotor symptoms and bone, health (Anderson, 1999). 
The efficacy of Cimicifuga racemosa for menopausal symptoms was assessed in a 
review of eight clinical trials. The review concluded that extracts of the herb may be a 
safe and effective alternative therapy for cases where oestrogen replacement therapy 
was contraindicated, (Lieberman, 1998). One study using Salvia officinalis and 
Medicago sativa to treat menopausal symptoms found that out of thirty menopausal 
women, hot flushes and night sweats were relieved in twenty women and the 
remainder all showed improvements in their symptoms (De Leo, 1998). 
105 
Academic and Business collaboration 
This project is a joint collaboration between Neal's Yard Remedies, Middlesex 
University and the Teaching Company Scheme (TCS), a government sponsored 
organisation linking businesses with Universities to provide mutual benefits and 
transfer of skills. Neal's Yard Remedies and Middlesex University have been awarded 
a research grant for the study from the Department of Trade and Industry. Currently 
the Herbal Medicine department at Middlesex University is establishing a research 
program to further the understanding and potential benefits of Herbal Medicine. 
Aims of the project 
The aim of this study is to develop an appropriate herbal formula, which will be used 
to alleviate symptoms of the menopause and to test its efficacy using a randomised, 
placebo controlled, double-blinded multicenter trial. 
Research Question 
Is the herbal formulation NYRIO more effective than placebo at treating symptoms of 
the menopause? 
Methodology 
Patient recruitment 
A total of 400 patients will be recruited locally through the media and via leaflets and 
posters placed in Neal's Yard Remedies shops. The subjects will be drawn from three 
areas for each trial centre, London, Edinburgh and Cardiff. Patients will initially be 
screened by telephone and then asked to attend an appointment at one of the three trial 
centres. 
inclusion criteria: 
" The absence of menstruation for at least six months. 
" Active menopausal symptoms- e. g. hot flushes. 
" The age-range for inclusion is 45-65 years. 
Exclusion criteria: 
" Patients who are currently taking HRT. 
" Patients who have taken HRT within two months of the clinical trial commencing. 
" Pregnancy 
" Patients with cognitive difficulties who are unable to fill-in a self-administered 
questionnaire. 
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Patients currently taking any drug whose bioavailability may be affected by 
interactions with Hypericurn perforaturn as listed in section 1. 
Medical contraindications: 
" Congestive heart failure 
" History of hormonally dependent cancers 
" Cancer 
" Diabetes 
" Glaucoma 
" Psychiatric disorders (including, clinical depression) 
" Chronic liver disease (hepatitis, liver cirrhosis) 
" Kidney disease (nephritis) 
" Epilepsy 
" Currently being treated for HIV infection 
" History of cerebral infarct 
" Thyrotoxicosis 
Treatment 
Patients will be randomised into two groups, to receive either the formula or placebo. 
Details of the formula and dosage are in section 1. 
Data collection procedures 
Response to treatment will be measured using The Women's Health Questionnaire 
(WHQ) (Hunter, 1991). After reviewing menopause specific questionnaires the WHQ 
was chosen as it was the most comprehensive and has been widely validated 
(Wiklund, 1993). The WHQ is a menopause specific quality of life questionnaire and 
is self-administered by each patient. A second questionnaire, the measure yourself 
medical outcome profile (MYMOP) (Patterson, 1996) will also be used. The 
questionnaire, while not specific to menopause, attempts to incorporate patient's 
personal experiences of illness into the measurement process and is proving to be a 
valuable tool in complementary health care settings. This involves the patient in 
deciding which symptoms or aspect of their illness are affecting them the most. 
Data Analysis Techniques 
The data generated from the questionnaire will be analysed using the Statistical 
Program for Social Science (SPSS). Non-parametric tests (Wilcoxin matched-pairs 
signed-rank test and the Friedman test) will be used to compare within patient change. 
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Planned Research Outputs 
The publication of at least two research papers is planned after completion of the 
clinical trial. 
Timescale for the proposed research 
The clinical trial will run from ............. Treatment for each patient will last for 12- 
weeks; an initial two-weeks without treatment (both active treatment and placebo 
group) to establish a baseline measurement, followed by 12-weeks of treatment with 
either the herbal formula or placebo. 
Details of negotiated access 
Permission has been granted by the NIMH Education Foundation to use the Archway 
Clinic of Herbal Medicine. Permission has been granted from Neal's Yard Remedies 
to use their own clinics at Cardiff and Edinburgh. 
Specific ethical matters: 
Confidentiality including record keeping 
Patient confidentiality will be respected at all times. Infon-nation held on each patient 
will be stored at the treatment clinics and by the researcher. No other person(s) will 
have access to the information. Information obtained will be kept in accordance with 
the 1998 data protection act. Middlesex University has existing registered cover with 
the data protection agency for the purpose of the study. 
Nature of any inducement 
Patients will not be offered an inducement for participating in the clinical trial. 
Patient Consent 
Informed consent will be sought from each patient as detailed in the example below. 
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Dear Madam, 
The Archway clinic of Herbal Medicine is committed to providing a high level of care 
and service to its patients. Part of our work involves scientifically evaluating the role of 
herbal medicine in health care. Currently we are carrying out a study to measure how 
menopausal symptoms respond to treatment with herbal medicine. At this stage we 
would like to explain to you in more detail what you will be asked to do. After reading 
this letter, if you are still interested in taking part in the study you will be asked to sign 
in the space provided giving your consent to participate in the study. 
Attending the Clinic 
You will be asked to attend the clinic on four occasions. Today will be the first 
appointment. The next appointment will be in two-weeks time. The third appointment 
will be in 7-weeks time, the fourth with be in 12-weeks time. All appointments after 
today will last for approximately 20 minutes. During each consultation you will be 
asked questions regarding you general health and will be asked to complete two 
questionnaires. A routine physical examination may be required if concerns for your 
well-being are identified during the consultation. A qualified herbal medicine 
practitioner would carry this out. 
The Treatment 
During the I st appointment your case history will be taken and the study will be 
explained to you. You will also fill in two questionnaires and receive the treatment, 
either a herbal medicine or a placebo. The placebo does not have any known therapeutic 
benefit. Neither you nor your herbal medicine practitioner will know whether you are 
receiving the herbal medicine or the placebo. This is to ensure that the study meets the 
highest standards for evaluating benefits to patients. 
The Questionnaires 
During each appointment you will be asked to complete two questionnaires. This is to 
measure whether you have experienced any changes in menopausal symptoms and 
general quality of life. Your practitioner will explain to you how to fill-in the 
questionnaires. You will be able to ask for advice at any time. 
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Benefits to patients 
Previous studies have shown that certain herbs and plant products have been effective in 
reducing menopausal symptoms. Patients participating in this study will receive either 
the herbal therapy or the placebo. As you know, you may receive the herbal treatment 
but there is an equal chance that you will be given the placebo throughout the trial. 
Pisks of participation 
The herbal medicines used for this study have been identified as safe to use in the dose 
being given in this study when taken on their own. However, interactions can occur 
between any medicines and it is therefore important that you inform your herbal 
practitioner of any other medicines you are taking. You should also inform your GP or 
health provider that you are taking herbal medicines. 
Cost of participation 
All consultations and medicines will be free of charge during your involvement in this 
study. 
Standard clauses 
1. The principal treatment and procedures in this project have been identified and 
explained to me in language that I can understand. 
2. The expected benefits from the procedures have been explained to me. 
3. The risks and discomforts from the procedures have been explained to me. 
4. An offer has been made to me to answer any questions that I may have about 
these procedures. If I have any questions before, during or after the study, I may 
(name of practitioner). 
5.1 have been told that I may refuse to participate or stop my participation in this 
project at any time without any prejudice. All new findings during the course of 
this research, which may influence my desire to continue or not to continue to 
participate in this study, will be provided to me as such information becomes 
available. 
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6. If I have any questions regarding my rights as a subject participating in this 
study, I may contact ..................... (name of practitioner). 
7. Infonnation will be kept in accordance with the 1998 data protection act and 
only statistical information will be released without identifying you in any way. 
I have a right to privacy, and all information that is obtained in connection with 
this study and that can be identified with me will remain confidential. The 
results of this study may be published in scientific journals without identifying 
me by name. 
8.1 understand that by agreeing to participate in the trial that I may receive either a 
herbal medicine or placebo treatment. The placebo does not have any known 
therapeutic benefit. 
9.1 understand that if my GP or health provider prescribes medicines, I will need 
to inform them that I am currently taking herbal medicines. 
I voluntarily agree to participate as a subject in the above named project. I 
understand that I will be given a copy of the consent form I have signed. 
Date ........................................ 
Patient's name (Please print) .................................... 
Patient's signature ................................................ 
III 
Evidence of undertaking appropriate risk assessment for the study 
All five herbs selected for the clinical trial to be used in the formula have a long 
traditional use for the relief of menopausal symptoms. An herbal formula was chosen 
in preference to a single herb as this reflects current and historical use of herbal 
medicine in the UK to treat health disorders including menopausal symptoms. The 
herbs to be evaluated for the study are currently used by practising Medical Herbalists 
in the treatment of menopausal complaints and no serious side effects have been 
reported in clinical trials or relevant pharmacopoeias using dosage levels 
recommended in the British herbal Pharmacopoeia. Evidence of safety for the herbs to 
be used for the clinical trial has been established through empirical use and clinical 
studies. The herbs, Hypericurn perforaturn, Cimicifuga racernosa and Glycyrrhiza 
glabra have been shown in studies to be safe and efficacious (Linde, 1996; Liske, 
1998; Bernardi, 1994). 
Cimicifuga racemosa 
Cimicifaga racemosa has been given in daily doses of 200mg without adverse affects, 
(Liske, 1998). Patient tolerance for Cimicifuga racemosa has been assessed as very 
good, with only gastrointestinal complaints of low frequency and degree having been 
reported in some studies (Stolze, 1982). The dosage to be used is more than one and a 
half times lower than the maximum recommended dosage as cited in Newall, (1996). 
Hypericum perforatum 
In clinical studies, Hypericum perforatum been shown to be well tolerated by patients, 
with an extremely low incidence of side effects (Kim, 1999). Concerns have arisen 
recently over potential interactions between prescribed medicines and Hypeficum 
perforatum. Although some studies have been inconclusive, two clinical reports 
indicate that Hypericum perforatum increased the rate of metabolism of warfarin and 
cyclosporin and that blood levels were reduced by approximately ý0% (Qin-Ying 
Yue, 2000; Ruschitzka, 2000). A study with Hypericum perforatum and digoxin also 
indicated that Hypericurn potentiated the effect of the drug, however the placebo 
group had a 9% decrease in digoxin levels and therefore the variation may reflect 
known variability in digoxin distribution or systematic availability (Johne, 1999). 
Nonetheless, real concerns regarding potential interactions mean that Hypericum 
perforatum should not be used concurrently with a range of prescribed medications. 
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The trial will follow the guidelines required by the Medicines Control Agency (2000) 
and patients who are taking drugs with a potential for interaction with Hypericum 
perforatum will be excluded from the trial (see Appendix 1). The dosage to be used is 
more than three times lower than the maximum daily dose recommended by the 
European Scientific Cooperation on Phytotherapy 1997 (ESCOP, 1997). 
Glycyrrhiza glabra 
Patients taking aqueous extracts of Glycyrrhiza glabra containing 814mg 
Glycyrrhetinic acid have been shown to develop arterial hypertension after two-weeks 
of ingestion. Patients taking 108mg and 217mg of Glycyrrhetinic acid daily did not 
develop any side effects including arterial hypertension (Bernardi, 1994). The daily 
dose of Glycyrrhiza glabra to be used in this study is 0.5 gram crude herb and will 
contain approximately 25mg Glycyrrhetinic acid, which is eight times lower than the 
known safe concentration identified. 
Salvid officinalis 
Salvia qjficinalis (dried herb leaf) as reported in the ESCOP monograph 1997 has no 
known contraindications or interactions with other medicines. However, the use of 
Salvia officinalis is not recommended during pregnancy as a precautionary measure. 
The daily dosage to be prescribed in this trial is five times lower than the safe 
recommended dosage stated in the ESCOP, 1997 monograph for this herb. 
Dioscorea villosa 
Dioscorea villosa is a poorly researched medicinal plant, although it is one of the 
original sources of isolated steroids first used to create the contraceptive pill. It has 
longstanding traditional use in the treatment of menopausal conditions. The British 
Herbal Pharmacopoeia 1983, though a somewhat outdated pharmacopoeia, indicates 
that it is a safe remedy at recommended dosage levels. The daily dosage to be used in 
this study is five times lower than the maximum daily dosage recommended by the 
BHP 1983. No reports of toxicity at these dosages have been recorded. 
Medicines Control Agency 
An application to the Medicines Control Agency will be submitted for approval of the 
proposed clinical trial. 
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SECTION I 
Patients on the drugs listed are to be excluded from the trial 
e HIV protease inhibitors (indinavir, nelfinavir, ritonavir, saquinavir) 
* HIV non-nucleoside reverse transcriptase inhibitors (efavirenz, nevirapine) 
o Warfarin 
9 Cyclosporin 
* Oral contraceptives 
e Anticonvulsants (carbamazepine, phenobarbitone, phenytoin) 
9 Digoxin 
e Theophylline 
o Triptans (sumatriptan, naratriptan, rizatriptan, zolmitriptan) 
* SSRI's (citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline) 
(MCA, 2000) 
Dosages to be used for the formula 
Patients are to receive 4.50 grams daily of the formula, or the placebo for a total 
period of 12-weeks. 
Proportion of herbs in the formula 
" Hypericum perforatum 27.8% 
" Cimicifuga racemosa 27.8% 
" Dioscorea villosa 16.7% 
" Salvia officinalis 16.7% 
" Glycyrrhiza glabra 11.0% 
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Appendix 11 
Practitioner's Operations Manual 
Background to the Study 
The Study is a joint project between Neal's Yard Remedies and Middlesex University. 
The clinical trial aims to evaluate the role of herbal medicines to relieve symptoms of 
the menopause. The trial will operate from three clinics, the Archway Clinic of Herbal 
Medicine in London and Neal's Yard Remedies clinics at Cardiff and Edinburgh. The 
trial will be co-ordinated from the Archway Clinic of Herbal Medicine. The Archway 
clinic will see approximately 300 patients during the trial. Neal's Yard Remedies will 
see 50 patients at each clinic. 
Patients will be recruited through advertisements in the London, Edinburgh and 
Cardiff area. Although patients will initially be telephone-screened centrally at the 
Archway clinic, they will be referred to their local clinic to arrange appointments. 
Patients will receive either a herbal treatment or placebo, which will be administered 
for 12 weeks. Patients will be assessed over 12-weeks with four appointments 
scheduled for weeks 1,2,7 and 12. Outcomes will be measured using two 
questionnaires. 
Patient screening 
The screening process is to ensure that patients meet the entrance criteria. If accepted 
patients are given the telephone number of their local clinic, to arrange an 
appointment with the practitioner. The patients will be randomly allocated to a 
treatment group and issued with a trial number in time for the 1" consultation. This 
information will be returned to your clinic by fax, so that the practitioner will know 
the patient's trial number and which treatment to prescribe. To ensure this process 
happens smoothly, the appointments will need to be held I week after the screening 
process to enable the patient's personal details to be recorded by the co-ordination 
centre at the Archway Clinic of Herbal Medicine. 
An example will clarify this process: 
After the initial telephone screening, the patients' details will be entered onto a 
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database and a trial number with the treatment they are to receive will be issued. This 
information (see example below) will be sent back to your clinic ready for the I st 
consultation. 
Example of details returned to each clinic before the I" consultation: 
Name Angela Smith 
Age 50 
D. O. B 20th February 1951 
Trial No. 45 
Trial Centre Archway 
Treatment 614 
Thus, each patient will have a unique trial number and will be randomly allocated to 
receive either the herbal treatment or placebo. Neither the practitioners nor the 
evaluator will know which treatment the patients are receiving. 
Patient eligibility criteria 
During the Ist consultation the patient will need to be reassessed to ensure that they 
meet the entry criteria (Table 1). There are four sections, which need to be reviewed: 
1. Inclusion criteria 
2. Exclusion criteria 
3. Medical contraindications 
4. Drug exclusion criteria 
Table 1. Patient screening criteria for eligibility 
1. Inclusion criteria: 
0 The age-range for inclusion is 45-65 years. 
Active menopausal symptorns- i. e. (6 hot flushes during the past week). 
The absence of menstruation for at least six months 
2. Exclusion criteria: 
" Patients who are currently taking HRT. 
" Patients who have taken HRT within two-months of the clinical trial 
commencing. 
" Patients with cognitive difficulties and are unable to fill in a self-administered 
questionnaire, 
_ ýMedlcal contraludications: 
Congestive heaft failure 
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Diabetes 
Glaucoma 
Psychiatric disorders (including clinical depression) 
Chronic liver disease (hepatitis, liver cirrhosis) 
Kidney disease (nephritis) 
Epilepsy 
History of cerebral infarct 
Thyrotoxicosis 
Uncontrolled hypertension 
Cancer or history of hormonally dependent cancers 
HIV infection 
4. Drug contraindication: 
" Warfarin 
" Cyclosporin 
Digoxin 
Anticonvulsants: (carbamazepine, phenobarbitone, phenytoin) 
Theophylline 
Tamoxifen 
Triptans: (sumatriptan, naratriptan, rizatriptan, zolmitriptan) 
SSRI's: (citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline) 
HIV medication: (indinavir, nelfinavir, ritonavir, saquinavir efavirenz, 
Treatment 
The medicines will be dispensed at each clinic. The containers will have the patient's 
name and unique treatment number. Patients will receive, in addition to their 
treatment schedule, an additional I weeks supply of medicine to allow for 
continuation of treatment if an appointment date is missed. 
Questionnaire completion 
Response to treatment will be measured using The Women's Health Questionnaire 
(WHQ). The WHQ is a menopause-specific quality of life questionnaire and is self- 
administered by each patient. A second questionnaire, the Measure Yourself Medical 
outcome Profile (MYMOP) will also be used. The questionnaire, while not specific to 
menopause, attempts to incorporate patients' personal experiences of illness into the 
measurement process. This involves the patient in deciding which symptoms or aspect 
of their illness are affecting them the most. Patients will need to fill-in two 
questionnaires at each consultation. The patient's records including both 
questionnaires will need to be photocopied and sent to The Archway Clinic of Herbal 
Medicine, which will act as the co-ordination centre for the 3 trial centres. 
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Adverse event reporting card 
Patients will be given an adverse event form to record any suspected reactions to the 
treatments. Patients will need to return the form on each appointment day and will be 
issued with a new form on each visit. The returned forms are to be copied and sent to 
the Archway clinic along with copies of the case notes and questionnaires. 
Informed consent 
Informed consent will be sought from each patient. Patients will be asked to read and 
sign the consent letter once the consultation is completed. 
Confidentiality including record keeping 
Patient confidentiality will be respected at all times. Information held on each patient 
will be stored at the treatment clinics and by the researcher. Only the researcher, 
practitioners and the medical consultant involved will have access to the information. 
NYR clinics will send copies of the case notes, questionnaires and adverse event 
forms to the Archway co-ordination centre. 
Nature of any inducement 
Patients will not be offered an inducement/payment(s) for participating in the clinical 
trial. No charge is to be made to patients for their involvement in the trial, including 
consultations and treatment. 
Patient assessment 
It is important to ensure that patients have no serious medical condition that would 
determine it inappropriate for them to participate in the trial. The patient's health 
status needs to be assessed against the medical and drug contraindications list for 
entry into the study. However, if you feel that the patient is too ill to be included into 
the study for a reason not cited on the medical contraindication list, then you must use 
your clinical judgement and exclude the patient if necessary. Go through each section 
in turn, using screening questions for each system and probe if fin-ther information is 
needed. For example, if a patient has stated that she does not have hepatitis, and yet is 
showing clinical signs of jaundice, then she must be excluded from the study and 
referred to her GP. 
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Physical examinations 
Physical examinations should be performed only when there is a clinical need. If a 
concern arises during the consultation, the appropriate physical examination must be 
performed. Therefore if you suspect that the patient has cardiovascular abnormalities 
then a CVS examination should be performed. 
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PRACTITIONER INSTRUCTIONS 
1" CONSULTATION 
Procedure to be followed: 
i) Personal details: The duration of the first appointment should last no longer than 
40-minutes. Record the patient's personal details using the patient's case history notes 
(section 1), including her trial and treatment numbers. Check that the patient meets 
the age range criteria, and record her demographic details. 
ii) Screening: Go through the screening check-list (questions 1-6) with each patient 
to ensure that the inclusion/exclusion criteria is met. 
iii) Previous Medical History: Ask the patient about her past medical history and 
record the details. 
iv) Systematic enquiry: Go through each system (CVS, RS, GIT, US, LM, NS, 
Repro) using the screening questions to check the patient's health status. If concerns 
arise, follow up with further enquiries and physical examination(s) if required. 
v) Blood Pressure: Take the patient's blood pressure and record the findings. 
vi) Informing patients 
Once the health screening is completed explain, briefly, to the patient what the study 
involves using the form provided (section 3). 
vii) Consent form: Give the patient the consent form and explain to the patient her 
rights. Ask the patient to sign if she agrees to participate. Give a copy of the consent 
form to each patient. 
viii) Questionnaires: Give the patient the Women's Health Questionnaire and the 
MYMOP questionnaire to fill in. You will need to give assistance to the patient to fill 
in the MYMOP questionnaire. 
ix) Medicine: Dispense the medicine to the patient (2 weeks) 
123 
x) Adverse Event Form: Give the adverse event form to the patient (section 6). 
Explain how the form should be completed using the instruction (section 5) and 
remind the patient to return the form at the next appointment. 
xi) Next appointment: Give the patient her appointment date and time. 
124 
2 nd CONSULTATION 
Procedure to be followed: 
i) Case-notes: Review the case-notes and highlight any areas of concern with the 
patient. Enquire about her well-being and how she has been coping with the medicine. 
ii) Adverse events: Check the adverse event card and follow up with further 
questions if necessary. 
iii) Compliance: Check the patient's compliance with the medicine and record the 
findings. 
iv) Blood Pressure: Take the patient's blood pressure and record the findings. 
v) Medicine: Dispense the medicine to the patient (5-weeks) 
vi) Adverse event card: Give the patient a new adverse event card. 
vii) Questionnaires: Assist the patient to complete the MYMOP questionnaire and 
give the (WHQ) to the patient for completion after the consultation. 
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3rd CONSULTATION 
Procedure to be followed: 
i) Case-notes Review the case-notes and highlight any areas of concern with the 
patient. Enquire about her well being and how she has been coping with the medicine. 
ii) Adverse events: Check the adverse event card and follow up with further 
questions if necessary. 
iii) Compliance: Check the patient compliance with the medicine and record the 
findings. 
iv) Blood Pressure: Take the patient's blood pressure and record the findings. 
v) Medicine: Dispense the final treatment to the patient- (5-weeks) medicine. 
vi) Adverse event card: Give a new adverse event card to the patient. 
vii) Questionnaires: Assist the patient to complete the MYMOP questionnaire and 
give the (WHQ) to the patient for completion after the consultation. 
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4th CONSULTATION 
Procedure to be followed: 
i) Case-notes Review the case-notes and highlight any areas of concern with the 
patient. Enquire about her well-being and how she has been coping with the medicine. 
ii) Adverse events: Check the adverse event card and follow up with further 
enquiries if required. 
iii) Compliance: Check the patient's compliance with the medicine and record the 
findings. 
iv) Blood Pressure: Take the patient's blood pressure and record the findings. 
v) Questionnaires: Assist the patient to complete the MYMOP questionnaire and 
give the (WHQ) to the patient for completion after the consultation. 
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Section 1 
Patient Case History Notes 
Name: .............................................................. Date of I st Appointment: .................................................. 
Trial No: ............................................................................ Treatment number ......................................................... 
Address: ............................................................................. 
........................................................................................... Post code ............................................................................ Telephone No. Home: ........................................................ Work: .......................................................... D. O. B: ............................................................................... Age: ................................. Age between 45-65 years - proceed 
Age is lower than 45 or greater than 65 - exclude the 
patient 
Clinic attending: (please circle to indicate) Archway Cardiff Edinburgh 
Weight .............. 
Height .................. 
Marital status: ................ 
Occupation: ............................................ 
Children: Yes/No .................................... 
if Yes, number of children .......................... 
Do you smoke? YesNo ............................ 
If Yes, average amount per week .................. 
Do you drink alcohol? YesNo .................... 
Yes, average units per week ................................. 
Do you take exercise? Yes /No ............................ 
I unit of alcohol = 1/2 pint 
beer, I glass of wine, I glass 
of sherry or I measure of 
spirits 
If Yes, which type of 
How often per 
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Screening check-list: 
Check that the patient is eligible for entry onto the study 
1) When did you have your last menstrual period? .................... Months[Years 
If the last menstrual period occurred less than 6-months ago, exclude the patient 
2) Do you have hot flushes or sweats? ......................................................... Yes/No 
No- exclude the patient 
Yes- How many hot flushes do you have each day? ......................................... Per/day 
If the patient has hot flushes less than once per day, exclude 
3) Are you taking or have you taken HRT in the last 2months? ................. 
Yes/No 
If yes- exclude 
4 Do you have any serious health condition9 .................................................. Yes/No 
If yes, please state ........................................................................................... 
5) Do you have any of the following conditions? 
N. B. please mark-off each condition with an X for no and, with a tick if yes 
" Heart disease ....... 
" Diabetes ........ 
" Glaucoma ......... 
4, Chronic liver disease (hepatitis, liver cirrhosis) .......... 
" Kidney disease (nephritis) ......... 
" Epilepsy ......... 
" History of strokes .......... 
Thyrotoxicosis .......... 
Uncontrolled hypertension ......... 
Psychiatric disorders (including clinical depression) .......... 
Cancer or history of hormonally dependent cancers ....... 
HIV infection ......... 
Exclude the patient if she has one or more of the above conditions 
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6) Current medication: 
Are you taking any drugs from your GP or hospital Doctor? ................... Yes/No Are you taking any self-prescribed medication? .................................. Yes/No 
Exclude the patient if any of the contraindicated drugs are being taken 
Drug contraindication list 
Warfarin ......... Anticonvulsants (carbamzepine, phenobarbitone, phenytoin) .......... Digoxin .......... Theophylline .......... Triptans (sumatriptan, naratriptan, rizatriptan, zolmitriptan) ......... SSRI's (citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline) .......... Tamoxifen .......... Cyclosporin .......... HIV medication (indinavir, nelfinavir, ritonavir, saquinavir) 
Previous medical history: 
Any serious illnesses? 
Any operations/ 
hospitalisations? 
Cardiovascular system 
Chest pain 
Palpitations 
SOB 
Peripheral oedema 
Respiratory system 
Cough 
Sputum production 
Haemoptysis 
Breathlessness 
Wheezing 
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Gastrointestinal system 
Urological system 
Heartburn/indigestion 
Nausea/ Vomiting 
Blood in stools 
Constipation 
Diaffhoea 
Recent weight loss 
Urinary frequency 
Pain on passing urine 
Lower back pain 
Incontinence 
Musculoskeletal system 
Muscle weakness 
Join pain 
Muscle pain 
Nervous system 
Visual problems 
Hearing problems 
Headaches 
Fits/faints/blackouts 
Muscle weakness 
Reproductive system 
Any Bleeding 
Blood pressure: ......................... 
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Findings on physical examination(s) 
2nd appointment date ......................... 
3rd appointment date .......................... 
4th appointment date .......................... 
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Section 2 
Telephone Checklist for Patient Eligibility 
Prior to appointments, patients will be pre-screened to ensure they meet the inclusion 
and exclusion criteria listed below. Go through the checklist with patients so as to 
enable you to decide whether to proceed or whether to exclude the patient. Patients 
will need to meet all the criteria set out below before they can be entered onto the 
study. 
If the patient has met all the inclusion criteria, then record her personal details. 
Ask the patient: 
1. Name ................................................................................................... 
2. Date of Birth .......................................................................................... 
3. Age 
........................................................................................................ 
4. Address 
.................................................................................................. 
5. Telephone no ............................... 
6. Clinic the patient is attending 
(Circle one, which applies) Archway Cardiff Edinburgh 
Inclusion/ exclusion criteria: 
Ask all the patients the following questions: 
1. What is your age? .......... 
(Years) 
if her age is lower than 45, or greater than 65, exclude the patient 
2. When did you have your last menstrual period? ...................... Months/Years 
If the last menstrual period occurred less than 6-months ago, exclude the patient 
3. Do you have hot flushes or sweats? ........................................... YesNo 
No- exclude the patient 
Yes- How many hot flushes do you have each day? .............................. Per/Day 
if the patient has hot flushes less than once per day, exclude 
4. Are you taking or have you taken HRT in the last 2 months? ............ Yes/No 
if yes- exclude 
5. Do you have any serious health 
condition? .............................................................................. 
Yes/No 
If yes, please state ................................................................. 
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6. Do you have any of the following conditions? 
N. B. please mark-off each condition with an X for no and, with a tick for yes 
" Heart disease ....... 
" Diabetes ........ 
" Glaucoma ......... 
" Chronic liver disease (hepatitis, liver cirrhosis) .......... 
" Kidney disease (nephritis) ......... 
" Epilepsy ......... 
" History of strokes .......... 
" Thyrotoxicosis .......... 
" Uncontrolled hypertension ......... 
" Psychiatric disorders (including, clinical depression) .......... 
" Cancer or a history of hormonally dependent cancers ....... 
" HIV infection ......... 
Exclude the patient if she has any of the above conditions 
7. Are you taking medication from your Doctor? .......................... Yes/ No 
Yes, Go through the drug list with the patient to see if she is taking any 
contraindicated medication. If the patient is taking any medicine(s) on the list, then 
exclude the patient. 
Drug contraindication list 
N. B. Please mark-off each condition with an X for no and, with a tick for yes 
" Warfarin ......... 
" Cyclosporin .......... 
" Anticonvulsants (carbamazepine, phenobarbitone, phenytoin) .......... 
" Digoxin .......... 
Theophylline .......... 
Triptans (sumatriptan, naratriptan, rizatriptan, zolmitriptan) ......... 
SSRI's (citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline) .......... 
Tamoxifen 
HIV medication (indinavir, nelfinavir, ritonavir, saquinavir efavirenz, 
nevirapine)...... 
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Section 3 
Patient Allocation Form 
Once the patient has been given an appointment, fill in the section below and send the 
details immediately to the Archway co-ordination centre. 
1. Name ..................................................................................................................... 
2. Patient's D. O. B ........................................................................................................ 
3. Patient's age ............................................................................................................ 
4. Dateoflst appointment ............................................................................................. 
5. Address ................................................................................................................... 
6. Telephone number ................................................................................................... 
7. Indicate which clinic the patient is attending 
(circle the one which applies) Archway Cardiff Edinburgh 
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Section 4 
Instruction Sheet for Patients Entered onto the Trial 
Please use the following infonnation to explain to patients what the study involves. 
1. The study is to evaluate the benefits of herbal medicine to alleviate symptoms of 
the menopause 
2. The treatment you will receive will be either a herbal medicine or placebo 
3. We will be asked to fill in 2 short questionnaires at each visit to measure 
changes in symptoms 
4. The potential benefits of the treatment are an improvement in your 
menopausal symptoms and general well-being 
5. The herbal treatment or placebo being given has been identified as safe 
although we will monitor your well-being during the 12 weeks as part of our 
policy of patient care 
6. The study will last for 12 weeks. During this time, you may stop your 
involvement with the study 
7. During the 12-weeks, you will be seen on 4 occasions, today being the first 
appointment 
8. You can contact (name of practitioner & clinic) if you have any questions 
about this study 
Is there anything you would like to ask? 
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Section 5 
Adverse Event Instruction Sheet 
Give each patient an adverse event Report Form 
Explain to the patient that: 
Although the medicine(s) are safe, as part of our policy for patient care, we would like 
to monitor your well being throughout the study for any potential reactions to the 
medicine. Therefore, if you experience any complaints or symptoms, record them on 
the record card. Please record all complaints or symptoms even if they appear 
unrelated and insignificant. It is not necessary to record the symptoms you would 
normally experience during the menopause. 
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Section 6 
Adverse Event Report Fonn 
Patient Details: Name D. O. B. 
Trial Number 
If you experience a symptom or complaint other than what you would normally experience during the 
menopause, please write them down on the form below. 
For Example: 
If you should experience a skin rash whilst taking the medicine, then write down the following: 
Symptomleomplaint (e. g. red skin rash on hand) 
Onset (e. g. 12 th March) 
Until (13ffi March) 
Severity using either mild moderate, or severe to indicate the severity 
Example of a reporting reaction 
Symptom/complaint Onset Until Severity 
Date Date Mild Moderate Severe 
Red Skin Rash on hand 120'March 14'h March X 
Symptom/complaint Onset Until Severity 
Date Date Mild Moderate Severe 
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Appendix III 
Are you suffering from 
Menopausal 
symptoms? 
Why not volunteer for a major 
clinical trial to assess the benefits of 
Herbal Medicine to relieve 
menopausal symptoms? 
e Pick up a leaflet inside for more information 
* Or call 020 8362 0000 for more information 
Locations: London, Cardiff and Edinburgh 
FIV I 
MIDDLESEX 
UNIVERSrrY 
National institute of 
Medical Herbalists 
MIDDLESEX 
UNIVERSrrY 
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Appendix V 
Tuesday Group A 
13'h March Al Group B 
20'h March B1 
27 th March A2 
3'd April B2 Group C 
I O'h April Cl Group D 
17 th April DI 
24'b April C2 
I st May A3 D2 Group F 
8 th May B3 Group E F1 
15 th May El 
22 nd May F2 
29th May C3 E2 
5 th June A4 D3 
12"' June B4 
19th June 
26th June F3 
P July C4 E3 
loth july D4 
17 Ih jUly 
24th July 
31" July F4 
7'h August E4 
Group A 8 patients 
Group B 8 patients 
Group C 8 patients 
Group D 8 patients 
Group E 8 patients 
Group F 5 patients 
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Appendix VI 
Please indicate how you are feeling now, or how you have been feeling THE LASr FEW DAYS, by 
a tick in the appropriate box to ilidicate your answer for each statement :I 
Yes, Yes, 
definitely Sometimes 
1. 1 wake during the night and then sleep badly .................. 
2. 1 get very frightened and have panic feelings 
for no apparent remn ............................................. 13 
1 1 feel miserable and sad ............................................ 
13 
4 1 feel anxious when I go out of the houw on my own ....... 
(3 
5. 1 have lost interest in things ....................................... 
13 
6. 1 get palpitations in my chest or a sensation of 
'butterflies" in my stomach ....................................... 
7. 1 still enjoy the things I used to .................................. 
13 
8. 1 feel Iffe is not worth living ...................................... 
13 
9. 1 feel tense or "wound up . ........................................ 
E3 
10. 1 have a good appetite .............................................. 
13 
11. 1 am restless and can't keep still ................................. 
13 
12. 1 am more initable than usual .................................... 
13 
13. 1 worry about growing old ........................................ 
13 
*Dr Myra HUM«, Univmity Coßege LundM Wdm UK 
WHQAUMWC 
No, No, 
rarely not at all 
0 1: 1 13 
13 1: 1 
13 13 
13 13 
13 0 13 
13 M 13 
13 0 13 
13 13 13 
El 0 13 
C3 13 0 
13 13 13 
C3 0 C3 
0 13 13 
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I lease indicate how you are feeling now, or how you have been feeling THE LAST FEW DAYS, by 
patting a tick in the appropriate box to indicate your answer for each statement :I 
yes, Yes, No, No, 
deftaitely Sometimm wely not at aU 
14. 1 get headaches ...................................................... 13 13 13 
15. 1 feel more tired than I usually do ............................... 
13 13 1: 1 
16. 1 have dizzy spells .................................................. 
13 13 13 
17. My breasts feel tender or uncomfortable ....................... C3 13 13 
18. 1 suffer from pain in my back, arms and legs ................. 
(3 13 13 13 
19. 1 gpt hot flushes ..................................................... 13 13 13 13 
20. 1 am more clumsy than usual ..................................... 
13 13 13 13 
21. 1 feel rather lively and enthusiastic .............................. 
13 0 13 
22. 1 have abdominal (Mnuny) cramps or discomfort ............. 
13 E3 
23. 1 feel sick or nauseated ............................................. 
24. 1 have lost interest in sexual activity ............................ 
0 (3 
25. 1 feel good in myself ............................................... 
C3 0 C3 0 
26. 1 have heavy periods ............................................... 
C3 13 E3 
(Piease omit if rio, periods at all) 
27. 1 suffer from night sweats ........................................ 13 13 13 
*Dr My= HUMU, Utdvemily Colkp Lmxkm% Landw UK 
wgQAE130. DOC 
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Please indicate how you are feeling now, or how you have been feeling THE LAsT FEw DAys, by 
putting a tick in the appropriate box to indicate your answer for each statement 
I 
Yes, Yes, No, No, 
definitely sometimes ruely not at all 
28. My stomach feels bloated .............. : .......................... 
13 13 13 13 
29. 1 have difficulty in falling asleep ................................. 
13 13 13 13 
30. 1 often have a feeling of pins and needles 
in my hands and feet ............................................... 
1: 1 1: 3 13 0 
31. 1 am satisfied with my current sexual relationship ........... 
1: 1 C3 0 1: 3 
(piease omit if wt sexually active) 
32. 1 feel physically attractive ......................................... 13 13 13 
33. 1 have difficulty in concentrating ................................. 
C3 13 13 C3 
34. As a result of vaginal dryness sexual intercourse 
has become uncomfbrtable ........................................ 13 13 13 
(pieaw omit if wt semally active) 
35. 1 need to pass urine/water 
more frequently than usual ........................................ 
13 0 13 
36. My memory is poor ................................................ 
(3 13 13 
37. is it very difficult to cope with any of 
the above symptoms? 
Please list them below: 
OM Myra Hinw, Univwity Conep Landon, I ondon UK 
WHQAUS&DOC 
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Appendix VI-I 
MYMOP2 
Full name ............................................................. Date of birth ... ............. 
Address and postcode ................................................................................................... ..................... 
Today's date ................... Practitioner seen .................................................. 
Choose one or two symptoms (physical or mental) which bother you the most. Write them on the lines. 
Now consider how bad each symptom is, over the last week, and score it by circling your chosen number. 
SYMPTOMI: ............. 012345 6 
.................................... As good as As bad as it could be 
..................................... 
It could be 
SYMPTOM 2: ............. 012345 6 
.................................... As good as As bad as it could be 
..................................... 
It could be 
Now choose one acIlivity (physical, social or mental) that is important to you, and that your problem makes 
difficuft or prevents you doing. 
Score how bad it has been in the last week 
ACTIVITY: ............ .... 012345 6 
.................................... As good as As bad as it could be 
..................................... 
It could be 
Lastly, how would you rate your general feeling of wellbeing during the lad week ? 
012345 6 
As good as As bad as 
it could be ft could be 
How long have you had your Symptom 1, either all the time or on and off ? 
Less than 2 weeks C3 24 weeks 0 4-12 weeks 0 
3 months- I year 0 Over I year 0 
Tick the box which best describes how you feel: 
Cutting down or avoiding medication 
is not important to me 13 
is a bit important to -me 13 
is very important to me 13 
If you have answered that medication IS important to you, wrile down what medication you would like to oil 
down or avoid, and how much of it you are taking at the moment. 
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MYMOP2. Follow-up 
Name 
............................................................. 
Today's date 
................................................... 
Please circle the number to show how severe your problem has been IN THE LAST WEEK 
This should be YOUR opinion, no-one else's! 
SYMPTOM1: ............. 
012 3456 
.................................... As good as As bad as 
..................................... 
it could be It could be 
SYMPTOM 2: ............. 012 3456 
.................................... As good as As bad as 
..................................... 
it could be It could be 
ACTRATY: ............. .... 012 
3456 
.................................... 
As good as As bad as 
..................................... 
it could be It could be 
WELLBEING: how 012 3456 
would you rate your 
general feeling of As good as As bad as 
wellbeing ? it could be It could be 
If an important new symptom has appeared please describe it and mark how bad it is below. 
Otherwise do not use this line 
SYMPTOM 3: ............. 0123456 
.................................... As good as As bad as it could be It could be 
..................................... 
The treatment you are receiving may not be the only thing affecting your problem. If there is anything else 
that you think is importaK such as changes you have made yourself, or other things happening in your life, 
please write it here (write ovedeaf if you need more space): 
If cutting down or avoiding medication is important to you , Itick the box to show how this has changed since 
your previous MYMOP form: 
Not much change 0 
Taking less medication C1 
Taking more medication 13 
if there has been a change write down what medication has changed, and how much of it you are taking 
now: 
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Appendix VIII 
A COMPLETED MLA-164 APPLICATION FOR SUBMISSION TO THE MCA 
FORM MLA 164 (Revised December 1995) MEDICINES ACT 1968 
NOTICE UNDER THE MEDICINES (EXEMPTION FROM LICENCES) 
(CLINICAL TRIALS) ORDER 1995 PART I 
1. Product name or company code. 
NYR10 
2. Full name and address of person 
submitting notification. 
John Rathbone, Neal's Yard Remedies, Ingate Place, Battersea, London, SW8 3NS 
3. Name and address of supplier 
if different from 2. above. 
Company number if known. 
4. Any other name under which the 
supplier carries on business. None 
5. Does this CTX notification refer 
to a NEW ACTIVE SUBSTANCE No 
6. Is this a BIOLOGICAL SUBSTANCE? Yes 
7. Has your company made any other submission relating to active 
substance(s) mentioned In this notification? 
No 
If YES, please give NUMBERS (MA, CTX, CTC), 
DECISION (GRANTED, REFUSED, WITHDRAWN, PARAGRAPH 5 ACTION ETC. ) and 
DATE 
MA/CTC/CTX CODE CODE LETTER DECISION DATE 
L7 III ID /IIII r7 
........................................ ............................. 
III ILI /11 11 71 ........................................ ............................. IIIIII[IFII ED ........................................ ............................. F -7 111 11] 1111: 1 ED ........................................ ............................. 8. Scientific evidence page 
i. Pharmaceutical and biological ............ ii. Non-clinical pharmacology and toxicology ............ iii. Human studies ............ Total (not to exceed 50-60 pages) ............ *delete 
as appropriate 
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IIIIIiIiIIIIIII 171 El 
IIIII11 171 
Part 11 
PARTICULARS OF PRODUCT AND TRIAL 
Product: 
Consisting of 5 herbs: Hypericum perforatum L, Cimicifuga racemosa L, 
Salvia officinalis L, Dioscorea villosa L and Glycyrrhiza glabra L. 
The herb material will be powdered and administered via capsules. 
The product will be produced from one batch of herbs 
The trial will be a randomised, double blind, placebo controlled study based at 3 trial centres: 
The Archway Clinic of Herbal Medicine and two Neal's Yard Remedies therapy Clinics based in 
Edinburgh and Cardiff. Patients will be recruited locally via newspaper articles. Patients will be screened 
for suitability and will be required to be menopausal with active symptoms and without any serious 
medical disorder. 
1. Name of product and strength: 
NYR10 
0.5 g per capsule 
(Official use only) 
II IT-] 
T-1 
2. Description of pharmaceutical form (eg tablets, slow-release tablets, capsules etc. ): 
Powdered herbs packed into vegetable capsules 
(Official use only) 
(Official use only) 
Date: 
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FORM MLA 164 (Revised December 1995) 
FcIiI 
use 
F-I 
3. Active constituents: (1) (2) (3) (4) 
(Official use only) Name Specification/ Unit or Quantity/Dose 
Reference 
% quantity Unit 
Hypericum perforatum ESCOP, 1997 EP, 2000 27.8 1.25g 
Cimicifuga racemosa ESCOP, 2000 (in press) BHP, 1996 27.8 1.25g 
BHC, 1992 
Salvia officinalis E COP, 1997 16.7 1 0.75g 
Dioscorea villosa BHP, 1996 16.7 0.75 
Glycyrrh iza bra BP, 1986, BHP, 1996 11.0 0.50g 
Details of any overages: these should not be included in the formulation columns but 
stated in this section. 
Please enter constituent(s) as actual substances included in the formulation, eg as 
salt and then as base equivalent where applicable. 
2) Specification reference: 
Where a specification does not refer to the latest published monograph, the 
relevant year should be included in the name column and not in the specification 
reference column. Where an ingredient has no official monograph please enter 
HSE in the Specification Reference column. Abbreviations to be used for 
specifications are: BP, EP, BPC, BNF, USP, NF, FRP, DAB, IP, NDP, JAP, PHV, 
BHP. 
3) In the case of liquid preparations: all quantities for oral preparations should relate 
to a 5-ml dosage. Please state in dosage information any deviation from this rule. 
Quantity should be expressed as a percentage for other liquid preparations, 
including parenterals; please insert WW, WV etc. as appropriate in the Unit 
column. DO NOT INSERT a percentage sign. 
4) The following abbreviations for units are recommended: - 
ng - nanograms; gg - micrograms; mg - milligrams; g- grams; kg - kilograms; gl 
- microlitres; ml - millilitres; I- litres; U- units; KU - kilounits (1,000 U); MU - 
megaunits (1,000,000 U); IU - International Units; gCi - microcuries; Bq - 
becquerels. 
5) Trailing zeros following the decimal point may be omitted. 
6) Please photocopy page if more space for constituents is required. 
Date: 
FORM MLA 164 evised December 5) ( fficial use only) 
Lqjj IIIIIIIIII -T-T- I F-I 
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Anticipated clinical use: 
The clinical use for the product NYR 10 is to treat symptoms of the menopause, including vaso-motor 
disturbances (hot flushes and night sweats) insomnia, depression, nervousness, palpitations and 
cognitive problems. 
e The age range of the patients for the clinical trial will be 45-65 years. 
9 The patients will be menopausal women who have not had a period for at least 6 months. 
9 The nature of the study will be a multicentre, placebo controlled, randomised, double-blinded trial. 
The purpose of the trial is to evaluate whether the herbal formula NYR 10 is significantly more 
effective than a placebo in alleviating menopausal symptoms and improving quality of life. 
This will be determined using two questionnaires, the Women's Health Questionnaire (a menopause 
specific quality of life questionnaire) and the Measure Your Own Medical Outcomes Profile (MYMOP) 
questionnaire, a patient centred questionnaire. 
official use only) 
1 91 11 
vaie: 
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FORM MLA 164 (Revised December 1995) 
Bl1I 
Offlcial use 
F-1 
5. Proposed dosage range and duration to be used for the trial and proposed route of 
administration: 
The pharmaceutical form used will be a capsule containing dried powdered herbs. The route 
of administration will be oral. The maximum daily dosage will be 4.5g. The maximum 
proposed duration of exposure by patients will be 12 weeks. 
The quantity of each herb per day is: 
Hypericum perforatum 1.25 gram 
Cimicifuga racemosa 1.25 gram 
Salvia officinalis 0.75 gram 
Dioscorea villosa 0.75 gram 
Glycyrrhiza glabra 0.5 gram 
Total: 4.5 
The minimum age of the patient will be 45 years. 
The maximum age of the patients will be 65 years. 
The maximum number of patients in the clinical trial will be 400. 
The placebo will be rice flour, administered orally via vegetable capsules. 
The maximum daily dosage will be 4.5g. 
The maximum proposed duration of exposure would be l2weeks. 
juate: 
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FORM MLA 164 (Revised December 1995) 
[ET1I 
Offlcial use 
F-I 
6. Other constituents: Specification Quantity/Dose 
(Official use only) Reference Unit or %quantity 
Name Unit 
Vegetable capsule 
Farmacapsulas 
Hydroxypropylmet- 
hylecellulose i. e. 
Carbohydrate gum 
derived from wood 
and cotton fibres 
USP 
FCC 
GRAS 
0.10 g 
Rice flour to be 
used as the 
placebo 
0.5g per 
capsule 
Please leave a line between different components of the dosage form, eg for capsule 
shell components, coating components. 
2) Please complete modifier column marked MOD as follows: 
Insert TO if final volume cannot be expressed as a complete quantity. 
Insert ND for substances not detectable in the final formulation, eg solvents. 
Insert QS if quantity not fixed e. g. for substances used to adjust pH. 
3) For notes on specification references, liquid preparations, abbreviations for units and 
decimals please refer to page 3. 
4) Please photocopy page if more space for constituents is required. 
Date: 
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FORM MLA 164 (Revised December 1995) 
Hill 
use o 
F-I 
7. Description of essential processes in the manufacture: 
After harvesting, the herb material is dried to organic soil association standards by following standard 
operating procedures, which include using separate storage facilities from non-organic material. 
The essential process comprises the grinding of herb material with an 8 inch Apex cutter mill with 
variable mesh sizes (lmm - 4mm). The raw ingredients are then mixed to the prescribed formula and 
encapsulated. Capsules are placed into tamper evident opaque sterile tubs and labelled /batched. 
At all times during the manufacturing procedure, raw materials, bulk containers and major items of 
equipment are labelled with an indicator of the product material being processed and its batch number. 
Each raw material is initially placed in a separate quarantine area and checked on delivery that the 
product complies with its specifications. Organoleptic checks are immediately carried out by the 
warehouse manager. All suppliers are required to supply certificates of analysis for starter materials and 
carry out their own laboratory testing in compliance with due diligence. 
Raw ingredients are randomly sampled with a clean container and the sample sent off for external 
microbial and heavy metal analysis. Finished products are randomly sampled and analysed for microbial 
and heavy metal concentrations. 
All fillers, encapsulators and mixers have to record the amount and weight of capsules and powders. 
These weights are checked during normal quality control procedures to ensure that they comply with the 
specification. Random checks are carried out to ensure that the mixers are accurately placing the correct 
quantity of raw ingredients into each formula. 
The process validation protocol for G&G Food supplies Ltd requires that Good Manufacturing Practice is 
followed at all times. G&G is an affiliated company of the Institute of Quality Assurance and is certified 
by the Soil Association to manufacture organic products. G&G supplies has a class V clean room facility 
for the manufacturing of all health food products, meeting the requirements of BS5295: 1989. 
8. Finished product specification: 
0 size vegetable capsule containing total maximum 
weight 0.5g of herbal formula. 
Hypericum perforatum 27.8% 
Cimicifuga racemosa 27.8% 
Salvia officinalis 16.7% 
Dioscorea villosa 16.7% 
r,, Ivrvrrhiza -alabra 
11% 
vate: 
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FORM LA 164 (Revised December 1995) 
use 
F-I 
9. Type of container(s), pack size(s), shelf life and storage precautions. 
The capsules will be stored in sterile plastic containers. 
The pack size will be 100 capsules per container. 
The containers will be opaque. 
10. Assembler(s) 11. Importer(s) into the UK 
G&G, Food supplies LTD, Vitality House, 2-3 
Imberhorne Way, East Grinstead, West Sussex The Organic Herb Trading Company 
RH19 1RL Milverton, Somerset, 
TA4 INF 
This Soil Association Standard affiliated company 
will be the supplier for all the herb material. 
12. Name(s) of manufacturer(s) and site(s) of manufacture of-. 
(a) the active substance(s) and (b) the dosage form. 
(a) The active substance(s) (b) The dosage form (including sterilisation 
if applicable) 
The Organic Herb Trading Company Manufacturing and filling/sterilisation: G&G, 
Milverton, Somerset, Food supplies LTD, Vitality House, 2-3 
TA4 INF Imberhorne Way, East Grinstead, West Sussex 
R1119 IRL 
13. Site and arrangements for quality control, including arrangements for testing on import Into 
UK if applicable. 
Chemical, physical and biological testing is carried out by Microsearch Ltd: on behalf of 
G&G, Food supplies LTD, Vitality House, 2-3 Imberhorne Way, East Grinstead, West Sussex 
RH19 IRL 
Date: 
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FORM MLA 164 (Revised December 1995) 
PART IIB - TRIAL PROTOCOLS 
Full details of the proposed trial, together with: 
I Protocol: 
1.1.1 Title (and company reference number if applicable). 
1.1.2 Natureoftrial. 
1.1.3 Aim of study. 
1.1.1 Study into the effects of herbal medicine to alleviate symptoms of the menopause. 
1.1.2 Placebo controlled, double-blind trial using herbal medicine to treat symptoms of the menopause. 
1.1.3 The aim of the trial is to investigate the efficacy of a herbal formula (NYRI 0) in alleviating 
menopausal symptoms. 
1.2 Duration of the trial: 
1.2.1 Duration of active treatment. 12 weeks per patient 
1.2.2 Overall duration of trial. 23 weeks 
1.3 Proposed number of patients involved: 400 
1.4 Criteria used in the selection of patients: 
1.4.1 Inclusion criteria. Women with active menopausal symptoms (hot flushes and sweats); 
without a menstrual period for at least 6-months and aged between 45-65 
years. 
1.4.2 Exclusion criteria. Women currently taking HRT or women who have taken HRT in 
the last 2-months; pregnant women with a serious medical condition, 
(refer to Protocol for the clinical trial NYR 10). 
1.4.3 Withdrawal criteria. Any serious deterioration in the subjects health which would 
normally exclude patients from continuing with the active or placebo treatment. 
The practitioner on the initial and follow-up consultations will assess this. 
Description of the safety monitoring procedures: 
Dr Ellis Snitcher will oversee safety procedures for the duration of the trial and will monitor 
patient welfare. Patients will be interviewed by qualified herbal medicine practitioners who 
are members of the professional body, The National Institute of Medical Herbalist. The 
practitioner will screen for any serious health conditions at the initial consultation by 
performing a multisystem check (cardiovascular system, respiratory system, 
gastrointestinal system, urogenital system, nervous system and gynaecological system). The 
patients' medical/drug history will be sought, providing a screen on their previous and current 
health. Further monitoriniz will continue at all follow-ulD atmointments. 
vate: 
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Part I 
Introduction, background and rationale for trial: 
The clinical use for the product NYRIO is to treat symptoms of the menopause, including 
vaso-motor disturbances (hot flushes and night sweats) insomnia, depression, nervousness, 
palpitations and cognitive problems. A multicentre, placebo controlled, randomised, double- 
blind trial is proposed to evaluate the effectiveness of a herbal formula (NYRIO) in alleviating 
menopausal symptoms and improving quality of life. This will be determined using two 
questionnaires, the Women's Health Questionnaire (a menopause specific quality of life 
questionnaire) and the MYMOP questionnaire (a patient centred questionnaire). 
Part 11 Pharmaceutical and Biological Data 
A: Composition 
I- Comnlete comnosition: 
Nameof Active Ingredients Other Ingredients Unit and/or % Function Reference to 
Ingredients formula standards 
Hypericum Hypericum Hypericin, Solid oral forms Antidepressant EP, 2001 
perforatum perforaturn Hyperforin 27.8% Anti-viral ESCOP, 1997 
Flavonoids 
Cimicifuga Cimicifuga racemosa 27-deoxyacetin Solid oral forms Treatment of ESCOP, 2000 
racemosa L. Acetin, Cimigenol, 27.8% climacteric (in press) 
Caffeic acid symptoms BHP, 1996 
BHP, 1992 
Salvia Salvia officinalis Essential oils- Solid oral forms Antihydrotic ESCOP, 1997 
officinalis L. alpha and beta 16.7% Oestrogenic 
thujone Carnosic 
acid, Rosmarinic 
acid 
Dioscorea Dioscorea. villosa. Dioscine Starch Solid oral forms Oestrogenic BHP, 1996 
villosa L. 16.7% Anti- 
inflammatory 
Glycyrrhiza Glycyrrhiza glabra Glycyrrhizin and Solid oral forms Oestrogenic BP, 1986 
glabra L. its aglycone 11% Anti- BHP, 1996 
glycyrrhetic acid inflammatory BHC, 1992 
Vegetable N/A Hydroxypropyl- N/A Encapsulation USP 
Capsule Methylecellulose. FCC 
Carbohydrate gum GRAS 
derived from wood 
and cotton fibre 
Herb Final composition/Amount per capsule Daily 
dosage 
Hypericum perforatum L. 0.138g 1.25g 
amicifuga racemosa L 0.138g 1.25g 
Salvia officinalis L. 0.083g 0.75g 
Dioscorea villosa L. 0.083g 0.75g 
Glycyrrhiza glabra L. 0.055g 0.5g 
2. Overage: N/A 
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3. Container: 
The capsules will be stored in sterile plastic containers (DUMA, PEHD). The pack size will be 
100 capsules per container. The containers will be opaque. 
4. Formulations used in reported clinical trials and /or bioavailability studies: 
No previous trials or bioavailability data have been performed for thisformula. 
5. Developmental Pharmaceutics: 
The individual herbs in this formulation are in accordance with uses indicated by herbal 
pharmacopoeias for menopausal complaints. The container to be used is opaque to minimise 
photo-oxidation. 
The formulation is based on the traditional and current practice of medical herbalists. 
Typically, 4-6 herbs are used in combination to treat conditions such as menopausal 
complaints. The rationale for the selection of individual herbs and the formulation in particular 
are as follows: 
Hypericum perforatum 
Extensive clinical research identifying safety and efficacy as an anti-depressant, with some 
anoxylitic, activity. Also indications in sleep quality (see data in part III Experimental and 
biological studies). 
Key active constituents- Hypericin and hyperforin 
Cimicifuga racemosa 
Moderately researched as a single herb. Current evidence supports its use in the treatment of 
climacteric symptoms such as hot flushing; limited research in combination with Hypericum 
perforatum suggests efficacy as a combination in climacteric symptoms, including mood 
changes. In vitro work suggests that Cimicifuga racemosa may have oestrogenic activity (see 
data in part III Experimental and biological studies). 
Key active constituents: 27-deoxyacetin 
Salvia officinalis 
Limited clinical research suggests the potential use of this herb for excessive sweating in 
menopause. The usage relates to long established use as a antihydrotic. The herb appears to be 
oestrogenic in vitro (see data in part III Experimental and biological studies). 
Key active constituents: essential oils- alpha and beta thujone, 
Dioscorea villosa 
Almost no clinical research has been carried out on this herb which has a limited traditional 
use during menopause. The oestrogenic activity of Dioscorea villosa has been established and 
shown to be due to the action of steroidal saponins. 
Key active constituents: Dioscine 
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G1 cyrrhiza glabra Y 
There has been detailed research into this herb's anti-inflammatory and adreno-corticol 
activity. Longstanding traditional use in relief of menopausal symptoms (see data in part III 
Experimental and biological studies). 
Key active constituents: Glycyrrhizin and its aglycone glycyrrhetic acid. 
B: Method of Preparation 
1. Manufacturing formula: 
The batch size will be 3 lkg, which translates for each individual herb to Hypericum 
perforatum 8.5kg, Cimicifuga racemosa 8.5kg, Salvia officinalis, 5.5kg Dioscorea villosa 5.5 
and 3. Okg of Glycyrrhiza glabra, to provide 60,000 capsules of the active treatment. Each 
container to hold 100 capsules. No substances will be removed in the manufacturing process. 
No excipients will be used in the manufacturing process. 
Manufacturing formula: 
Herb Percentage composition Batch starting material (Kg) 
Hypericum perforatum 27.8% 8.5 
Cimicifupa racemosa 27.8% 8.5 
Salvia officinalis 16.7% 5.5 
Dioscorea villosa 16.7% 5.5 
Glycyrrhiza glabra 1 11% 13.0 
2. Manufacturing process, in-process controls and assembly process: 
The essential process comprises the grinding of herb material with an 8** Apex cutter mill with 
variable mesh sizes between Imin & 4mm. Then the raw ingredients are mixed to a prescribed 
recipe and encapsulated. Capsules are filled to the required amount into tamper evident opaque 
tubs and labelled /batched. At all times during the manufacturing procedure, all raw materials, 
bulk containers and major items of equipment are labelled with an indicator of the product 
material being processed with its batch number. Each raw material is initially placed in a 
separate quarantine area and checked on delivery that the product complies with its 
specifications. The warehouse manager immediately carries out organoleptic checks. All 
suppliers are required to supply certificates of analysis for starter materials and carry out their 
own laboratory testing in compliance with due diligence. Cleaning procedures for the 
equipment and manufacturing areas are conducted in accordance with written specifications 
and procedures. Cleaning schedules for each area of the premises are in existence. The 
effectiveness of cleaning is microbiologically evaluated using damp swabs to wipe down all 
surfaces. The swabs are then analysed. 
All materials are recorded with product and supplier's name, batch number and date of receipt. 
The batch number is used to identify the product in storage and processing. It is recorded at 
every stage of manufacture in order to ensure that any batch of finished product can be 
correlated with the deliveries of the respective raw materials used in its manufacture and with 
any corresponding laboratory records. Records are kept for all batches. All retained records 
permit full batch traceability from the customer through the factory back to the supplier of the 
individual raw ingredients. 
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Raw ingredients are randomly sampled for external microbial and heavy metal analysis. 
Finished products are randomly sampled and analysed for microbial and heavy metal 
concentrations. All fillers, encapsulators and mixers have to record the amount and weight of 
capsules and powders. These weights are checked during quality control to ensure that they 
comply with the specification. Random checks are carried out to ensure that the mixers are 
accurately placing the correct quantity of raw ingredients into each formula. The process 
validation protocol for G&G Food supplies Ltd requires that GMP be followed at all times. 
G&G are an affiliated company of the Institute of Quality Assurance and are certified by the 
Soil Association to manufacture organic products. G&G supplies has a class V clean room 
facility for the manufacturing of all health food products, meeting the requirements of 
(BS5295: 1989). 
3. Validation of the process 
G&G Food Supplies Ltd, perform routine random checks with the mixing/encapsulating 
machinery to ensure the composition is uniform. All packaging machinery is calibrated 
annually or more frequently if required and calibration records kept for referral. An external 
contracted company calibrates all scales on an annual basis. Internal scale calibration tests are 
carried out on an annual basis by the quality control department. 
C: Control of starting material 
I- Active inizredients 
Herb Ac ive ingredients 
Hypericum perforatum Hypericin, hyperforin 
Cimicifuya racemosa 27-deoxyacetin 
Salvia officinalis Essential oil, alpha and beta thujone 
Dioscorea villosa Dioscine 
Glycyrrhiza glabra Glycyrrhizin and its agl cone glycyrrhetic acid, 
1.1 Specification and routine tests: 
All herbs will be examined macroscopically and microscopically to ensure correct identification 
of the herb material. Ash value will be measured against pharmacopoeia values to ensure 
conformity. The starting material will be sent to a UCAS accredited public analyst for 
confirmation of correct identity of the herb(s) material and testing according to British Herbal 
Compendium specifications. 
I Active ingredients described in a pharmacopoeia: 
The material used for the trial will be plant/herb material and is not 'manufactured' from a new 
source. The herb material will be obtained from organically grown crops. Herbal medicine 
principally uses the whole plant, which contains many constituents. As no manufacturing 
process is used no chemical synthesis and no synthetic impurities will occur. 
The herb material will be inspected to ensure that they comply with the herbal monograph. that 
is macroscopic and microscopic examination, TLC, HPLC and total viable count to ensure 
correct identification and compliance with the biological load for herb material. 
Total viable aerobic count: Not more than 1,000,000 aerobic bacteria 
Not more than 100,000 fungi per g 
Absence of Escherichia coli per g 
Absence of Salmonella per 10.0 g 
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European Pharmacopoeia (4hed. ) 2001 Herbal remedies Category 4B 
1.1.2 Active ingredients not described in a pharmacopoeia: 
Assay(s) and/or other evaluation of potency- The action of the whole plant(s) is 
being investigated and no assumptions is been made for'active ingredients'. Specifications 
will be provided to G&G to ensure the fon-nulation criteria are followed to GMP. 
o Characteristics/Description- N/A 
Identification tests -Thin layer chromatography and fingerprinting of the chemical 
composition will be performed. 
Physical and chemical purity tests including limits for named, total, 
other single, unidentified total impurities- Loss on drying and ash values will 
be performed. 
Potential contamination by microorganism, pesticides, toxic metals, 
radioactivity, fumigants etc- Total viable count and heavy metal analysis will be 
performed for the herbs. Organic certification for the growers states that no fumigants or 
pesticides are to be used. 
Assay(s) of constituents of vegetable drugs or vegetable drug preparations 
with known therapeutic activity- HPLC/ TLC chromatograms; will be used to provide 
a fingerprint analysis of the herb material. 
9A monograph of the vegetable drug (see pages 26-36) 
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Vegetable Drug Monograph 
Botanical name: Hypericum perforatum L. 
Common name: St. John's wort 
Hypericum perforatum foliage 
Definition: 
Hypericurn consists of the dried aerial parts of Hypericum perforatum L. (Fam. 
Hypericaceae) gathered during the flowering periods or shortly before. The plant is a 
native British herb up to 90 cm tall, upright, branching with opposite, oblong, entire, 
sessile leaves exhibiting numerous pellucid dots and bearing heads of bright yellow 
five-petalled flowers with numerous stamens (BHP, 1996). There are approximately 
370 species in the genus Hypericum (Mabberley, 1997). Hypericum perforatum is 
native to all of Europe and Asia except for the Arctic regions. 
Physical characteristics: 
Macroscopical: 
Both petals and leaves are characterised by numerous, punctate glands approximately 
0.5-Imm in diameter. These can be readily observed with a IOX hand lens. The leaf 
glands appear translucent when held against light. Those on the petals appear as black 
dots along the margins. 
Stems: Cylindrical with two equidistant longitudinal ridges base brown and woody 
with hollow centre, upper portion green and branched to form a terminal cyme. Stem 
pieces are cylindrical, hollow, faintly two-ribbed on opposite sides, pale green (BHP, 
1996). 
Leaves: Mainly green fragments of the glabrous leaves containing oil glands as a 
transparent areas, with some small black'dots'on the lower surfaces. Opposite, sessile 
pairs; grey-green, linear oblong, 8-30mm in length, entire margin revolute when 
dried, obtuse apex, base even. Surface glabrous but exhibiting brown 'dots', on heating 
with chloral hydrate solution those in central areas become translucent but in marginal 
positions reveal red pigments (BHP, 1996). 
Flowers: Groups of flower buds with yellow petals enclosed by lanceolate green 
sepals, all finely black dotted 2cm in diameter; five green lanceolate sepals, 
acurninate apex, joined at base, surface with brown 'dots'; five yellow linear-ovate 
petals, longer than sepals, dark 'dots' on terminal margins only; numerous stamens 
with long filaments and anthers, with single, terminal pigment dot; ovary elongated 
and conical with parietal placentation, containing numerous brown triangular seeds 
with one rounded surface (BHP, 1996). 
Microscopical: 
Leaf epidermal cells with sinuous anticlinal. walls, those of the upper surface being 
beaded. Stomata anomocytic, in the lower epidermis only. Trichomes and calcium 
oxalate crystals absent. The mesophyll contains clear schizogenous oil glands and 
dark hypericin glands which yield a red pigment, especially at the leaf margins and on 
the flower parts, including the anthers. Pollen grains ellipsoidal, with smooth exine 
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and 3 pores, about 20-25 gm in diameter (BHP, 1996). 
Odour: Distinct, slightly sweet and aromatic, somewhat balsamic. 
Taste: Slightly sweet, mildly bitter, somewhat resinous and astringent 
Total Ash: Not more than 8% 
Acid insoluble ash: Not more than 2.5% 
Traditional uses: Mild to moderate depressive states, anxiety insomnia (BHP, 1996) 
Key constituents: 
It contains not less than 0.04 per cent of naphthodianthrones of the hypericin group 
(so called total hypericin) calculated as hypericin. Characteristic constituents are the 
naphthodianthrones (usually 0.1-0.15%) mainly hypericin and pseudohypericin. 
Lower levels than 0.1% may result from harvesting of lower parts of the herb. 
Another group of constituents consists of flavones and flavonols (24%) mainly 
quercetin glycosides including hyperoside (0.7%) quercitrin, isoquercitrin and rutin 
(0.3% each); also the aglycones quercetin, kaempferol, luteolin and myricetin. 
Biflavonoids, such as 3', 8"-biapigenin and 3', 8"biapigenin (0.01-0.5%) are mainly 
present in the flowers. Phloroglucinol derivatives, principally hyperforin (2-4%) 
which is unstable (Escop, 1997). 
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Botanical name: Cimicifuga racemosa L. 
Common name: Black cohosh, Black snakeroot 
Definition: Cimicifuga consists of the dried rhizome and roots of Cimicifuga racemosa (Fam. 
RanuncUlaceae) a perennial herb indigenous to Canada and the USA. It is collected in the 
autumn (BHP, 1996). 
Physical characteristics 
Macroscopical: 
Rhizome Dark brown externally, hard, subcylindrical and somewhat knotted, 1-2 cm 
in diameter and 5-15cm long. Has several stout ascending branches marked with 
encircling leaf scars terminating in a cup shaped scar. Undersurface has attached long 
brittle roots sometimes broken or represented as root scars. Fractures homey, 
internally dark brown and waxy, or sometimes white. Exhibits a thin dark bark, a 
distinct cambium line and a radiate xylem 4-5mm. thick consisting of pale wedges 
separated by darker medullary rays; pith 3-5 mrn in diameter. The root is 
quandrangular, dark brown externally and longitudinally wrinkled, fracture short, 
internally dark brown and exhibiting a 4-rayed xylem. Odourless; taste bitter and 
acrid (BHP, 1996). 
Microscopical: 
Light to dark brown powder; starch grains numerous, simple or compound, individual 
grains 3-15um in diameter, spheroidal with a central cleft, fragments of lignified 
vessels with scalariform thickening or bordered pits. Heavily lignified xylem fibres, 
thin walled; irregular yellow brown fragments of suberised epidermal cells, 
sometimes elongated, with thickened walls (BHP, 1996). 
Total Ash: Not more than 10% 
Acid insoluble ash: Not more than 4% 
Key constituents: 
Triterpene glycosides: 
The constituents of Cimicifuga racemosa are not completely known. However, the 
triterpene glycosides are considered the main active constituents (Liske, 1998). 
Cimicifuga racemosa contains principally: Xylosides: actein (aglycone: acetylacteol) 
and cimicifugoside (aglycone: cimigenol) also called cimigoside, deoxyacetylacteol 
and 27-deoxyacetin (Leung & Foster 1996; Schaper & Brurnmer 1997). Three novel 
cyclolanostanol xylosides were recently isolated: cimicifugosides H-1, H-2, and H-5. 
All of these constituents contain a cyclopropane and are structurally related to 
cycloartenol (Koeda et al, 1995). 
Isoflavones: 
Formononetin has been isolated previously, but more recent studies of the commercial 
preparation, Remifemin, failed to show its presence in the isopropyl/ethanolic 
aqueous extract (Struck et al. 1997). 
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Alkaloids: 
N-methyleytisine, and related unknown quinolizidine alkaloids, have been reported 
(Newall et al. 1996) as have phenolic acids: Isoferulic and salicylic acids (Leung & 
Foster, 1996). 
Other Constituents: 
Include tannin, resins cimicifugin = macrotin, volatile oils, palmitic, gallic, butyric, 
and oleic acids, starches and sucrose (Duke 1985). Newall et al. (1996) fin-ther 
quantifies cimicifugin (15-20%), described as a resinous mixture containing 
racemosin, and other unspecified phytosterols, as well as acetic acid, caffeic acid and 
actein. 
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Botanical name: Salvia officinalis L. 
Common name: Sage 
Salvia officinalis leaves 
Definition: 
Salvia consists of the dried herb Salvia officinalis (Fam. Labiatae) (Escop, 1997). A 
perennial herb growing up to 50cm in height. Salvia is indigenous to Southern Europe 
and the USA (BHP, 1996). 
Macroscopical: 
Leaves oblong-lanceolate or ovate, 2- 10 cm long and 1-2.5cm broad; apex acute, base 
rounded to somewhat cordate, frequently lobe; margin crenulate; upper surface grey- 
green and pubescent when young, nearly smooth with a depressed midrib and veins 
when older; lower surface light green, prominent midrib, minutely reticulate and 
densely pubescent. Petiole up to about 4 cm long, on the upper surface, greenish-grey 
to purplish, densely pubescent (BHP, 1996). 
Microscopical: 
Dark green powder; epidermal fragments polygonal and thick-walled, stomata 
caryophyllaceous; covering trichomes long narrow, uniseriate, 2-6 celled with thick 
walls and sharply acute apices; glandular trichomes of two types, 1-4 celled stalk and 
a mono or bicellular head, sessile rosette-shaped trichomes with 6-8 encapsulated 
cells (BHP, 1996). 
Odour: Aromatic 
Taste: Aromatic and bitter 
Total: Ash: not more than 8% 
Traditional uses: Hyperhidrosis, pharyngitis 
Key constituents: 
Essential oil, up to 2.5% containing monoterpenoids such as alpha and beta thujone 
(up to 60% and 10% respectively) camphor and cineole. 
Monoterpenoid glycosides. Diterpenoids: abietanes such as camosic acid and its 
derivatives e. g. camosol. 
Triterpenoids: oleanolic acid. 
Flavonoids, 5-methoxysalvigenin 
Phenolic compounds, rosmarinic acid (Escop, 1997). 
Rosmanol, epirosmanol, camosol, rosmadial, camosic acid, methyl camosate 
salvianolic acid and sagerinic acid (Yinrong, 1999; Cuvelier, 1994). 
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Botanical name: Dioscorea villosa L. 
Common name: Wild Yam 
Definition: 
Dioscorea consists of the dried underground parts of the Dioscorea villosa (Fam. 
Dioscoreaceae). The plant is common in eastern and central United States and is a 
herbaceous twining perennial. Dioscorea contains steroidal glycosides including 
dioscine and starch (BHP, 1983). 
Physical Characteristics: 
Macroscopical: 
Irregular yellow hard woody chips of rhizome, up to 3x I cm often with cork missing 
exposing brown exterior. Fine strands of brown fibrous roots present. Pale cream 
inner surface with small scattered yellow areas. (BHP, 1983). 
Microscopical 
Powder, yellow brown. Abundant simple spherical or ovoid starch grains up to 30 ýLrn 
in diameter. Numerous, fragments of lignified parenchyma with thick walls 
containing slit-like pits. Groups of lignified tracheids with small bordered pits. 
ocassional groups of fibres with narrow lumen and pitted lignified walls. Few pieces 
of thin walled brown cork cells. A few calcium oxalate needles (BHP, 1983). 
Total Ash: not more than 7% 
Acid insoluble ash: not more than 2% 
Traditional uses: Dysmenorrhoea 
Taste: bitter, starchy and persistently acrid 
Key constituents: Saponins- Dioscine 
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Botanical name: Glycyrrhiza glabra L. 
Common name: Licorice 
Glycyrrhiza glabra foliage 
Definitions: 
Glycyrrhiza is the dried root and stolon of Glycyrrhiza glabra L. (Fam. 
Leguminosae), a tall erect herbaceous perennial distributed over Southern Europe. It 
is obtained mainly from Turkey Russia, Syria and Iran (BHP, 1983). 
Macroscopical: 
Nearly cylindrical tapering pieces of root 15-20cm long, 0.5-3 cm in diameter. 
Externally brown traces of lateral roots; cork coarsely fibrous, longitudinally striated; 
inner surface where exposed, white to yellow and fibrous. Stolons cylindrical, 1-2 cm 
in diameter and may be up to several metres in length. Fractures of both root and 
stolon fibrous and granular. Transverse section shows thin cork, wide, yellow 
secondary phloem, cyrindrical yellow xylem with a radiate structure. Stolon exhibits 
central pith. (BHP, 1983). 
Glycyrrhiza glabra root 
Microscopical: 
Light yellow powder; starch grains numerous, mainly single, ovoid toellipsoidal 2- 
20gm in diameter; fragments of large oval medullary ray cells; phloern fibres 
lignified, long, occur single or in groups, frequently surrounded by a layer of 
parenchyema cells, each containing a single prism of calcium oxalate, 10-25gm wide; 
large vessel walls with closely arranged bordered pits, often associated with lignified 
parenchyma; red brown cork fragments, cells polyhedral and tabular (BHP, 1983). 
Total ash: not more than 10% 
Odour: characteristic 
Taste: Sweet and faintly astringent 
Acid insoluble ash: not more than 2% 
Traditional uses: Gastric or duodenal ulcer, anti-inflammatory, expectorant (BHP, 1996) 
Key constituents: Saponins- Glycyrrhizin and its aglycone glycyrrhetic acid 
Flavonoids: glucoliquiritin apioside, prenyllicoflavone, shinflavanone, 
shinpterocarpin and 1-methoxyphaseollin 
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1.3 Scientific data vegetable drugs 
3. I. Nomenclature 
Scientific name Variety Chemotype Part used Preparation 
Hypericum perforatum L. 
- 
Not Known Not Known Aefial Dried & powdered 
Cimicifuga racemosa L. NotKnown Not Known Root Dfied & powdered 
Salvia officinalis L. Not Known Not Known Leaves Dried & powdered 
Dioscorea villosa L. NotKnown Not Known Root Dried & powdered 
Glycyrrhiza glabra L. NotKnown NotKnown Root Dried & powdered 
1.3.2 Description of Main constituents 
Hypericum perforatum 
Naphthodianthrones 
Characteristic constituents are the naphthodianthrones (usually 0.1-0.15%) mainly 
hypericin and pseudohypericin. Levels lower than 0.1% may result from harvesting of 
lower parts of the herb. The naphthodianthrones include hypericin, pseudohypericin, 
isohypericin and emodin-anthrone. In the fresh plant material, protohypericin and 
protopseudohypericin are also present. These biosynthetic precursors are transformed 
into hypericin and pseudohypericin by exposure to light (Escop, 1997). 
Flavonoids 
The proanthocyanidins, consisting of dimers, trimers, tetramers and high polymer of 
catechin and epicatechin represent approximately 12% of the dried weight of the 
aerial portion of the plant. 
The following flavonols have also been identified: kaempferol, luteolin, myricetin, 
quercetin; flavonol glycosides, quercitrin, isoquercitrin, hyperin/hyperoside, 13,118- 
biapigenin and rutin. 
Phloroglucinols: Hyperforin. 
Other compounds: Choline, pectin, cysteine, GABA and tannins. 
Cimicifuga racemosa 
Triterpene glycosides 
The constituents of Cimicifuga racemosa are not completely known however the 
triterpene glycosides are considered the main active constituents (Liske, 1998). 
Cimicifuga racemosa contains principally: Xylosides: actein (aglycone: acetylacteol) 
and cimicifugoside (aglycone: cimigenol) also called cimigoside, deoxyacetylacteol. 
and 27-deoxyacetin (Leung & Foster 1996; Schaper & Brummer, 1997). 
Three novel cyclolanostanol xylosides were recently isolated: cimicifugosides H-l(l), 
H-3(2), and H4(3). All of these constituents contain a cyclopropane ring as a common 
structural feature, and are structurally related to cycloartenol (Koeda et al. 1994). 
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Isoflavones 
Formononetin was previously isolated, but more recent studies of the commercial 
preparation, Remifemin, failed to show its presence in the isopropyl/ethanolic 
aqueous extract (Struck et al. 1997). 
Alkaloids: 
N-methyleytisine, and related unknown quinolizidine alkaloids, have been reported 
(Newall et aL 1996). 
Phenolic Acids: 
Isoferulic and salicylic acids are reported in Cimicifuga racemosa (Leung &Foster 
1996). 
Other Constituents: 
Include tannin, resins cimicifugin = macrotin), volatile oils, palmitic, gallic, butyric, 
and oleic acids, starches and sucrose (Duke 1985). Newall et al. (1996) further 
quantifies cimicifugin (15-20%), described as a resinous mixture containing 
racemosin, and other unspecified phytosterols, as well as acetic acid, caffeic acid, 
acetin, and cimigenol. 
Salvia officinalis 
Essential oil, up to 2.5% containing monoterpenoids such as alpha and beta thujone 
(up to 60% and 10% respectively) camphor and cineole. Monoterpenoid glycosides. 
Diterpenoids: abietanes such as carnosic acid and its derivatives, for example, 
carnosol. Triterpenoids: oleanolic acid. Flavonoids. Rosmarinic acid (Escop, 1997). 
Dioscorea villosa 
Saponins- Dioscine. 
Glycyrrhiza glabra 
Saponins- Glycyrrhizin and its aglycone glycyrrhetic acid. 
Flavonoids: glucoliquiritin apioside, prenyllicoflavone, shinflavanone, 
shinpterocarpin and I -methoxyphaseollin. 
1.3.3 Manufacture 
Geographical source of vegetable drug- Europe. 
The Soil Association Certification scheme is a certification scheme for licensing 
organic food production. It involves the independent inspection and certification 
of organic food from its production through the processing and distribution chain. 
The certification scheme is registered with the United Kingdom Register of 
Organic Food Standards (UKROFS) and is licensed to certify organic food 
production and processing under European Commission Regulation No 2092/91. 
All herb material will be identified from its country of origin. The herb material 
will be organically produced to the standards of the Soil Association or their 
equivalent. 
The criteria for organic certification are: 
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Organic production must take place on clearly defined units of land such that 
the production and storage areas are clearly separate from those of any other 
unit not producing in accordance with these standards. 
The avoidance of fertilisers in the form of soluble mineral salts. 
The prohibition of agro-chernical pesticides. 
Prohibition of synthetic pesticides 
Heavy metals in manure should not exceed the levels specified for manures. 
Sewage sludge, effluents and sludge based composts are prohibited. 
Seed dressing based on mercurial and organo-chlorine compounds (including 
gamma HCH, lindane and BHC) are prohibited. 
No pesticides used. 
Herbs grown on uncontaminated soil. 
Herbs to be grown away from crops produced using pesticides. 
Organic herb material to be stored separately from non-organic herbs. 
Harvesting to take place when the plants are at their best possible quality. 
Equipment is to be cleaned and in technically perfect working order. 
The use of ionising radiation and synthetic chemicals as an aid to preservation 
is prohibited. 
Processing steps e. g. Drying, comminuting, extraction: 
Drying equipment, including conveyors and other ancillary equipment, are to 
be clean, free from non-organic crop residues and any other materials that may 
contaminate the produce. 
Harvesting and storage: 
Harvesting equipment, including vehicles and containers used for transporting 
the produce are clean, free from non-organic crop residues and any other 
materials which may contaminate the produce. 
1.3.4 Development for active ingredient of vegetable origin 
" Description of the vegetable drug (macroscopic and microscopic). 
" Composition and analytical research for constituents and physical characteristics. 
" Investigation for adulterants or known toxic constituents. 
" Analytical development and validation. Commentary on the choice of routine tests 
and specifications. 
Hypericum perforatum 
Macroscopical: 
Mainly green fragments of the glabrous leaves containing oil glands as a transparent 
areas, with some small black dots on the lower surfaces. Groups of flower buds with 
yellow petals enclosed by lanceolate green sepals, all finely black dotted. Stem pieces 
cylindrical, hollow, faintly two-ribbed on opposite sides, pale green (BHP, 1996). 
Stems: Cylindrical with two equidistant longitudinal ridges, base brown and woody 
with hollow centre, upper portion green and brown to form a tenninal cyrne (BHP, 
1996). 
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Leaves: Opposite, sessile pairs; grey-green, linear oblong, 80-30mm. in length, entire 
margin revolute when dried, obtuse apex, base even. Surface glabrous but exhibiting 
brown dots, on heating with chloral hydrate solution those in central areas become 
translucent but in marginal positions reveal red pigments (BHP, 1996). 
Flowers: 2cm in diameter; five green lanceoldte sepals, acurninate apex, joined at 
base, surface with brown dot; five yellow linear-ovate petals, longer than sepals, dark 
dots on terminal margins only; numerous stamens with long filaments and anthers, 
with single, terminal pigment dot; ovary elongated and conical with parietal 
placentation, containing numerous brown triangular seeds with one rounded surface 
(BHP, 1996). 
Microscopical: 
Leaf epidermal cells with sinuous anticlinal walls, those of the upper surface being 
beaded. Stomata anomocytic, in the lower epidermis only. Trichomes and calcium 
oxalate crystals absent. The mesophyll contains clear schizogenous oil glands and 
dark hypericin glands which yield a red pigment, especially at the leaf margins and on 
the flower parts, including the anthers. Pollen grains ellipsoidal, with smooth exine 
and 3 pores, about 20-25 gm in diameter (BHP, 1996). 
Cimicifuga racemosa 
Macroscopical: 
Rhizome: dark brown externally, hard, subcylindrical 1-2 cm. in diameter and up to 
15cm long. bears several stout ascending branches marked with encircling leaf scars 
terminating in a cup shaped scar. Undersurface has attached long brittle roots 
sometimes broken or represented as root scars. Fractures horny, internally dark brown 
and waxy, or sometimes white. Exhibits a thin dark bark, a distinct cambium line and 
a radiate xylem 4-5mm thick consisting of pale wedges separated by darker medullary 
rays; pith 3-5 mm in diameter. The root is quadrangular, dark brown externally and 
longitudinally wrinkled, fracture short, internally dark brown and exhibiting a 4-rayed 
xylem. Odourless; taste bitter and acrid (BHP, 1996). 
Microscopical: 
Light to dark brown powder; starch grains numerous, simple or compound, individual 
grains 3-15ýtrn in diameter, spheroidal with a central cleft, fragments of lignified 
vessels with scalariform thickening or bordered pits. Heavily lignified xylem fibres, 
thin-walled; irregular yellow brown fragments of suberised epidermal cells, 
sometimes elongated, with thickened walls (BHP, 1996). 
Saivia officinalis 
Macroscopical: 
Leaves oblong-lanceolate or ovate, 2-10 cm long and 1-2.5cm broad; apex acute, base 
rounded to somewhat cordate, frequently lobe; margin crenulate; upper surface grey- 
green and pubescent when young, nearly smooth with a depressed midrib and veins 
when older; lower surface light green, prominent midrib, minutely reticulate and 
densely pubescent; petiole 1-5 cm long, upper side grooved, grey purple (BHP, 1983). 
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Microscopical: 
Dark green powder; epidermal fragments polygonal and thick-walled, stomata 
caryophyllaceous; covering trichomes long narrow, uniseriate, 2-6 celled with thick 
walls and sharply acute apices; glandular trichomes of two types, 1-4 celled stalk and 
a mono or bicellular head, sessile rosette-shaped trichomes with 6-8 encapsulated 
cells (BHP, 1983). 
Dioscorea villosa 
Macroscopical: 
Irregular hard woody chips of rhizome, up to 3x I cm often with cork missing 
exposing brown exterior. Pale brown outer surface. Fine strands of brown fibrous 
roots present. Pale cream inner surface with small scattered yellow areas (BHP, 
1983). 
Microscopical: 
Powder, yellow brown. Abundant simple spherical or ovoid starch grains up to 30 gm 
in diameter. Numerous, fragments of lignified parenchyma with thick walls 
containing slit-like pits. Groups of lignified tracheids with small bordered pits. 
Occasional groups of fibres with narrow lumen and pitted lignified walls. Few pieces 
of thin walled brown cork cells. A few calcium oxalate needles (BHP, 1983). 
Glycyrrhiza glabra 
Macroscopical: 
Nearly cylindrical tapering pieces of root 15-20cm long, 0.5-3 cm in diameter. 
Externally brown traces of lateral roots; cork coarsely fibrous, longitudinally striated; 
inner surface where exposed, white to yellow and fibrous. Stolons cylindrical, 1-2 cm 
in diameter and may be up to several metres in length. Fractures of both root and 
stolon fibrous and granular. Transverse section shows thin cork, wide, yellow 
secondary phloem, cylindrical yellow xylem with a radiate structure. Stolon exhibits 
central pith. Odour characteristic; taste sweet and faintly astringent (BHP, 1983). 
Microscopical: 
Light yellow powder; starch grains numerous, mainly single, ovoid to ellipsoidal 2- 
20um in diameter; fragments of large oval medullary ray cells; phloem. fibres 
lignified, long, occur single or in groups, frequently surrounded by a layer of 
parenchyema, cells each containing a single prism of calcium oxalate, 10-25111P wide; 
vessels large, walls with closely arranged bordered pits, often associated with 
lignified parenchyema; red brown cork fragments, cells polyhedral and tabular (BHP, 
1983). 
1.3.5 Impurities 
-Potential degradation products- A UCAS public analyst will be used to ensure 
the herb material conforms to the quality parameter set by the British Herbal 
compendium. 
-Analytical test procedures and their limits of detection 
-Impurities and structural deviants found 
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-Methods of detecting potential contamination of vegetable drugs by 
micro-organisms and products of micro-organisms, pesticides, fumigation 
agents, toxic metals, radioactivity etc. 
Microbiological test will be performed to ensure that the herb material conforms to 
the European pharmacopoeia (2001), Herbal remedies Category 4B purity standards. 
Producers of the herb material are required to conform to the organic standards set. 
These requirements are to provide herb material that has not been treated with 
pesticides, irradiation or fumigants and is not cultivated on land that is contaminated 
with heavy metals. 
-Potential falsification and adulteration 
The herb material will be examined microscopically and macroscopically by trained 
personnel to ensure that the correct species is identified. Herbs are grown and 
harvested by trained staff as required by organic good manufacturing procedures. 
Heavy metal analysis was undertaken with herbs samples. All were found to be within 
the normal range as reported by the Food Standards Agency. 
Heavy metal analysis results for herbs used in NYR 10 
Herb Concentration Pb Concentration Cd Concentration Hg Concentration Cu Concentration Zn DW* ppmt DW ppm DW ppm DW m 
Hypericum 0.48 0.12 <LODt 4.51 20.65 
erforatum L. 
Cimicifuga 1.40 0.20 <LOD 3.10 12.82 
racemosa L. 
Salvia 0.68 0.07 <LOD 1.22 15.70 
officinalis L. 
_ Dioscorea 1.38 0.14 <LOD 2.14 28.36 
villosa 
_ Glycyrrhiza 0.50 I 0.80 I <LOD I 3.00 I 17.10 I 
_fflabra 
L. I 
*DW - Dry Weight 
tppm -Parts per million 
$<LOD- Below limits of detection 
1.3.6 Batch Analysis 
Batches tested - All fillers, encapsulators and mixers have to record the amount used and 
weight of capsules and powders. They are checked during quality control to ensure that 
they comply with the specifications. One hundred (g) sample(s)will be retained for 
testing against initial fingerprint analysis. 
Results of test with numerical values where appropriate. 
* Reference material (analytical results), primary and others. 
2. Other ingredients- No other ingredient will be used in the fonnula. 
2.1 Specification and routine tests 
2.1 .1 Ingredients 
described in a pharmacopoeia 
177 
The herb material will be inspected to ensure that it meets the criteria for its 
monograph. 
2.1.2 Ingredients not described in a pharmacopoeia 
No other ingredients other than the herbs material will be used in the preparation of 
the formula. 
2.2 Scientific data 
No excepient will be used in the manufacture/assembly of the herbal capsules 
3 Packaging material (immediate packaging) 
No other packaging material is to be used other than that stated in Part 11 A, section 3. 
D: Control tests on intermediate products (if necessary) No intermediate products 
are to be used. 
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E: Control Tests on the Finished Product 
1. Specifications and routine tests 
1.1 Product specifications and tests for release at time of manufacture 
9 Description/characteristics- 
Identification tests for the active ingredient(s) and antimicrobials or 
chemical preservatives if present- No antimicrobial or chemical preservative are 
in the formula. 
Quantitative determination of active ingredients/constituents of known 
therapeutic activity. No individual constituents is considered active since the 
whole herb(s) are therapeutic in combination. 
Purity tests 
Microbiological test will be performed to ensure that the herb material conforms to 
the European pharmacopoeia (2001) Herbal remedies Category 4B purity standards 
for total viable count. 
Total viable aerobic count: Not more than 1,000,000 aerobic bacteria 
Not more than 100,000 fungi per g 
Absence of Escherichia coli per g 
Absence of Salmonella per 10.0 g 
Thin layer chromatography and HPLC tests will be performed to monitor the herbs 
chemical profile. 
Phannaceutical tests e. g. dissolution 
N/A 
Tests from the appropriate general monograph 
The herb material will undergo microscopic and macroscopic examinations to ensure 
correct identity. Ash values will be undertaken to ensure that they meet the 
specification on the herbal monographs. These will be performed by a UCAS 
accredited public analyst. 
2. Scientific data 
2.1 Analytical validation of methods- A UCAS accredited public analyst will be 
used to ensure the herb material conforms to the standards required by BHP. These 
will include: 
" Thin layer chromatography/HPLC 
" Ash values 
" Macroscopic and microscopic examination 
" Microbiological tests 
" Heavy metal testing 
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2.2Batch analysis 
" Batches tested (date, place of manufacture, batch size) 
" Results obtained, including appropriate numerical data 
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F: Stability 
1. Stability tests on active ingredients 
" Batch(es) tested 
" General test procedures: 
- Accelerated test conditions 
- Normal test conditions 
" Analytical test procedures: 
- Assay 
" Determination of degradation products 
" Validation of all test procedures including limits of detection 
" Results of tests 
" Conclusions and how the retest period is established if not readily apparent 
2. Stability tests on the finished product 
" Quality specification for the proposed shelf life 
" Batches tested and packaging 
" Study methods: 
- real time studies 
- studies under other conditions 
Accelerated stability study will be per rmed on the following physical parameters: 
Appearance of capsule 
Appearance of capsule powder 
Average weight 
Moisture content of capsule powder 
pH of 2% aqueous suspension 
Disintegration time 
Thin layer chromatography and HPLC will be conducted on samples to monitor any changes 
in chemical profile. 
Characteristics studied: 
- physical characteristics 
- chemical characteristics 
- microbiological characteristics 
- chromatographic characteristics 
- characteristics of packaging 
- evaluation test procedures 
- description of test procedures 
- validation of test procedures 
" Results of tests 
" Conclusions 
" Shelf life and storage conditions 
Shelf life after reconstitution 
ongoing stability studies 
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A study by Bilia et al, (2001) measured the thermal and photostability of Hypericum 
perforatum dried extracts using flavonols, hyperforins and hypericins as markers. The 
results were compared with the International Conference of Harmonisation test conditions 
as recommended by The European Agency for the Evaluation of Medicinal Products. 
Photostability testing showed all constituents to be photosensitive in the tested 
conditions. Long term thermal stability testing showed a very low stability (less than four 
months) hyperforins and hypericins t-90, even if ascorbic and citric acids were added to 
the formulation. Bilia et al, (2001) failed to describe how the herbal extract was 
produced. A whole or powdered Hypericum perforatum sample is substantially different 
to a Hypericurn extract and the stability data provided by this study cannot be extended to 
non-extract herb material. In another study by Sloley (2000), the chemical profile of 
various standardised Hypericum extracts was found to vary substantially in the 
concentration of various characteristic chemicals. 
Q: Other information 
Placebos 
The placebo to be used is rice flour 4.5g per capsule. 
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Part III - Experimental and Biological studies 
A: Non-Clinical Pharmacological and Toxicological Studies 
1. Pharmacology 
1.1 
Hypericum perforatum 
Action relevant to the proposed therapeutic use: 
In a study by Perovic and Muller (1995), Hypericum perforatum was shown to inhibit 
the uptake of serotonin dose-dependent in isolated rat synaptosomes, thus increasing 
the concentration of this transmitter. A 50% inhibition (IC-50 value) was calculated 
from the dose-response curve. An IC-50 of 6.2 gg/ml of Hypericurn extract was 
found. 
In another study by Yu (2000), Hypericurn was shown to weakly inhibit activities 
towards MAO activity. Mouse brain activities were unchanged following either acute 
or chronic administration of Hypericurn extract. 5-HIAA levels were found to be 
significantly increased in the cerebral cortex, hypothalamus, hippocampus and 
caudate 3 hours after treatment at a dose as low as 10mg/kg. An increase in 5-HT 
levels was also observed in the hypothalamus and hippocampus. Plasma tryptophan 
levels, the precursor of 5-HT, were significantly reduced. The authors concluded, that 
the increased 5-HIAA and 5-HT levels following administration of Hypericurn were 
probably unrelated to inhibition of 5-HT re-uptake. Conventional 5-HT re-uptake 
blockers, for example, fluoxetine, sertraline, paroxetine, cause a significant decrease 
in cortical 5-HIAA. The reduction of brain blood tryptophan and the increase of brain 
S-HIAA and 5-HT seem to suggest that the utilisation of tryptophan was enhanced 
following treatment of Hypericurn extract. 
Animal studies in mice with hydroethanolic preparations Hypericum perforatum 
(corresponding to 2-12mg/kg orally) have revealed CNS activitiy which can be 
interpreted as a antidepressant effect. Oral administration of an extract equivalent to 
1,2, or 3mg/kg of hypericin in mice resulted in a reserpine antagonism, which is also 
indicative of antidepressant effects (Escop, 1997). 
A study using different types of Hypericum perforatum preparations: Crude ethanol 
extracts, Ethyl acetate extract, aqueous extract and an Infusion were investigated on 
pentobarbital induced sleeping time, intestinal motility and analgesic activity. Crude 
ethanol extracts and Ethyl acetate extract exhibited significant qtimulatory and 
antidepressant effects on the CNS. Both extracts prolonged sleep, increasing time up 
to more than 25 minutes. Ethyl acetate extract exhibited strong analgesic activity, 
reducing abdominal stretching activity (induced by acetic acid) by nearly 50%. Crude 
ethanol extracts, ethyl acetate extract and the aqueous extract exhibited spasmolytic 
activity (Jakovljevic, 2000). 
1.2 Other actions sought (secondary pharmacology) 
1.3 Drug Interactions 
183 
Hypericum perforatum 
Concerns have arisen recently over potential interactions between prescribed 
medicines and Hypericum perforatum. Although some studies have been 
inconclusive, two clinical reports indicate that Hypericum perforatum increased the 
rate of metabolism of warfarin and cyclosporin and that blood levels were reduced by 
approximately 50% (Qin-Ying Yue, 2000; Ruschitzka, 2000). A study with 
Hypericum perforatum and digoxin also indicated that Hypericum. potentiated the 
effect of the drug. However, the placebo group had a 9% decrease in digoxin levels 
and therefore the variation may reflect known variability in digoxin distribution or 
systematic availability (Johne, 1999). Nonetheless, real concerns regarding potential 
interactions mean that Hypericum perforatum should not be used concurrently with a 
range of prescribed medications. 
2. Pharmacokinetics 
Hypericum perforatum 
The bioavailability of hypericin and pseudohypericin was established using doses 
equivalent to 0.1% and 0.3% hypericin (Staffeldt, 1994). The t-max of hypericin 
administered at 0.1% has been found to be 2.5 hours, with a C-max of 4.3 ng/ml, and 
a plasma half-life of approximately 6 hours. The t-max of hypericin administered at 
0.3% was 4-6 h, with a C-max 1.5-14.2 ng/mI and a plasma half-life of 24.8-26.5h. 
The t-max of pseudohypericin was 2-4h, with a C-max of 2.7-30.6 ng/ml, plasma 
half-life 16.3-36 hours (Staffeldt, 1994). Median half time elimination of hypericin 
was found to be 24.8 to 26.5 hours and the median half time elimination of 
pseudohypericin was found to be in the range of 16.3 to 36 hours (Staffeldt, 1994). 
3. Single and repeat dose toxicity studies 
Hypericum perforatum 
In clinical studies, Hypericum perforalum has consistently been shown to be well 
tolerated by patients, with an extremely low incidence of side effects (Kim, 1999). 
Therapeutic dosages of total hypericin, (up to lmg daily over 8 days), have been 
shown not to induce photo-sensitivity in 40 volunteers, (Escop, 1997). A study using 
synthetic hypericin given intravenously to HIV-infected patients found that 
(reversible) symptoms of photo-sensitivity were observed at the highest dosage 
regime but that these symptoms were reversible. The dosage found to induce photo- 
sensitivity was 35 times higher than the highest oral dosage of total hypericin used in 
the treatment of depressive disorders (Escop, 1997). 
In a ftuther study by Broclanuller, (1997) 13-volunteers received either a single dose 
of hypericin at dosages of 900,1800 or 3600mg of a standardised Hypericum extract 
containing 2.81,5.62 and 11.25 mg of total hypericin or a placebo. All treatments 
were combined with solar simulated irradiation. No differences were found between 
patients receiving placebo or Hypericum extracts and no dose-related trend in light 
sensitivity was observed. 
4. Mutagenicity No data available 
5. Carcinogenicity No data available 
6. Reproductive toxicology No data available 
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Other information - No further studies conducted. 
8. Presentation of non-clinical pharmacological and toxicological studies 
B: Clinical Data and Previous Human Experience 
Human Pharmacology 
Pharmacological studies in humans 
Depression may be caused by a deficiency in biogenic amines, e. g. serotonin (5- 
hydroxytryptamine) and norepinephrine. Antidepressants act by increasing 
availability of these neurotransmitters. Consequently, a series of modes of action of a 
potential antidepressant can be postulated: inhibition of monoamine oxidase, (MAO) 
inhibition of serotonin or reuptake modulation of synthesis of biogenic amines. 
In a study, six women with depressive symptoms were given a standardised 
hydroethanolic extract of Hypericum perforatum equivalent to 0.5-mg total hypericin 
or lAg herb. A significant increase in urinary neurotransmitter metabolites was 
observed 2-hours after administration. The same preparation was studied for a 4-week 
duration on 40 depressive patients. Relaxing effects were observed as indicated by 
EEG tests which showed an increase in theta activity, decrease in alpha activity and 
no change in beta activity (Escop, 1997). 
2. Human Pharmacokinetics 
Hypericum perforatum 
The bioavailability of hypericin and pseudohypericin was established using doses 
equivalent to 0.1% and 0.3% hypericin. The hypericin administered at 0.1% had a t- 
max of 2.5 hours, C-max 4.3 ng/ml, plasma half-life of approximately 6 hours. The 
0.3% extract for hypericin was t-max 4-6 h, C-max 1.5-14.2 ng/ml, plasma half-life 
24.8-26.5h. Pseudohypericin t-max 2-4h, C-max 2.7-30.6 ng/ml, plasma half-life 
16.3-36 hours (Staffeldt, 1994). Median half time elimination of hypericin is 24.8 to 
26.5 hours. Median half time elimination of pseudohypericin ranged between 16.3 to 
36 hours (Staffeldt, 1994). 
3. Normal volunteer studies 
4. Patient studies 
One hundred and eleven female patients aged between 43-65 were recruited from a 
general medical and psychotherapy practice. Patients had either pre-or 
postmenopausal climacteric symptoms. All patients received Hypericum perforatum 
preparations for 12-weeks. The dosage was standardised to 30ORg total hypericin per 
tablet, three times per day. After 12-weeks climacteric complaints had diminished or 
disappeared completely in a clear majority of women (76.4% by patient self-rating 
[p<. 00 I] and 79.2% by physician rating [p<. 00 I ]. Only four women reported adverse 
events, which consisted in an increase in, sleep disturbances, slight nausea, dizziness 
and headache. All adverse events were recorded in the first week of treatment. No 
patient withdrew from treatment because of these adverse events (Grube, 1999). 
5. Post market surveillance - N/A 
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6. Extensive previous human use 
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Cimicifuga racemosa 
1. Pharmacology 
1.1 Action relevant to the proposed therapeutic use: 
Constituents of Cimicifuga racemosa rhizome have been shown to bind to oestrogen 
receptors in rat uteri and pituitary glands (Hamischfeger, 1985), but some controversy 
exists as to what oestrogenic effects result from occupying these sites. Duker et al 
(1991) characterised pharmacological responses to various chromatographically 
separated fractions of C. racemosa lipophilic extract in ovarectornized rats. Three 
endocrinologically active fractions were isolated. Fraction I inhibited Lutenising 
hormone (LH) secretion but did not bind to oestrogen receptors. Fractions IV to VI 
were active in both assays, while fraction VIII displayed the most potency in 
oestrogen receptor binding assays, and did not suppress LH secretion after chronic 
treatment. This fraction did inhibit LH after a single acute injection; single injections 
of oestradiol showed a similar activity profile. 
The authors suggest that the lack of an effect on Follicular Stimulating Hormone 
(FSH) inhibition is due to FSH secretion being under the control of steroids plus 
inhibin, while LH secretion is mediated only by gonadal steroids. The authors 
speculated that Fraction VIII, which acutely but not chronically inhibited LH 
secretion may contain oestrogenically active compounds, which are rapidly 
metabolised so that only a transient suppressive effect on LH secretion is produced. 
This may provide a rationale for the demonstrated clinical efficacy of C. racemosa in 
the treatment of menopausal hot flushes. The pulsatile release of LH is inhibited, but 
overall LH levels are not suppressed. 
Fraction I, which was non-oestrogenic but did suppress LH secretion, may contain 
alpha-2 agonists similar to clonidine, which suppresses LH secretion without binding 
to the oestrogen receptor (Duker et al, 1991). While this and other studies (Jarry and 
Harnischfeger, 1985) on ovarectornized rats, as well as menopausal women, 
demonstrated reduced (LH) levels, a new study by Einer-Jensen, (1996) indicates a 
lack of oestrogenic effects in rats and mice. 
A recent study by Liske (1998) also found no significant decrease in LH (or other 
hormonal changes) or other measures of oestrogenic activity such as, increased 
vaginal epithelium thickness are attributable to the Cimicifuga racemosa preparation, 
at least when the new lower dose is used. 
Isopropanolic aqueous extracts of Cimicifuga racemosa inhibit in vitro proliferation 
of oestrogen-dependent breast cancer cell lines in a dose-dependent manner. This is 
interpreted as an oestrogen-receptor blockade by the extract (Nesselhut et al, 1993). 
In a follow-up study, Cimicifiga prevented the stimulation of oestrogen-dependent 
cancer cells when oestrogen was added in vitro. Tamoxifen and Cimicifuga may act 
synergistically to block oestrogenic proliferation of breast cancer cells, 
because the 
combined inhibitory effect was greater than the sum of the effect of each substance 
alone (Nesselhut et al, 1998, submitted). 
Two recent studies of other Cimicifuga species, C foetida and C heracleffiblia, 
demonstrated inhibition of parathyroid hormone-induced bone reabsorption in tissue 
culture (Li et al. 1996) and in ovarectomized rats (Li et al, 1995). This anti. 
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osteoporotic effect has not, as yet, been discussed in the literature, in terms of the 
oestrogen receptor-binding activity of Cimicifuga, although mention was made of the 
positive influence of C racemosa on osteoporotic states by Murray (1997). 
Results of a recent study on the influence of an isopropanolic aqueous extract of 
Cimicifuga racemosa on the proliferation of MCF-7 cells showed that the extract did 
not stimulate the proliferation of oestrogen receptor-positive breast cancer cells 
(Liske, 1998). 
A double-blind randomised clinical study by Liske et al (1998)looked at the effects 
of two different dosages of an isopropanolic Cimicifuga racemosa extract (Remiferin) 
in 152 patients with climacteric complaints. The dosages were 40mg vs. 127mg of the 
preparation per day for six months. Efficacy was measured using the Kupperman 
menopause index, Self-assessment Depression Scale (SDS), the Clinical Global 
Impressions scale (CGI), vaginal cytology indexes, and hormone status (lutenising 
hormone (LH), follicle stimulating hormone (FSH), estradiol 17 beta (E2), prolactin 
and sex hormone binding globulin (SHBG) levels). 
The two dosages showed similar results in efficacy and safety. The product did not 
influence hormone levels of LH, FSH SHBG, prolactin and oestradiol. Vaginal 
cytology (degree of proliferation) was not changed (Liske, 1998). 
A summary of outcomes showed a statistically significant decrease in the Kupperman 
index and SDS depression scale under treatment with Remifemin, at both dose levels. 
Efficacy was rated as good or very good by both doctors and patients in about 80% of 
the cases. The treatments at both dose ranges were rated as well tolerated, by 95% of 
the women and 92% by their doctors. The company reports 'no conspicuous changes' 
in vaginal cytology parameters or in the course of hormone concentrations for 
treatments at both dose levels. Although no details are given on adverse effects, they 
report no serious adverse events or clinically toxicological effects (Shaper & 
Brummer, 1997). 
1.2 Other actions demonstrated or sought (secondary pharmacology) 
1.3 Drug interactions - No data available 
Pharmacokinetics - No data available 
Single and repeat dose toxicity studies 
In a multicentre drug monitoring study of 704 individuals with climacteric 
complaints, women were treated with C. racemosa extract for 6-8 weeks. In 93% of 
patients, tolerability was very good. Mild and transitory symptoms, gastrointestinal 
complaints were observed in only 7% (Stolze, 1982). 
In another study by Vorberb (1984), tolerability in all cases was described as good to 
very good, only four patients reported mild gastrointestinal problems at the beginning 
of therapy. 
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A 6-month oral toxicity study in rats followed by an 8-week recovery period indicated 
no toxic potential of the isopropanolic C. racemosa preparation, even at very high 
doses (up to 5000-mg kg body weight). No abnormalities were noted in clinical, 
chemical, histopathological, or macroscopic organ findings compared with the 
simultaneously treated control group (Murray, 1997; Levy, 1997; Remifemin, 1997). 
Toxicity assessments for the chloroform extract (Minimum lethal dose, MLD) range 
from as low as >3.0 mg/kg (s. c, 30 days) in the rabbit to as high as >1 g/kg (oral, 30 
days) in the rat (Napralert). In Wistar rats given up to 5000 mg Rernifernin 
granulate/kg for 26 weeks, no conspicuous chemical or organ toxicity was observed 
(Kom, 1991). In human studies with the fluid extract, up to 890 mg/day was given 
with no evidence of toxic effects (Novitch & Schweiker, 1982). 
Overdoses may produce nausea with vomiting, and dizziness, and may reduce pulse 
and induce perspiration (Duke, 1985). Occasional gastric problems are the only noted 
adverse effects noted by (Schaper & Brummer 1997). Willard (1991), describes a 
mild non-violent emetic property, which can cause nausea as well as giddiness and 
headache in large doses. Shengma (mainly C foetida, C dahurica) can cause 
vomiting due to gastric irritation (Chang & But 1986). 
Cimicifuga racemosa has been given in daily doses of 200mg without adverse affects, 
(Liske, 1998). Patient tolerance for Cimicifuga racemosa has been assessed as very 
good, with only gastrointestinal complaints of low frequency and degree having been 
reported in some studies (Stolze, 1982). The dosage to be used is more than one and a 
half times lower than the maximum recommended dosage as cited by Newall (1996). 
4. Mutagenicity 
In vitro Salmonella microsome assays (Ames test) showed no evidence of a 
mutagenic potential of C. racemosa. Compared with the negative control, neither a 
dose related doubling or a biologically relevant increase in the mutant count with or 
without 'S9-mix' (simulation of mammalian metabolic effects by homogenized 
mammalian liver together with cofactors) was observed (Beuscher, 1995; Remiferin, 
1997). 
Extracts of C racemosa have not shown any toxic or mutagenic properties 
demonstrated in any animal or human studies. After chronic application to mice of a 
commercial preparation over a period of 6-months, no clinically or 
histopathologically relevant results were found. For the trial doses of up to 5g/kg 
body weight were used (Clay, 1996). 
A 40% isopropanolic dry extract of C. racemosa equivalent to 535.5 mg/kg body 
weight/day of the drug, which is approximately 700 times the human therapeutic dose 
given orally to rats for 6-months, produced no relevant clinical or histopathological. 
changes and using the Ames test, revealed no mutagenic activity in a concentration 
equivalent to 30.3 mg of the drug per plate (Boblitz, 2000). 
Ames test (in vitro Salmonella microsomal assay) results showed no evidence of 
mutagenic potential of the isopropanolic extract of C racemosa (Liske, 1998). 
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Dosages of 0.32 to 1000 micrograms per plates were used with negative and positive 
controls (Schaper & Brummer, 1997). 
5. Carcinogenicity- No data available 
6. Reproductive toxicology -No data available 
7. Other information -No ftirther studies conducted 
8. Presentation of non-clinical pharmacological/toxicological studies 
B: Clinical Data and Previous Human Experience 
1. Human pharmacology 
A randomised, double blind study was conducted with 80 female volunteers with 
menopausal symptoms (Stoll, 1987). Patients received Remifemin, (2 x Img tablets, 
b. i. d. ), or conjugated oestrogens (0.625 mg) or placebo for 12 weeks. Remifemin 
treated patients showed a significant increase in proliferation of vaginal epithelium 
compared to oestrogens and placebo, and significant improvements of somatic and 
psychological parameters (Kupperman menopausal Index, Hamilton Anxiety Scale) 
compared to oestrogen and placebo. No clear improvements were seen in the 
perimenopausal of the placebo group 
2. Human pharmacokinetics 
3. Normal volunteer studies 
4. Patient studies 
An open study was conducted on 50 female patients with severe menopausal symptoms, 
who converted from an oestrogen injection regime to oral Remifemin, (2 x Img tablets, 
2X/day), with additional hormonal injections given in cases of severe complaints (Petho, 
1987). Over the course of the study (6 months), clear improvements were observed in 
symptoms, as measured by the menopausal index (reduction from 17.6 to 9.2, p<0.001). 
Over half (56%) of the patients required no ftu-ther hormone injections; additional 
hormone injections were needed in only 18% of the patients. Side effects were minimal 
and well tolerated, with 82% of the patients reporting the success of the Remifemin 
therapy as very satisfactory. 
5. Post market surveillance -N/A 
6. Extensive previous human use 
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Salvia officinalis 
1. Pharmacology 
1.1 Actions relevant to the proposed therapeutic use 
A dialysate of the aqueous extract of fresh sage showed antihydrotic activity in 
humans. Excessive sweat production induced by pilocarpine was inhibited (Escop, 
1997). In an open study of 80-patients with idiopathic hyperhidrosis 80 patients were 
treated for four weeks. 40 patients were given 440mg of dried aqueous sage leaf 
extract. This corresponds to 2.6 mg of the drug and 40-patients were given an infusion 
(4.5g daily). The reduction of sweat secretion achieved (less than 50%) was 
comparable for both treatment groups, although slightly stronger in the group treated 
with extract (Escop, 1997). 
Intravenous injections of extracts from S officinalis in cats at a dose of 100 mg/kg 
caused a 30 per cent decrease in blood pressure after 90 minutes. A duodenal injection 
of S officinalis in cats at a dose of 300mg/kg, produced a decrease in blood pressure 
by 15 per cent. Spasmolytic activity on smooth muscle action was also investigated 
and S officinalis extract inhibited smooth muscle contractions by 70-85 per cent 
(Todorov et al, 1984). 
Salvia qjficinalis has been shown to suppress pilocarpine induced hyperhydrosis 
almost completely. The essential oil has a spasmolytic action acetylcholine induced 
contractions of isolated rat intestine are immediately suppressed by Salvia qjfIcinalis 
(Braun, 1974). 
1.2 Other actions sought (secondary phan-nacology) 
1.3 Drug interactions 
Salvia officinalis (dried herb leaf), as reported in the ESCOP monograph 1997, has no 
known contraindications or interactions with other medicines. However, the use of 
Salvia officinalis is not recommended during pregnancy as a precautionary measure. 
The daily dosage to be prescribed in this trial is five times lower than the safe 
recommended dosage stated in the 1997 ESCOP monograph for this herb. 
2. Pharmacokinetics - No data available 
3. Single and repeat dose toxicity studies- No data available 
4. Mutagenicity - No data available 
5. Carcinogenicity - No data available 
Reproductive toxicology - No data available 
Other infonnation 
8 Presentation of non-clinical pharmacological and toxicological studies 
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B: Clinical Data and Previous Human Experience 
Human pharmacology -No data available 
2 Human pharmacokinetics -No data available 
Normal volunteer studies -No data available 
Patient studies -No data available 
5 Post market surveillance -N/A 
6 Extensive previous human use 
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Dioscorea villosa 
1. Phannacology 
1.1 Action relevant to the proposed therapeutic use 
1.2 Other actions sought (secondary pharmacology) 
1.3 Drug interactions- No data available 
2. Pharinacokineties - No data available 
3. Single and repeat dose toxicity studies - No data available 
4. Mutagenicity - No data available 
5. Carcinogenicity No data available 
6. Reproductive toxicology No data available 
Other information 
8. Non-clinical pharmacological and toxicological studies- No data available 
B: Clinical Data and Previous Human Experience 
1. Human pharmacology- No data available 
Human phartnacokinetics- No data available 
Nonnal volunteer studies- No data available 
4. Patient studies - No data available 
5. Post market surveillance- N/A 
6. Extensive previous human use 
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Glycyrrhiza glabra 
I Pharmacology 
A methanolic extract of Glycyrrhiza glabra was used to elucidate the possible in vivo 
interaction of acetaminophen (AAP) with herbs. Acetaminophen is a widely used 
analgesic and antipyretic, which produces hepatotoxicity in both humans and laboratory 
animals at excessive doses (Moon, 1996). The effect of Glycyrrhiza glabra was 
measured on the overall biotransformation of AAP in rats. This was achieved by 
measuring the effect of Glycyrrhiza glabra on the activity of UgtlA as well as on the 
concentration of UDP-glucuronic acid to determine if Glycyrrhiza glabra affects 
glucuronidation in rat liver. Biliary and urinary excretion of AAP-glucuronide was 
increased by Glycyrrhiza glabra without influencing the excretion of AAP-sulphate and 
Aap-thioether conjugates. The finding suggests that Glycyrrhiza radix (GR) activates a 
dctoxifaction pathway of AAP mediated by UGT in rats. The increased urinary excretion 
of AAP-glucuronide does not seem to be due to a diuretic effect of GR since GR did not 
change the urine flow rate and total urine volume significantly. The author concluded 
that this result, along with the reported effects of G. glabra on enzyme leakage from 
injured rat hepatocytes, suggested a possible application of Glycyrrhiza glabra for 
detoxification of xenobiotics. 
1.1 Actions relevant to the proposed therapeutic use 
1.2 Other actions demonstrated or sought (secondary pharmacology) 
1.3 Drug interactions - No data available 
2. Pharmacokinetics 
The active principle of Glycyrrhiza glabra is Glycyrrhizin also known as 
(glycyrrhizic acid) (G) and its main metabolite is glycyrrhetic acid (GA). Glycyrrhetic 
acid is formed presystematically by enzymatic hydrolysis in the intestines and is a 
potent competitive inhibitor of II -B-Hydroxysteroid dehydrogenase (I I -B-HSD). Its 
type two isoenzyme II -B-HSD2 converts the mineralcocorticoid and glucocorticoid 
cortisol into its active metabolite cortisone. When II -B-HSD2 activity is impaired, 
intrarenal cortisol concentrations will rise. Edema, hypertension and electrolyte 
disturbances may become apparent due to increased mineralcocorticoid activity 
(Walker and Edwards, 1994). In subjects who developed adverse affects after 
repeated (G) intake, II -B-HSD2 activity was impaired (Armanini, 1996). 
The pharmacokinetics of pure Glycyrrhizin (G) and it aglycone, glycyrrhetic acid 
(GA) were compared with 'crude' Glycyrrhiza glabra containing equivalent levels of 
G and GA. Significantly lower concentrations of G were found in bile samples from 
rats administered with 'crude' Glycyrrhiza glabra compared with pure G. 
Furthermore, Glycyrrhiza glabra presented a significant choleretic affect 20% 
reduction in time of elimination of G after oral consumption, which increases the 
excretion rate of G. Based on the ratio of AUC-16h for pure G and Glycyrrhiza 
glabra, exposure to the effects of G is 7.4 times less in the case of Glycyrrhiza glabra 
compared to a physiologically equivalent dose of pure G (Cantelli-forti, 1997). 
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Pharmacokinetic Model 
The pharmokinetics of glycyffhetic acid (GA) in humans after ingestion of both GA 
and Glycyffhizin G were described in a model developed by Ploger and Mensinga 
(2000). In this model, the gastrointestinal tract (GI) is described by a two- 
compartmental model, representing the stomach and the gut. In this model, a first 
order transit rate of GI contents is assumed. In the gut, G is absorbed as its aglycon 
GA after first order enzymatic hydrolysis by commensal bacteria. A two- 
compartmental model, representing the liver and remaining tissues, describes the 
systemic kinetics of GA. After hepatic uptake, GA is metabolised instantaneously and 
its metabolites are subsequently excreted into the bile (Ploeger and Meulenbelt, 
2000). After biliary excretion, metabolites are stored in the gallbladder. It is assumed 
that these metabolites are excreted instantaneously into the gut when a fat-containing 
meal is consumed. Once excreted, the metabolites are reconverted into GA by 
commensal bacteria and reabsorbed into the systemic circulation. 
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3. Single and repeat dose toxicity studies 
No effect level. Results from experimental data in humans established a no effect 
level for a daily intake of 2-mg/kg-body weight. An acceptable daily intake of 0.2- 
mg/kg-body weight can be extrapolated with a safety factor of 10. This means 
consumption of 12mg glycyrrhizic acid per day for a person with a body weight of 
60kg. This would be equal to 6g of Glycyrrhiza glabra a day, assuming that 
Glycyrrhiza glabra contains 0.2% of glycyrrhizic acid (Van Geldren, 2000). 
Patients taking aqueous extracts of Glycyrrhiza glabra containing 814mg 
Glycyrrhetic acid GA have been shown to develop arterial hypertension after two- 
weeks of ingestion. Patients taking 108mg and 217mg of GA daily did not develop 
any side- effects including arterial hypertension (Bemardi, 1994). The daily dose of 
Glycyrrhiza glabra to be used in this study is 0.5g crude herb and will contain 
approximately 25mg GA, which is eight times lower than the known safe 
concentration identified. 
4. Mutagenicity - No data available 
5. Carcinogenicity- No data available 
6. Reproductive toxicology - No data available 
7. Other information 
8. Presentation of non-clinical pharmacology and toxicological studies 
B: Clinical Data and Previous Human Experience 
Human pharmacology 
Glycyrrhiza glabra extract has been shown to stimulate exocrine pancreatic secretions in 
rats (Ishii, 1979). Also Glycyrrhiza extract administered in the duodenum causes a 
significant increase in plasma secretin concentrations in humans (Shiatori, 1984). A more 
recent study by Shiatori (1986) investigated the effects of Glycyrrhiza extract on release 
on endogenous secretin in seven human volunteers. Intrajejunal administration at three 
different doses (200,400 and 800 mg/30min) resulted in significant increases in both 
plasma secretin concentration and pancreatic bicarbonate output in a dose dependent 
manner. However, it did not influence pancreatic secretion or protein amylase. 
2. Human pharmacokinetics 
3. Normal volunteer studies 
4. Patient studies 
5. Post market surveillance -N/A 
6. Extensive previous human use 
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